Document:

EX-10.20

 Exhibit 10.20 

BioNTech SE 
  

 
 BioNTech
Shareholders’ Agreement 
 (Consolidated version reflecting amendment dated 30 August 2019) 

 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	TABLE OF CONTENTS	  	 	2	 
	KEYWORD INDEX	  	 	3	 
	ANNEXES	  	 	5	 
	RECITALS	  	 	6	 
	1.	 	 General Obligations, Prior Agreements, Preferences, Definitions
	  	 	7	 
	2.	 	 Use of Investments; Further Equity Financing
	  	 	9	 
	3.	 	 Corporate Bodies, Extension of Supervisory Board, Corporate Governance, Articles of
Association
	  	 	9	 
	4.	 	 August 2019 Amendments
	  	 	10	 
	5.	 	 Voting Rights and Shareholders’ Meetings of the Company
	  	 	12	 
	6.	 	 Support of Company’s strategy
	  	 	16	 
	7.	 	 Foundation Withdrawal Right
	  	 	17	 
	8.	 	 Employee Stock Ownership Plan
	  	 	17	 
	9.	 	 Share Disposal Restrictions
	  	 	18	 
	10.	 	 Obligation to Tender and Right of First Refusal
	  	 	18	 
	11.	 	 Tag Along Right
	  	 	20	 
	12.	 	 Drag Along Right
	  	 	21	 
	13.	 	 Indirect Transfers
	  	 	22	 
	14.	 	 Transfer to Affiliates and other Shareholders
	  	 	22	 
	15.	 	 Liquidation Preference
	  	 	23	 
	16.	 	 Initial Public Offering (IPO)
	  	 	26	 
	17.	 	 Anti-Dilution Protection
	  	 	28	 
	18.	 	 Reporting, Information, Inspection Rights and Further Undertakings
	  	 	30	 
	19.	 	 Confidentiality
	  	 	31	 
	20.	 	 No Assignment
	  	 	31	 
	21.	 	 Form of Notices; Written Form; Special Notice
	  	 	32	 
	22.	 	 Delivery Addresses and Authorized Recipients
	  	 	32	 
	23.	 	 Accession to Shareholders’ Agreement
	  	 	33	 
	24.	 	 Scope and Amendment of this Agreement
	  	 	33	 
	25.	 	 Term and Termination
	  	 	34	 
	26.	 	 Governing Law
	  	 	34	 
	27.	 	 Massachusetts Business Trust
	  	 	34	 
	28.	 	 Arbitration
	  	 	34	 
	29.	 	 Amendments
	  	 	35	 
	30.	 	 Interpretation
	  	 	36	 
	31.	 	 No side agreements
	  	 	36	 
	32.	 	 Consent to Sideletter
	  	 	36	 
	33.	 	 Costs
	  	 	36	 
	34.	 	 Currency Conversion
	  	 	37	 
	35.	 	 Announcements
	  	 	37	 
	36.	 	 Independent Nature of Investors’ Obligations and Rights
	  	 	37	 
	37.	 	 Severability
	  	 	37	 
	SUMMER 2019 PARTIES	  	 	38	 

 KEYWORD INDEX 

 

					
	 2017 Capital Increase
	  	 	7	 
	 2017/2018 LiqPref Share
	  	 	7	 
	 2017/2018 LP Shareholder
	  	 	7	 
	 2018 Qualifying Investment
	  	 	7	 
	 2018 Qualifying Investor
	  	 	7	 
	 2018 Qualifying Share
	  	 	7	 
	 2019 LiqPref Share
	  	 	7	 
	 2019 LP Shareholder
	  	 	7	 
	 Affiliate
	  	 	23	 
	 Agreement
	  	 	6	 
	 Articles
	  	 	7	 
	 Asia Growth Fund
	  	 	44	 
	 ATI
	  	 	38	 
	 August 2019 Amendment
	  	 	10	 
	 August 2019 General Meeting
	  	 	10	 
	 August 2019 Restriction
	  	 	12	 
	 Authorization Resolution
	  	 	17	 
	 Authorized Capital Amendment I
	  	 	10	 
	 Authorized Capital Amendment II
	  	 	10	 
	 Authorized Recipients
	  	 	32	 
	 Average Investor Share Price
	  	 	28	 
	 BMGF Investment Agreement
	  	 	17	 
	 Bond Authorization
	  	 	10	 
	 Boorberg
	  	 	44	 
	 Business Day
	  	 	19	 
	 BVCF
	  	 	44	 
	 C.Huber2008
	  	 	38	 
	 Common Share
	  	 	7	 
	 Company
	  	 	6	 
	 Compensatory Issuance
	  	 	29	 
	 Compensatory Shares
	  	 	29	 
	 Conditions of Transfer
	  	 	18	 
	 Confidential Information
	  	 	31	 
	 DIS
	  	 	22	 
	 Disposal
	  	 	18	 
	 Down-round Clauses
	  	 	30	 
	 Dr. Poetting
	  	 	42	 
	 Drag Along Notice
	  	 	21	 
	 Drag Along Right
	  	 	21	 
	 Drag Along Sale
	  	 	21	 
	 Effective Date of the Tender
	  	 	19	 
	 Eli Lilly
	  	 	43	 
	 Employee Stock Ownership Plan
	  	 	17	 
	 ESOP
	  	 	17	 
	 ESOP Amendment
	  	 	10	 
	 Existing Shareholder
	  	 	39	 
	 Existing Shareholders
	  	 	39	 
	 Expert
	  	 	22	 
	 Fidelity CIPHEAL
	  	 	41	 
	 Fidelity CONT2
	  	 	41	 
	 Fidelity EPG
	  	 	41	 

					
	 Fidelity F/EQG
	  	 	41	 
	 Fidelity FAHEAL
	  	 	40	 
	 Fidelity FASEGFD
	  	 	41	 
	 Fidelity FSGRWCO
	  	 	41	 
	 Fidelity GROWTHCO
	  	 	41	 
	 Fidelity GRTHCOCP
	  	 	41	 
	 Fidelity HEAL
	  	 	40	 
	 Fidelity Investor
	  	 	41	 
	 Fidelity VIPG
	  	 	41	 
	 Fidelity VIPHLT
	  	 	41	 
	 Filet Capital
	  	 	42	 
	 First Capital
	  	 	42	 
	 First Preferred Allocation
	  	 	23	 
	 First Purchase Term
	  	 	19	 
	 First Qualified Financing
	  	 	29	 
	 First Tender Offer
	  	 	18	 
	 Foundation
	  	 	8, 44	 
	 Foundation Investment
	  	 	7	 
	 Foundation Share
	  	 	8	 
	 Further Amendment
	  	 	10	 
	 Further Equity Financing
	  	 	9	 
	 Further Financing Round
	  	 	28	 
	 Further Financings Price
	  	 	28	 
	 Fynveur
	  	 	40	 
	 Group Company
	  	 	8	 
	 Heiligeland
	  	 	43	 
	 HMJ
	  	 	43	 
	 Initial Public Offering
	  	 	26	 
	 Interested Purchaser
	  	 	18	 
	 Investment
	  	 	8	 
	 Investment Agreement
	  	 	7	 
	 Investment per Share
	  	 	8	 
	 IPO
	  	 	26	 
	 IPO Lock-Up Period
	  	 	27	 
	 Janus Fund
	  	 	41	 
	 Janus Investor
	  	 	42	 
	 Janus PLC
	  	 	42	 
	 Jebsen & Company
	  	 	43	 
	 Kendal Global
	  	 	42	 
	 Klösges
	  	 	43	 
	 Legal Terms
	  	 	36	 
	 Liquidation Event
	  	 	25	 
	 Liquidation Proceeds
	  	 	25	 
	 Lock-Up Period
	  	 	18	 
	 MAGI HK
	  	 	44	 
	 Majority Shareholder
	  	 	39	 
	 Majority Shareholders
	  	 	39	 
	 MAS HK
	  	 	44	 
	 Material
	  	 	13	 
	 Medine
	  	 	38	 
	 MIG 7
	  	 	38	 

 
 

  
 3/44 

 

					
	 MIG 8
	  	 	38	 
	 MIG 9
	  	 	38	 
	 MIG-Fonds
	  	 	38	 
	 Mr. Jeggle
	  	 	39	 
	 Mr. Krauth
	  	 	39	 
	 Mr. Marett
	  	 	42	 
	 New Investor
	  	 	42	 
	 New Investors
	  	 	42	 
	 New Letter Shares
	  	 	35	 
	 New Preferences
	  	 	35	 
	 Notice
	  	 	32	 
	 Offered Shares
	  	 	18	 
	 Other Shareholders
	  	 	18	 
	 Participating Investor
	  	 	29	 
	 Parties
	  	 	6	 
	 Party
	  	 	6	 
	 PEF
	  	 	44	 
	 Permitted Transfer
	  	 	18	 
	 Pfizer
	  	 	43	 
	 PIHF
	  	 	44	 
	 Pre-Amendment Shareholder
	  	 	8	 
	 Preference Share
	  	 	8	 
	 Preferred Allocation
	  	 	24	 
	 Preferred Shareholder
	  	 	8	 
	 Principal
	  	 	23	 
	 Pro Rata Share
	  	 	24	 
	 Prof. Dr. Huber
	  	 	42	 
	 Prof. Dr. Sahin
	  	 	42	 
	 Proposal for Amendment
	  	 	35	 
	 Qualified Financing
	  	 	30	 
	 Redmile 1
	  	 	39	 
	 Redmile 3
	  	 	40	 
	 Redmile 4
	  	 	40	 
	 Redmile 5
	  	 	40	 
	 Redmile 6
	  	 	40	 
	 Redmile 7
	  	 	40	 
	 Redmile 8
	  	 	40	 
	 Redmile Investors
	  	 	40	 
	 Redmile Nomination Right
	  	 	9	 
	 Remedial Issuance
	  	 	28	 
	 Requesting Shareholder
	  	 	25	 
	 Restricted Matter
	  	 	13	 
	 Restricted Matters
	  	 	13	 
	 Return Threshold
	  	 	12	 
	 Right to Purchase
	  	 	19	 

					
	 RLG
	  	 	39	 
	 RoP EB
	  	 	10	 
	 RoP SB
	  	 	10	 
	 Sa Bassa
	  	 	43	 
	 Salvia
	  	 	39	 
	 Sanofi
	  	 	43	 
	 Second Preferred Allocation
	  	 	24	 
	 Second Purchase Term
	  	 	19	 
	 Second Qualified Financing
	  	 	29	 
	 Second Tender Offer
	  	 	19	 
	 Secondary Placement
	  	 	27	 
	 Series A Investor
	  	 	42	 
	 Series A Investors
	  	 	42	 
	 Series A Majority
	  	 	16	 
	 Series A Share
	  	 	8	 
	 Series A Share Price
	  	 	8	 
	 Series A Total Investment
	  	 	8	 
	 Series B Investment
	  	 	8	 
	 Series B Investor
	  	 	8	 
	 Series B Majority
	  	 	16	 
	 Series B Return Threshold
	  	 	16	 
	 Series B Share
	  	 	8	 
	 Share Register
	  	 	18	 
	 Shareholder
	  	 	7	 
	 Shareholder Intending to Sell
	  	 	18	 
	 Shareholders exercising Right to Purchase
	  	 	19	 
	 Shareholders’ Resolution
	  	 	8	 
	 Shares
	  	 	7	 
	 Shortfall Amount CoC
	  	 	13	 
	 Shortfall Amount IPO
	  	 	14	 
	 Special Notice
	  	 	32	 
	 Spin-out
	  	 	28	 
	 Steam Athena
	  	 	44	 
	 Stock-Split
	  	 	10	 
	 Summer 2019 Amendment
	  	 	6	 
	 Summer 2019 Parties
	  	 	6	 
	 Tag Along Right
	  	 	20	 
	 Tofino
	  	 	39	 
	 Trust
	  	 	34	 
	 Ultimate Parent
	  	 	23	 
	 Underlying Valuation
	  	 	8	 
	 VAT
	  	 	25	 
	 Withdrawal Right
	  	 	17	 

 
 

  
 4/44 

 ANNEXES 

 

			
	Annex Summer 2019 Parties	  	List of the Parties as of the Summer 2019 Amendment Date
	Annex 3.4.1	  	RoP EB
	Annex 3.4.2	  	RoP SB
	Annex 6	  	Document “Cash Position and Use of Proceeds”
	Annex 8.1	  	cornerstone ESOP
	Annex 12.4	  	Drag along conditions
	Annex 17.3	  	Antidilution Calculation
	Annex 18.2.4	  	Reporting to Redmile and Fidelity
	Annex 22.1	  	Authorized Recipients
	Annex 31.2	  	Surviving Agreements
	Annex 32	  	Side Letter

  
 5/44 

 RECITALS 

 

	(A)	 This Agreement (the “Agreement”) in its original form has been entered into on
29 December 2017 and has subsequently been amended with effect as from 20 July 2018, 31 May 2019 and 27 August 2019. It has most recently been further amended by way of the procedure stipulated in Clause 29.2 of the Agreement,
which most recent amendment has taken effect on 30 August 2019 (the “Summer 2019 Amendment Date”), to receive this current form. As a result of certain parties acceding to the Agreement in its original form or ceasing to be
parties to the Agreement as in effect at the relevant time, as of the Summer 2019 Amendment Date the parties to the Agreement are those listed in Annex Summer 2019 Parties (the “Summer 2019 Parties”) and BioNTech SE, a
Societas Europaea (SE) organized and existing under the laws of Germany, having its registered office at An der Goldgrube 12, 55131 Mainz, Germany, and being registered with the commercial register of the local court of Mainz under
HRB 48720 (the “Company”). 

  

	(B)	 It is expected that more parties will accede to this Agreement. Each of the Summer 2019 Parties, each of the
parties that will so accede hereto (after having acceded hereto) and the Company, in each case other than any party that has ceased to be a party to this Agreement, is hereinafter referred to as a “Party” and several or all of them,
as the context may suggest, are referred to as (the) “Parties”. 

  

	(C)	 The Parties other than the Company and those certain Parties who are referred to in para. (D) are the sole
shareholders of the Company. The Company’s business is the research, development and manufacture of pharmaceuticals for individualized immunotherapies (diagnosis and treatment) of cancer and other diseases. 

 

	(D)	 The purpose of this Agreement is to coordinate the Parties’ interests in connection with the
shareholders’ respective (current and future) direct and, with respect to Mr. Marett, Dr. Poetting, Prof. Dr. Sahin and Prof. Dr. Huber indirect, shareholdings in the Company and, to that end, supplement the general
provisions of the Company’s articles of association (Satzung) as amended from time to time. 

  
 6/44 

	1.	 General Obligations, Prior Agreements, Preferences, Definitions 

 

	1.1	 The Shareholders shall at all times exercise their powers as Shareholders of the Company, including, without
limitation, their voting rights, in accordance with the terms and conditions of this Agreement. For the sake of clarification, this Agreement shall apply to any shares of the Company existing from time to time (the “Shares”) and any
party being a shareholder in the Company shall be a “Shareholder” as such term is used in this Agreement. Any breach of any obligation set forth in this Agreement by one of the Parties shall entitle the other Parties to this
Agreement to all remedies available by law, including but not limited to, claims for damages and/ or the remedies provided for in this Agreement. 

  

	1.2	 Where the terms and conditions of this Agreement conflict with anything within the Company’s articles of
association (Satzung) (the “Articles”) the Shareholders shall exercise their rights as shareholders of the Company such that the purposes of this Agreement will be achieved to the greatest extent permitted by law and upon
request of any Shareholder the Articles shall be amended accordingly. 

  

	1.3	 Except (i) as far as any provision has already been fully executed and/or (ii) as expressly set forth
otherwise herein, any agreement by and between the Parties regarding the rights of any Party with respect to its shareholding in the Company, including, but not limited to, the shareholders’ agreement dated 10 November 2008, as amended
through and as of the date hereof including on 10 May 2010 and 7/12 February 2014, shall cease to apply and shall be superseded by this Agreement as in effect from time to time. 

 

	1.4	 Each Share carries one vote in the general meeting. In addition, certain of the Shares provide for certain
preferences as attributed to them by this Agreement. 

  

	1.5	 Capitalized terms not defined in this Agreement shall have the meaning given to them in the Investment
Agreement dated 29 December 2017 (the “Investment Agreement”). In addition to the definitions made elsewhere in this Agreement, the following terms shall have the meanings ascribed to them: 

 

	1.5.1	 “2017 Capital Increase” means the capital increase of the Company that has been registered
with the commercial register on 1 February 2018. 

  

	1.5.2	 “2017/2018 LiqPref Share” means any Series A Share and any 2018 Qualifying Share.

  

	1.5.3	 “2017/2018 LP Shareholder” means any holder of 2017/2018 LiqPref Shares.

  

	1.5.4	 “2018 Qualifying Investment” means any of the capital increases of the Company the
implementation (Durchführung) of which was registered with the commercial register on 18 October 2018, 29 January 2019, or 24 April 2019, respectively. 

 

	1.5.5	 “2018 Qualifying Investor” means any Shareholder in relation to its 2018 Qualifying Shares.

  

	1.5.6	 “2018 Qualifying Share” means any Share issued under a 2018 Qualifying Investment.

  

	1.5.7	 “Summer 2019 LP Shareholder” means any holder of Summer 2019 LiqPref Shares.

  

	1.5.8	 “Summer 2019 LiqPref Share” means any Series B Share and any Foundation Share.

  

	1.5.9	 “Common Share” means any Share that is not a Preference Share. 

 

	1.5.10	 “Foundation Investment” means any investment into the Company that has been made by the
Bill & Melinda Gates Foundation against the issuance of Shares if and to the extent the following prerequisites are met: 

  
 7/44 

	 	a)	 the Shares have been issued pursuant to an agreement between the Company and the Bill & Melinda Gates
Foundation in which the Shares to be issued to the Bill & Melinda Gates Foundation are referred to as “Foundation Shares”, and 

  

	 	b)	 the Shares have been issued against a contribution in cash (including any premiums or similar payments into the
free capital reserves of the Company) (i) prior to the Stock-Split as defined in Section 4.1.1 of at least USD 325.82 per Share and (ii) following the Stock-Split as defined in Section 4.1.1 of at least USD 18.10 per Share
(provided that where the pertinent agreement between the Company and Bill & Melinda Gates Foundation provides for a contribution of at least the aforesaid US-Dollar amount but the payment of the
contribution is to be made in Euro, the payment of the Euro equivalent of such US-Dollar amount as determined pursuant to the provisions of such agreement shall in any event suffice). 

 

	1.5.11	 “Foundation Share” means any Share issued under the Foundation Investment.

  

	1.5.12	 “Foundation” means any Shareholder in relation to its Foundation Shares.

  

	1.5.13	 “Group Company” means any of the Company and any of its subsidiaries 

 

	1.5.14	 “Investment” (i) as to each Series A Investor means the amount of its contribution under the
2017 Capital Increase and (ii) as to each 2018 Qualifying Investor means the amount of its 2018 Qualifying Investment. 

  

	1.5.15	 “Investment per Share”, for each Shareholder and in relation to the relevant Shares held by
such Shareholder, means the average contribution per Share against which the relevant Shareholder (or its predecessor) has been issued those Shares (adjusted for any stock splits, reverse stock splits or receipt of free Shares).

  

	1.5.16	 “Pre-Amendment Shareholder” means any party who is a
Shareholder as of the date when a Proposal for Amendment is made. 

  

	1.5.17	 “Preference Share” means any Series A Share, any 2018 Qualifying Share, any Series B Share and
any Foundation Share. 

  

	1.5.18	 “Preferred Shareholder” means any Shareholder in relation to its Preference Shares (if any).

  

	1.5.19	 “Series A Share” means any Share that has come to existence by virtue of the 2017 Capital
Increase. 

  

	1.5.20	 “Series A Share Price” means [***]. 

 

	1.5.21	 “Series A Total Investment” means the total of the contributions made for the Series A Shares,
being [***]. 

  

	1.5.22	 “Series B Investment” means any of the capital increases of the Company the implementation
(Durchführung) of which was registered with the commercial register 26 June 2019 and on 16 August 2019, respectively. 

  

	1.5.23	 “Series B Investor” means any Shareholder in relation to its Series B Shares.

  

	1.5.24	 “Series B Share” means any Share issued under a Series B Investment. 

 

	1.5.25	 “Shareholders’ Resolution” means any shareholders’ resolution of the Company.

  

	1.5.26	 “Underlying Valuation” means the valuation of the Company at [***]. 

  
 8/44 

	2.	 Use of Investments; Further Equity Financing 

 

	2.1	 The funds raised under any of the Series A Total Investment, any of the Series B Investments and the Foundation
Investment shall be exclusively used for further development of the Company’s and the Group Companies’ products and services (including as set-out in a letter agreement between the Company and the
Foundation), including its mRNA technology, execution of the Company’s and the Group Companies’ business plan and financing working capital, without the Company incurring any legal undertakings to effect any of the measures stipulated in
such business plan, provided however that the funds provided by the Series A Investors, the Series B Investors or by the Foundation must not be used for distributions to shareholders or any economically comparable measures, except for purposes to
effect the Foundation Withdrawal Right (as defined in Section 7). 

  

	2.2	 Each Party acknowledges that the Company plans for a further equity financing round latest in 2020 (the
“Further Equity Financing”) in the amount of up to € 400 million, provided that the Company is not publically listed and provided that all Shareholders shall have subscription rights pro rata their shareholding in the
Further Equity Financing. All Shareholders hereby agree in principle to such Further Equity Financing. All Shareholders hereby already agree that all investors participating in such Further Equity Financing may receive a liquidation preference
ranking senior to the liquidation preferences provided for in Section 15 of this Agreement (with such preferred allocation in each case to be limited to the respective investment and deductible from the relevant investor’s entitlement as
would otherwise persist in any allocation pro rata to shareholdings as may apply), provided however that any and all other terms and provisions of this Agreement remain untouched, especially Clause 17 and that the investors participating
in such Further Equity Financing shall accede to this Agreement without any other modification except the liquidation preference. 

  

	3.	 Corporate Bodies, Extension of Supervisory Board, Corporate Governance, Articles of Association

  

	3.1	 The statutory corporate governance regime of the Company provides for a
two-tier board structure with 

  

	 	a)	 an executive board (Vorstand) (as of the Summer 2019 Amendment Date consisting of four managing
directors (Vorstandsmitglieder)), and 

  

	 	b)	 a supervisory board (Aufsichtsrat), which as of the Summer 2019 Amendment Date consists of six members.

  

	3.2	 The Redmile Investors shall have the right to nominate one individual, to be appointed by the general meeting
as a member of the Company’s supervisory board (“Redmile Nomination Right”). All Shareholders undertake to vote in favour of the appointment of such individual nominated if and to the extent the candidate nominated by Redmile
has been also approved by a Series A Majority (not taking into account any Series A Shares subscribed for by Existing Shareholders), such approval not to be unreasonably withheld, as a result of the Redmile Nomination Right from time to time in the
general meeting of the Company, unless there is reasonable ground to withhold such affirmative vote relating to the individual nominated (wichtiger Grund) whereas the Parties agree that a reasonable ground shall be given if the individual
nominated by Redmile is not skilled in the art of biotechnology/pharmaceutical development and/or commercialization (which is under ordinary circumstances not given in case the individual is a lawyer). The Redmile Nomination Right shall be exercised
from time to time by Redmile Investors having obtained the Series A Majority (not taking into account any Series A Shares subscribed for by Existing Shareholders), such approval 

  
 9/44 

	 	
not to be unreasonably withheld with respect to the individual nominated and shall include the right to withdraw from and to appoint the respective board member to the Company’s supervisory
board. 

  

	3.3	 Fidelity Management, Research Company shall have the right to appoint a board observer which shall be
authorized to attend each and any meeting of the supervisory board and shall receive all written information presented to the supervisory board; provided, however, that the supervisory board shall be permitted to exclude such observer from attending
such portion of any meetings and receiving such portion of any information, if attendance at such portion of the meeting or access to such information could adversely affect the attorney-client privilege between the Company and its counsel or result
in disclosure of trade secrets or a conflict of interest. Such observer shall hold all information received in the meetings of the supervisory board or otherwise provided pursuant to this Section 3.3 in confidence and trust on behalf of the
Company. 

  

	3.4	 The supervisory board of the Company has adopted rules of procedure for the executive board (“RoP
EB”) attached hereto as Annex 3.4.1 and rules of procedure for the supervisory board (“RoP SB”) attached hereto as Annex 3.4.2, and neither the RoP EB nor the RoP SB shall be amended without the prior written
consent of (i) the Series A Majority and (ii) the Series B Majority. 

  

	4.	 August 2019 Amendments 

 

	4.1	 Background 

  

	4.1.1	 As of 15 August 2019, the Company is planning to shortly effect the IPO by way of a public offering of
shares of the Company in the form of American Depositary Shares, following which American Depositary Shares representing the shares of the Company would be listed on the NASDAQ Stock Market. In order for the Articles to be suitable for a publicly
listed company, the Company has recently convened a general meeting to be held on 19 August 2019 (the “August 2019 General Meeting”) for the purpose of resolving (i) a stock-split (the
“Stock-Split”), (ii) the increase and amendment of the existing authorization to grant share options to management and employees and a corresponding change to the pertinent conditional capital (the “ESOP
Amendment”), (iii) an authorization to issue convertible bonds and, in certain circumstances, exclude pre-emptive rights of shareholders (the “Bond Authorization”), (iv) an
amendment to the Articles as concerns the authorized capital (in the framework of the restatement of the Articles to be resolved under agenda item 9 of the August 2019 General Meeting) by which the authorized capital is increased and the
authorizations to management to exclude pre-emptive rights are expanded (the “Authorized Capital Amendment I”), (v) various further individual amendments to the Articles (each a
“Further Amendment”), (vi) an amendment to the Articles as concerns the authorized capital (in the framework of the restatement of the Articles to be resolved under agenda item 10 of the General Meeting) by which, with effect
from the IPO, the authorizations to management to exclude pre-emptive rights are further expanded (the “Authorized Capital Amendment II”, with the amendments pursuant to (i) through (vi)
collectively the “August 2019 Amendments” and any one of them an “August 2019 Amendment”). 

  

	4.1.2	 The Shareholders in principle support the August 2019 Amendments to enable the Company to make preparations as
deemed necessary for the IPO, based on the assumption that the IPO will shortly be effected, but subject to the proviso that, until the IPO actually occurs, the procedures and requirements as set forth in this Agreement will be complied with
irrespective of the August 2019 Amendments having been consented to in the August 2019 General Meeting, their rights and preferences as set forth in this Agreement are not prejudiced by the August 2019 Amendments and the August 2019

  
 10/44 

	 	
Amendments do not in any way or form constitute or shall be interpreted as an express or implied amendment to this Agreement. 

 

	4.2	 The following shall apply in connection with the August 2019 Amendments: 

 

	4.2.1	 No prejudice to position under this Agreement 

It is acknowledged and agreed that none of the August 2019 Amendments themselves or the circumstance of any Beneficiary voting for and
consenting to any Amendment do in any way alter the preferences and rights (nor any obligations) of any of the Shareholders hereunder. In particular, none of the August 2019 Amendments shall constitute an express or implied written consent of the
Series A Investors and/or Series B Investors with respect to Sections 5.2(ii) and 5.8. Moreover, the Parties agree that the August 2019 Amendments shall not constitute and express or implied amendment to this Agreement. In particular, the Parties
acknowledge and agree that the deletion of the catalogue of matters requiring consent by the supervisory board from the Articles as proposed as one of the Further Amendments shall not in any way impact the continuous requirement to obtain consent
for the matters listed in Section 5.2 from the Series A Investors and/or the Series B Investors, that such catalogue shall remain part of the RoP SB and that the Parties shall treat each other for the purposes of this Agreement as if such
catalogue of restricted matters had not been deleted from the Articles as part of the Further Amendments. In addition, the Parties agree that the deletion of the provisions as to restrictions on transfers of Shares and related remedies from the
Articles shall not amend the restrictions on transfer of Shares for the Shareholders as agreed in this Agreement. 
  

	4.2.2	 Nomination and Appointment Rights 

The Parties acknowledge and agree that the Redmile Nomination Right as set forth in Section 3.2 of this Agreement shall not be affected by
the proposed reduction of the supervisory board to four members as part of the Further Amendments. The same shall apply for the observer appointment rights of Fidelity Management and Research Company as set forth in Section 3.3. 

 

	4.2.3	 Classes of Shares; references to amounts in this Agreement 

The Parties acknowledge and agree that any new Share to which to a Shareholder a Shareholder is entitled and which it holds as a result of the
Stock-Split pursuant to § 212 of the German Stock Corporation Act shall qualify as a Share of the same class (Series A Shares, Series B Shares, 2018 Qualifying Shares and Common Shares) as do the Shares that give rise to such entitlement
and such new holding pursuant to that provision. In the event Shareholders hold different classes of Shares prior to the Stock-Split, the Shares issued under the Stock-Split shall be allocated to the relevant share classes pro rata reflecting the
ratio in which the Shares were held prior to the Stock-Split. The Parties further hereby record their assumption that, as a result of the Stock-Split, among other similar adjustments applying by way of construction of this Agreement, any reference
made in this Agreement to a specific absolute USD or EUR amount when relating to any one Share (other than any reference to the par value of that Share) shall be read as a reference to the relevant amount divided by 18 (unless where this very
adjustment in the event of a measure such as the Stock-Split is provided already elsewhere in this Agreement). 
  

	4.3	 Company not to use expansions of authorizations to issue financial instruments 

 

	4.3.1	 For as long as the IPO has not occurred, the Company agrees to each Shareholder not to issue any financial
instruments such as Shares, share options for management or employees, or bonds or issue such financial instruments in a manner (e.g. excluding pre-

  
 11/44 

	 	
emptive rights) if, absent any of the ESOP Amendment, the Bond Authorization or the Authorized Capital Amendment I, it could not have issued such financial instruments or could not have issued
them in such manner without the consent of the Series A Majority and Series B Majority provided that this shall not restrict the Company in any such issuances which it indeed could effect also absent the afore-mentioned of the August 2019
Amendments (the “August 2019 Restriction”). 

  

	4.3.2	 ATI and Medine agree to each Shareholder to use their best efforts to procure that the Company will comply with
the Restriction. The Parties acknowledge and agree that the provisions of the SHA shall apply in the event of a violation of the August 2019 Restriction. 

  

	4.4	 Reversion of certain of the Amendments upon request of Beneficiary 

The Company, ATI, and Medine agree to each Shareholder to use best efforts to effect the reversion of any one or more of the ESOP Amendment,
the Bond Authorization, the Authorized Capital Amendment I and any Further Amendment by way of a repeal of the pertinent resolution of the August 2019 General Meeting or an amendment to the Articles for same to take the form they would be in absent
the relevant August 2019 Amendment if any Shareholder so requests in writing, which request can be made at any time after 31 December 2019; best efforts shall include the submission of a request to the Company to call an extraordinary general
meeting with respective agenda items or to amend agenda items of a scheduled general meeting (§ 122 AktG) and the commitment to use their voting rights from the respective Shares to vote in favour for the aforementioned reversion.

  

	5.	 Voting Rights and Shareholders’ Meetings of the Company 

 

	5.1	 Subject to the provisions of this Agreement and any requirements for a higher majority imposed by the
Company’s articles of association (Satzung) or mandatory law, and to the extent legally permissible under applicable law, there shall be no measures which shall require more than the simple majority of the votes cast.

  

	5.2	 However, the Parties agree that the following actions and measures shall not be implemented without the prior
written consent of a Series A Majority as defined in Section 5.9 below: 

  

	 	(i)	 a Liquidation Event as defined below under Clause 15.3.1 in which the Series A Investors receive, for each
Series A Share held by such Series A Investor, per Series A Share proceeds of less than 1.35x of the Series A Share Price (the “Return Threshold”), except in case of Section 5.3, 

 

	 	(ii)	 an IPO in which the Company’s Shares are sold at less than the Return Threshold, except in case of
Section 5.4, 

  

	 	(iii)	 amending the rights, preferences, and privileges of the Series A Shares or the Series A Investors,

  

	 	(iv)	 declaration or payment of dividends, distributions of profits, redemptions, and repurchases of Company
securities (other than pursuant to the Company’s SAR programs or in connection with the Foundation Withdrawal Right described in Section 7), including shareholders resolutions granting authorizations to the Company for redemptions and/or
repurchases of securities issued by the Company, 

  

	 	(v)	 increasing the size of the supervisory board of the Company beyond six (6) members, 

  
 12/44 

	 	(vi)	 incurring debt, or creating any debt security for the Company and its subsidiaries of more than EUR 40,000,000
(in words: EUR forty million) in the aggregate, whereas such limiting amount shall be increased in the same ratio as the capital of the Company (“Grundkapital der Gesellschaft”) will be increased after the 2017 Capital Increase,

  

	 	(vii)	 encumbering or granting a security interest in a Material (as defined below) portion of the assets of the
Company, except as a security for admitted loans according to Section (vi) above, 

  

	 	(viii)	 acquiring a Material (as defined below) amount of assets of another entity, including through a merger,
purchase of capital stock, or other similar transaction, whereas in case of earn out payments a 3 years period is relevant for the determination of the materiality threshold as defined below, 

 

	 	(ix)	 creating or holding capital stock in any subsidiary (except wholly-owned subsidiaries or subsidiaries already
being held by the Company as of the execution of this Agreement), or disposing of any subsidiary (other than JPT) stock or all or substantially all of any subsidiary assets, 

 

	 	(x)	 Material (as defined below) interested party transactions or related party transactions, in the event that said
such activities (i) provide an economic advantage to one Shareholder or group of Shareholders at the expense of the others or (ii) are not entered into in the ordinary course of business, whereas in case of licenses or earn out payments a
3 years period or the time period until a termination of the agreement is possible – whatever is earlier – is relevant for the determination of the materiality threshold as defined below, 

 

	 	(xi)	 selling, transferring, licensing, assigning, or otherwise disposing of any of the Company’s Material (as
defined below) assets or intellectual property (for the avoidance of doubt Parties agree that such transaction has to be legal anyway), in the event that said activities advantages one Shareholder at the expense of the others, except for the
licenses granted under the side letter agreement entered into between the Company and the Foundation. 

 Lit.
(i) through (xi) above each a “Restricted Matter” and collectively “Restricted Matters”. “Material” means more than EUR 40,000,000 (in words: Euro forty million) in either (a) a single
transaction or series of related transactions, or (b) in the aggregate in any calendar year. 
  

	5.3	 If the prior written consent of the Series A Majority is not obtained as otherwise required by Section 5.2
(i), then, in connection with the applicable Liquidation Event, such consent shall be deemed granted (but only to the extent otherwise required pursuant to Section 5.2 (i) and not with respect to any other consent required by law, otherwise
required herein) if the Existing Shareholders, or to their discretion the Company, commit themselves to pay to each of the Series A Investors the shortfall amount between (i) the actual proceeds received from such change of control transaction
per sold Series A Share and (ii) the Return Threshold (“Shortfall Amount CoC”) as provided for herein provided that such commitment to pay (or payment) by the Company must not result in the actual proceeds of any Shareholder
other than an Existing Shareholder from the relevant transaction being less than the proceeds that would accrue to that Shareholder absent such commitment or payment. If any of the 2018 Qualifying Investors or the Foundation keeps any of its
respective Shares, such commitment to pay (or payment) by the Company requires the consent of such 2018 Qualifying Investor and the Foundation, respectively. 

  
 13/44 

 In case the Existing Shareholders decide that the Company shall pay the Shortfall Amount CoC
such decision shall be pursuant to the unanimous consent of all Existing Shareholders. In such case the Existing Shareholders shall indemnify and hold harmless the Series A Investors from any repayment obligation towards the Company which might
arise from a payment by the Company to the Series A Investors under this Section 5.3. In the event that a payment by the Company to the Series A Investors is not permitted by law or the prerequisites for the Company to so pay pursuant to the
preceding paragraph are not satisfied (e.g. absent the requisite consent by a 2018 Qualifying Investor or the Foundation) or such payment by the Company is otherwise not possible, the Existing Shareholders shall put the Series A Investors in the
same position they were in if the Company was permitted to make such payment. In either way, such payment by the Company, or, in case of a payment by the Existing Shareholders, will be made no later than five (5) days following the closing of
the Liquidation Event. For the avoidance of doubt: In the event that no unanimous consent of all Existing Shareholders exists as to a payment by the Company and also the Existing Shareholders have not bindingly committed themselves to such payment,
the consent as referred to in Section 5.2 (i) shall be not be deemed granted pursuant to this Section 5.3. 
  

	5.4	 If the prior written consent of the Series A Majority is not obtained as otherwise required by Section 5.2
(ii), then, in connection with the IPO, such consent shall deemed granted (solely to the extent required pursuant to Section 5.2 (ii) and not with respect to any other consent required by law or otherwise required herein) if the Existing
Shareholders, or to their discretion the Company, commit themselves to “pay” to the Series A Investors the shortfall amount between (i) the IPO Issuance Price and (ii) the Return Threshold (“Shortfall Amount
IPO”) as provided for herein provided that the Company may make such commitment to pay (or make such payment) only with the consent of each 2018 Qualifying Investor and the Foundation unless such commitment (or payment) does not
result in the IPO Issuance Price being less than the IPO Issuance Price that would prevail absent such commitment or payment. The “IPO Issuance Price” shall be the price at which the Shares are offered in an Initial Public Offering.
The Shortfall Amount IPO can be paid in cash or in Shares that are, at the time of issuance for all terms and conditions equal to the Series A Shares. In case the Shortfall Amount IPO is paid in Shares the IPO Issuance Price shall be the basis for
the calculation of the number of Shares to be transferred. 

 In case the Existing Shareholders decide that the Company
shall pay the Shortfall Amount IPO in cash such decision needs a unanimous consent of all Existing Shareholders. In such case the Existing Shareholders shall indemnify and hold harmless the Series A Investors from any repayment obligation towards
the Company which might arise from a payment by the Company to the Series A Investors under this Section 5.4. In the event that it turns out that a payment by the Company to the Series A Investors is not permitted by law or the prerequisites
for the Company to so pay pursuant to the preceding paragraph are not satisfied (e.g. absent the requisite consent by a 2018 Qualifying Investor or the Foundation) or such payment by the Company is otherwise not possible, the Existing Shareholders
shall put the Series A Investors in the same position they were in if the Company was permitted to make such payment. For the avoidance of doubt: In the event that no unanimous consent of all Existing Shareholders exists as to a payment by the
Company and also the Existing Shareholders have not bindingly committed themselves to such payment, the consent pursuant to Section 5.2 (ii) shall not be deemed granted pursuant to this Section 5.4. 

In either way, such payment by the Company, or, in case of a payment by the Existing Shareholders, or in case of a transfer of Shares the
payment or transfer will be made no later than five (5) days following the first day of trading following the closing of the IPO. 

  
 14/44 

 For the avoidance of doubt the provisions under Clause 16 shall be unaffected by a consent
or deemed consent under this Clause 5.4. 
  

	5.5	 Any outstanding details with respect to the transactions contemplated by Section 5.3 and Section 5.4
shall be finally negotiated between the respective Parties and the Series A Investors prior to the execution of the Liquidation Event or the IPO, respectively. For the avoidance of doubt, the Company or the Existing Shareholders shall not be
authorized to conduct a change of control transaction or an IPO before the payment of the Shortfall Amount CoC or the Shortfall Amount IPO is secured. 

  

	5.6	 To the extent measures and actions listed in Section 5.2 (which shall also be included in the Articles as
respective supervisory board’s consent requirements) fall within the scope and responsibility of the executive board under mandatory stock corporation law, the Shareholders shall, as far as legally permissible, use their best efforts to procure
that the supervisory board shall withhold such consent in the absence of a consent of the Series A Majority. 

  

	5.7	 In the event, that a Restricted Matter is implemented or threatened to be implemented (as specified below)
without the consent or deemed consent of the Series A Majority otherwise required according to Section 5.2, the following shall apply: 

  

	 	(i)	 If the supervisory board (a) has approved within its own and free discretion (except in a test vote as set
forth in the RoP SB) any of the Restricted Matters in the absence of the consent of the Series A Majority (relating to such Restricted Matters which fall in the competence of the executive board) or (b) puts an agenda item on the agenda of a
supervisory board meeting despite the fact that the same agenda item has been a matter of a test voting as set forth in the RoP SB in the absence of the consent of the Series A Majority (relating to such Restricted Matters which fall in the
competence of the executive board) or (c) deletes the provisions regarding the procedure of test voting and delay of agenda items in case of a Restricted Matter as set forth in the RoP SB or does not adhere to such procedure, the following
shall apply: 

  

	 	•	 	 on a prompt request of one of the New Investors, the Shareholders are obligated to withdraw all members of the
supervisory board except the one elected according to the Redmile Nomination Right at once and elect new members of the supervisory board mutually acceptable to the majority of the Shareholders and to the majority of New Investors;

  

	 	•	 	 the obligation to withdraw all members of the supervisory board shall not apply in the case that despite all
provisions of the RoP SB having been observed (including the provisions of timely invitation of a supervisory meeting before an approval by the supervisory board), the member of the supervisory board elected according to the Redmile Nomination Right
has not notified the other members of the supervisory board beforehand, with detailed substantiation that the item of the agenda concerns a Restricted Matter (such notification obligation only to arise from the date upon which the Redmile Nomination
Right has been exercised and implemented for the first time). 

 If the member of the supervisory board elected according
to the Redmile Nomination Right has notified the other members of the supervisory board with detailed substantiation that an item of the agenda concerns a Restricted Matter and the other members of the supervisory board require a withdrawal of such
notification and the notification is not withdrawn within 5 days and it turns out later on, that the measure was not a Restricted Matter, on a prompt request of 

  
 15/44 

 
one of the New Investors, the Shareholders are obligated to withdraw the members of the supervisory board elected according to the Redmile Nomination Right. 

 

	 	(ii)	 If the general meeting has decided to approve any of the Restricted Matters in the absence of the consent of
the Series A Majority (relating to such Restricted Matters which fall in the competence of the general meeting) and on a prompt request of one of the New Investors the Shareholders are obligated to elect for the next 3 years as much members of the
supervisory board of the Company according to a respective nomination by the Redmile Investors that such members of the supervisory board so nominated hold the majority of seats in the supervisory board. 

 

	 	(iii)	 Any further claims of the New Investors for a breach of this Shareholders Agreement shall remain unaffected.

  

	 	(iv)	 For clarity, if a member of the supervisory board that was elected according to the Redmile Nomination Right is
withdrawn, Redmile shall continue to retain the Redmile Nomination Right but any further nominee shall also require the approval of a majority of the Shareholders. 

 

	5.8	 Any action or measure that pursuant to Section 5.2 or any other provision of this Agreement requires the
prior consent of a Series A Majority shall also require the prior consent of a Series B Majority (as defined in Section 5.10 below) in the same form as is required for the relevant consent of the Series A Majority and Section 5.3 and
Sections 5.5 through 5.7 shall apply mutatis mutandis in relation to the Series B Investors provided 

  

	 	a)	 that (A) no such Series B Majority shall be required for an IPO (Section 5.2(ii)) and (B) a Series B
Majority shall be required for a Liquidation Event (Section 5.2(i)) only where such is a sale of Shares pursuant to the Drag Along Right in which any of the Series B Investors receives, for each Series B Share held by such Series B Investor,
proceeds of less than 110% of the relevant Investment per Share (the “Series B Return Threshold”), and 

  

	 	b)	 for the purposes of this Section 5.8, the terms “Series A Investor”, “New Investors”,
“Series A Majority”, and “Return Threshold” shall mean “Series B Investor”, “Series B Investors”, “Series B Majority”, and “Series B Return Threshold”, respectively. 

 

	5.9	 “Series A Majority” shall mean Shareholders collectively holding the majority of the Series A
Shares. 

  

	5.10	 “Series B Majority” shall mean Shareholders collectively holding the majority of the Series B
Shares. 

  

	5.11	 Parties agree that in case that a consent which is required under Section 5.2 is refused and such refusal
constrains the business of the Company or other Group Companies they will try to solve the problem in good faith. 

  

	6.	 Support of Company’s strategy 

Each Shareholder undertakes to support the strategy as outlined in the document “Cash Position and Use of Proceeds” for the Company
as attached hereto as Annex 6, including the financial planning set out therein, without the Shareholders incurring any legal undertakings to effect any of the measures stipulated in such document. 

  
 16/44 

	7.	 Foundation Withdrawal Right 

 

	7.1	 The Parties acknowledge that the Foundation is investing for charitable purposes under the United States tax
code and in connection therewith is entitled under certain conditions, as set out in an investment agreement between the Company and the Foundation (the “BMGF Investment Agreement”), to have the Shares held by the Foundation or its
Affiliates redeemed by the Company or to sell such Shares to third parties (the “Withdrawal Right”). Sections 9 through 13 shall not apply to such transfer. 

 

	7.2	 On August 19, 2019, a shareholders’ meeting of the Company (Vollversammlung) was held whereby
the Shareholders waived all statutory provisions and provisions of the Articles as to holding and convening a shareholders’ meeting and in this shareholders’ meeting have passed a unanimous shareholders’ resolution pursuant to §
71 para. 1 no. 8 AktG authorizing the Company for a period of five years to acquire the Foundation Shares for such purchase price as is specified in such resolution (the “Authorization Resolution”). The Shareholders hereby each
undertake (i) not to vote in favour of any subsequent shareholders’ resolution resulting in a revocation of the Authorization Resolution and (ii) to vote in favour of any subsequent shareholders’ resolution as the Company will
propose to renew the Authorization Resolution prior to the lapse of the authorization period, and (iii) in case an IPO is about to occur, to vote in favour of any shareholders’ resolution immediately prior to the IPO to renew the
Authorization Resolution for the maximum period legally allowed. 

  

	7.3	 To the extent that pursuant to the BMGF Investment Agreement (i) the Company is required to procure that
no dividends are paid, no Shares are redeemed by the Company and no other distribution to any other Shareholder of the Company in respect of the share capital held by such Shareholders is made and (ii) annual profits shall be contributed to the
unrestricted reserves in the meaning of section 71 para. 2 sentence 2 German Stock Corporation Act (Aktiengesetz, AktG) (and no exemptions or limitations under the BMGF Investment Agreement from such requirements pursuant to (i) or (ii),
respectively, apply), the Parties will not vote in favour of any resolution that would result in or cause any dividend, redemption or other distribution as set out under (i) above to occur and will not vote against any resolution that the
annual profits be allocated to unrestricted reserves, provided however that ATI and Medine shall vote in favour of any resolution that the annual profits so be allocated to unrestricted reserves. 

 

	7.4	 Notwithstanding anything in this Agreement to the contrary, any amendment to this Section 7 shall require
the prior written consent of the Foundation. 

  

	8.	 Employee Stock Ownership Plan 

 

	8.1	 The Parties acknowledge and agree that, with the consent of the Company’s supervisory board, present or
future managers of the Company or any of its subsidiaries or other key employees of the Company or any of its subsidiaries may be granted an employee participation at the level of the Company pursuant to an authorization granted by the general
meeting of the Company of 18 August 2017 (the “Employee Stock Ownership Plan” or “ESOP”). The volume and the general terms and conditions are stipulated in Annex 8.1. 

 

	8.2	 Any material deviation from the volume and the general terms and conditions from what is set out in Annex 8.1
which deviation has an additional dilutive effect of at least 5% shall be subject to the consent of the Series A Majority. 

  

	8.3	 The Parties acknowledge and agree that the ESOP shall be established in preparation of an envisaged IPO.

  
 17/44 

	9.	 Share Disposal Restrictions 

 

	9.1	 Subject to the provisions set out in Section 16 (IPO) and subject to Permitted Transfers (as defined
below) and unless where the relevant Shareholder has a Drag Along Right, no Disposal of any Shares by a Shareholder shall be permitted without consent of Shareholders holding a minimum of 90% of the Shares of the Company, until 30 June 2022
(the “Lock-Up Period”), provided that should Shareholders holding a minimum of 90% of the Shares of the Company consent to a Disposal of Shares then the further restrictions and limitations regarding a Disposal of Shares as
set forth in this Agreement shall apply. Upon expiry of the Lock-Up Period, any Disposals of any Shares shall only be permitted as set forth in this Agreement. However, the Parties agree that any approval of a Disposal of any Shares after
31 December 2020 until 30 June 2022 shall not be unreasonably withheld. 

  

	9.2	 Except for a transfer of Shares permitted in Section 14 below and option grants according to Annex 8.1
(collectively, a “Permitted Transfer”), none of the Shareholders shall without the prior consent of the Company’s supervisory board: 

  

	9.2.1	 sell, transfer, dispose of or otherwise deal with any right or interest in any Share (including the grant of
any option over or in respect of any Share), or enter into a sub-participation (Unterbeteiligung) of whatsoever nature (including silent partnerships (stille Beteiligungen)) on, or trusteeship
over, Shares, or similar arrangements; 

  

	9.2.2	 create or permit to exist any pledge, mortgage, lien, fixed or floating charge or other encumbrance over any
Share or any interest in any Share; or 

  

	9.2.3	 enter into any voting trust, or any agreement with any person other than its Affiliates (as defined below) in
respect of the votes attached to any Share (or parts thereof), 

 9.2.1 to 9.2.3 each a “Disposal”. 

 

	9.3	 Each Disposal of any Share in the Company shall only become effective in accordance with the Articles as
amended from time to time, and shall be subject to prior consent of the Company’s supervisory board. Parties shall use their best influence that the consent of the supervisory board shall be granted without undue delay in the event that the
conditions for a Disposal according to this Agreement and the Articles are fulfilled. 

  

	9.4	 Any Disposals, transfers of, or liens on, any Shares not made in accordance with the provisions of this
Agreement shall not be registered in the share register of the Company (the “Share Register”). 

  

	9.5	 No Disposal, in particular no transfer of any Shares (other than a transfer to another Shareholder or as part
of an IPO) shall be recognized or permitted unless the beneficiary of the Disposal, in particular any transferee in case of a transfer, validly accepts the offer to accede to this Agreement made to it by the Parties in Clause 24.4 below.

  

	10.	 Obligation to Tender and Right of First Refusal 

 

	10.1	 Without prejudice to Section 9.1, if a Shareholder intends to directly or indirectly transfer
(“Shareholder Intending to Sell”) any of its Shares (“Offered Shares”) in the Company to a third party, except as stipulated in Annex 3.4.1 or Annex 3.4.2 the following shall apply: 

 

	10.1.1	 The Shareholder Intending to Sell shall offer the Offered Shares to all other Shareholders (“Other
Shareholders”) by written notice by stating the name of the potential purchaser interested in the transfer (“Interested Purchaser”) and the details of the intended transfer and/or purchase conditions as set out in
Section 10.1.2 (the “Conditions of Transfer”) (“First Tender Offer”). The Shareholder Intending to Sell 

  
 18/44 

	 	
shall also give notice of the First Tender Offer to the Company. The date of receipt of the First Tender Offer by the Other Shareholders shall be the “Effective Date of the
Tender”. 

  

	10.1.2	 The First Tender Offer shall contain the following information (if available) regarding the Conditions of
Transfer: 

  

	 	a)	 Name/company and address/registered office of the Shareholder/s Intending to Sell; 

 

	 	b)	 Percentage of registered share capital represented by the Offered Shares; 

 

	 	c)	 Name and address/registered office of the prospective buyer/acquirer including those of its controlling (as
defined in sections 15 et seq. German Stock Corporation Act (AktG)) shareholders, if any; 

  

	 	d)	 purchase price and/or any other consideration for the intended sale/transaction, due date, right to profits;
and 

  

	 	e)	 guarantees and representations the Shareholder Intending to Sell is willing to give. 

 

	10.1.3	 The Other Shareholders shall each have the right to acquire the Offered Shares in accordance with the
Conditions of Transfer in proportion to their respective share interest ratio in the Company’s registered share capital after deduction of the nominal value of the Shares held by the Shareholder(s) Intending to Sell from the Company’s
registered share capital by written notice (“Right to Purchase”). The Other Shareholders have to exercise their Right to Purchase within twenty (20) Business Days after receipt of the First Tender Offer (“First Purchase
Term”). The notice to exercise their Right to Purchase has to include, and shall be effective only upon, the respective Other Shareholder’s willingness to acquire all Offered Shares not acquired by the Other Shareholders according to
their pro rata Right to Purchase (i.e. in effect the Right to Purchase as a whole can be exercised only with regard to all of the Offered Shares). A “Business Day” shall mean any day other than a Saturday or Sunday on which banks
are open for business in Munich. 

  

	10.1.4	 If individual Other Shareholders do not exercise their Right to Purchase at all or not within the First
Purchase Term, the Shareholder Intending to Sell shall give written notice to the Shareholders exercising Right to Purchase of the Offered Shares not purchased within ten (10) Business Days after the end of the First Purchase Term
(“Second Tender Offer”), and the Other Shareholders who have exercised their Right to Purchase (“Shareholders exercising Right to Purchase”) shall have the right and the obligation to additionally acquire the
percentage proportion of the Offered Shares for which the Right to Purchase has not been exercised in accordance with the Conditions of Transfer, in relation to the respective share interest ratio the respective Shareholder exercising Right to
Purchase has on the Effective Date of the Tender in the sum of all Shares of the Shareholders exercising Right to Purchase within thirty (30) Business Days after receipt of the Second Tender Offer by written notice (the “Second Purchase
Term”), provided that the Shareholders exercising Right to Purchase may mutually agree upon another ratio as to who of the Shareholders exercising Right to Purchase acquires the Offered Shares for which Other Shareholders have not exercised
their Right to Purchase within the First Purchase Term. 

  

	10.1.5	 The Shareholder Intending to Sell and the Shareholders exercising Right to Purchase are obligated to execute
the transfer of the Offered Shares purchased without undue delay and to undertake all steps and actions necessary and useful for the transfer to become 

  
 19/44 

	 	
effective, which shall occur no later than ten (10) Business Days after the Shareholders exercising Right to Purchase have exercised their rights. 

 

	10.1.6	 If the Other Shareholders have not effectively exercised their Right to Purchase under this Section 10
(e.g. if no Other Shareholder has exercised its Right to Purchase or if the notice to exercise their Right to Purchase does not include the willingness to acquire all Offered Shares not acquired by the Other Shareholders) the Shareholder Intending
to Sell shall be free, subject to Section 9, to transfer the Offered Shares to one or more third parties within a period of three (3) months following the expiry of the Second Purchase Term, provided that such sale and transfer occurs at
no more favorable conditions than outlined in the Conditions of Transfer. 

  

	10.2	 The Shareholder exercising Right to Purchase with the highest share interest in the Company is entitled to
fractional amounts, if any. 

  

	10.3	 Section 9.5 shall apply mutatis mutandis. 

 

	10.4	 The provisions of this Section 10 and the Right to Purchase set forth herein shall apply mutatis
mutandis to any other Disposal of any Offered Shares, except donations of a Shareholder for the benefit of the respective Shareholder’s spouse or descendants in the first degree (zu Gunsten von Ehegatten oder Abkömmlingen 1.
Grades). 

  

	11.	 Tag Along Right 

 

	11.1	 In the event that the Shareholder(s) Intending to Sell individually or collectively sell or contribute more
than 25% of the Shares in the Company to a third party in one or more related transactions, each other Shareholder who has not exercised his Right to Purchase according to Section 10 may request that the Shareholder(s) Intending to Sell
procure that such other Shareholder can sell or contribute and transfer a pro rata portion of its Shares to the onward purchaser at the same terms and conditions as set forth in the First Tender Offer provided that such terms and conditions, where
such other Shareholder does not hold at least 10% of the Shares, must, as concerns the period following completion of the relevant transaction, not impose any restrictions upon such other Shareholders (such as
non-compete or non-solicit) other than customary confidentiality obligations in relation to the relevant transaction (the “Tag Along Right”).

  

	11.2	 The Tag Along Right shall be exercised within ten (10) Business Days after the lapse of any Right to
Purchase as provided for in Section 10, and shall be sent by the Shareholder(s) entitled to co-sell to the Shareholder/s Intending to Sell. If the prospective buyer/acquirer does not wish to purchase all
the Shares which the Shareholders entitled to co-sell wish to sell, the Shareholder/s Intending to Sell shall notify the co-selling Shareholders of the prospective
buyer’s/acquirer’s wish, and, the relevant co-selling Shareholders must declare to the Shareholder/s Intending to Sell, within ten (10) Business Days of receipt of the notification, whether
it/they intend to demand the sale of their Shares on a pro rata basis, or whether they decide not to co-sell their Shares. If the co-selling Shareholders demand the sale
of their Shares on a pro rata basis, the Shareholder/s Intending to Sell and the co-selling Shareholders shall sell their Shares pro rata to their participation in the Company at the day of receipt of the
First Tender Offer. 

  

	11.3	 The Shareholders are obliged to actively participate in preparing and implementing a due diligence customary to
a transfer of Shares, to support the sale provided for therein to their best extent possible and to undertake all actions required or necessary for the transfer to come into effect, as long as the provisions according to this Agreement are adhered
to by the Shareholder/s Intending to Sell. 

  
 20/44 

	12.	 Drag Along Right 

 

	12.1	 Without prejudice to Sections 10 and 11, in the event that either (a) Shareholder(s) individually or
collectively holding more than 50% of the Shares in the Company or, (b) for so long as Medine holds at least 1,738,692 Shares in the Company (whereas any sale of Shares based on the Agreement mentioned in Clause 31.2 shall not trigger the
Drag Along Right), Medine (individually an “Exiting Shareholder” or collectively the “Exiting Shareholders”), intend(s) to sell all of their/its Shares to a bona fide third party, or to contribute all of
their/its Shares in the framework of a business combination to a third party willing to acquire all of the Shares, such Exiting Shareholder(s) at their sole discretion is/are collectively entitled to require the other Shareholders to sell or
contribute, as the case may be, immediately prior or immediately subsequent to or simultaneously with such Exiting Shareholder(s) to the third party all Shares in the Company held by them (the “Drag Along Right”), provided, however,
that the exercise of the Drag Along Right shall further be subject to (i) the requirements of consents according to Sections 5.2 and 5.8 or deemed consents according to Sections 5.3 and 5.8 and (ii) as to each Shareholder, the
proceeds from the sale per Share to which it is entitled being at least equal to its Investment per Share or it having consented to such sale. 

  

	12.2	 Such sale or contribution shall be at the same price and on the same terms and conditions which have been
offered to the Exiting Shareholder(s) by the potential purchaser. Concerning representations, warranties, undertakings and other restrictions and limitations in such a sale or contribution, the same representations, warranties, undertakings and
other restrictions and limitations which have been offered by the Exiting Shareholders in the share purchase or contribution agreement shall apply to the other Shareholders’ shareholding and shall be given by the other Shareholders provided
that, where the individual other Shareholder does not hold at least 10% of the Shares, such individual other Shareholder must not (i), as concerns the period following completion of the relevant transaction, be subject to any restrictions (such as non-compete or non-solicit) other than customary confidentiality obligations in relation to the relevant transaction, (ii) be required to amend, extend or terminate any
contractual or other relationship with the Company, the acquirer or their respective affiliates, or (iii) in connection with such sale or contribution incur liability joint with any third party or exceeding the total amount of the consideration
actually received by such Shareholder in such sale or contribution. Drag Along Rights can only be exercised if the full consideration is in cash or in freely disposable listed securities within the meaning of section 31 para. 2 of the
German Takeover Act (WpÜG). 

  

	12.3	 The Drag Along Right must be exercised prior to or within ten (10) Business Days after a purchase or
contribution agreement has been entered into with the potential purchaser by written notice (the “Drag Along Notice”) to the other Shareholders. 

 

	12.4	 The other Shareholders shall, at the sole discretion of the Exiting Shareholder(s), be obliged to sell and
transfer or contribute as sellers and assignors or contributors all of their Shares in the Company upon the exercise of the Drag Along Right (the “Drag Along Sale”) directly to the purchaser or acquirer and to enter with purchaser
into all relevant agreements. The Shareholders undertake to make any and all declarations necessary and to perform any and all acts required in connection with any such sale and transfer or contribution of the Shares in Company except as provided
for in Annex 12.4. 

  

	12.5	 The Parties agree that the provisions under this Section 12 shall also apply to a merger of the Company
with another company in which those Parties which do not consent to the merger but are dragged along have the right to require cash compensation instead of a share compensation as remuneration for the merger (cash compensations due to non-consent or prior settlement as the parties may agree upon), and further provided that the 

  
 21/44 

	 	
Shareholders shall only consent to a merger if such cash compensation for the benefit of the Parties which do not consent to the merger is provided for. If the Parties are unable to reach an
unanimous vote to the amount of the cash compensation within ten (10) Business Days after a Party has asked for cash compensation according to sentence 1, expertise proceedings (Gutachterverfahren) pursuant to the DIS Rules on Expertise
(Gutachtensordnung der Deutschen Institution für Schiedsgerichtsbarkeit e.V.) of the German Institution of Arbitration (Deutsche Institution für Schiedsgerichtsbarkeit e.V., “DIS”) shall be
conducted with the proviso that, contrary to Sec. 1.1 of the DIS Rules on Expertise according to which the application of these rules is limited to a non-binding opinion, the nominated expert shall
determine and resolve the dispute by way of a binding written opinion pursuant to Sec. 317 BGB. The Parties shall instruct the nominated expert (the “Expert”) to complete his/her review and determination within thirty
(30) Business Days of receipt of the Expert’s written declaration of acceptance of the office by the DIS. The Parties shall be given the opportunity to present their views in English in writing and at an oral hearing chaired by the Expert.
The Expert shall determine the valuation of the Company following the rules of IDW S1. Any amount so determined by the Expert shall be paid to the dragged Party/ies by the other Parties within ten (10) Business Days after receipt of the along
written decision by the Expert. Contrary to Sec. 20 of the DIS Rules on Expertise, the costs of the expertise proceedings shall be borne pursuant to the principles set forth in Sec. 91 et. seqq. German Civil Procedure Code
(Zivilprozessordnung). 

  

	12.6	 In the event that the Drag Along Right is exercised, the obligation to tender and right of first refusal as
provided for in Section 10 shall not be applicable. 

  

	13.	 Indirect Transfers 

As regards the Parties Medine, C.Huber2008, Salvia, Tofino and RLG Sections 9 through 12 shall apply mutatis mutandis to any
indirect transfer of any indirect interest in any Shares as well as any other indirect disposition over, or liens on, Shares, including, without limitation, the transfer of any direct or indirect interest in a Shareholder (a “Prohibited
Transfer”). Section 14 shall remain unaffected. Any Prohibited Transfer or other breach of such restrictions shall authorize the Shareholders to decide in a shareholder meeting the redemption of the Shares affected by the respective
breach; any Shareholder that are a (direct or indirect) transferor or transferee of such Prohibited Transfer shall be prohibited from voting. In case that at least 5% of the votes in such shareholder meeting vote (excluding any Shares or voting
rights of any transferor or transferee of such Prohibited Transfer) for the redemption all Shareholders are obliged to vote for the redemption irrespective of any quorum required by the Articles. A redemption under this Section 13 does neither
require a Series A Majority consent according to Section 5.2(iv) nor a Series B Majority consent according to Section 5.8. 
  

	14.	 Transfer to Affiliates and other Shareholders 

 

	14.1	 The restrictions and provisions in Sections 9 through 13 shall not apply with respect to transfers and sales of
Shares to (x) any Affiliate, (y) any other Shareholder or any Affiliate thereof, or (z) transfers of 143,310 Shares from Medine to a trustee of the Shares provided that the trusteeship is dated for a time period before December 2017,
in each case provided that 

  

	 	a)	 Section 9.5 shall apply; and 

 

	 	b)	 in the case of any transfer to a party other than another Shareholder or a Principal the transfer agreement
must establish an obligation of the transferor and the respective transferee vis-à-vis the Company and all other Shareholders

  
 22/44 

	 	
under which the transferor and the transferee shall be required to procure that the Shares be transferred to that Principal or any Affiliate thereof in the event that the transferee for whatever
reason ceases to be an Affiliate of that Principal or becomes a competitor of the Company or any of its subsidiaries. 

  

	14.2	 “Affiliate” shall mean any of (i) the Ultimate Parent, (ii) any entity that is
directly or indirectly wholly owned by the relevant entity or its Ultimate Parent, (iii) in the case of an entity which is an investment fund, any other investment fund advised or sub-advised by the same
investment advisor or an Affiliate thereof, (iv) in the case of an entity which is an investment fund with at least 10 investors and a capital commitment of the investors of at least 40 million Euros, any other investment fund having those
characteristics and being under the management of the fund manager of the first investment fund or an Affiliate thereof, (v) any trust whose sole beneficiary is the relevant entity or the relevant entity’s Ultimate Parent and, vice
versa, where the Shares are held in trust, the trustor of the relevant entity or person, (vi) the beneficial owner of the relevant entity or an entity that likewise is beneficially owned by that beneficial owner, (vii) in the case of
the Foundation (a) any successor charitable organization of the Foundation from time to time that is a tax-exempt organization as described in Section 501(c)(3) of the U.S. Internal Revenue Code, or
(b) any tax-exempt organization as described in Section 501(c)(3) of the U.S. Internal Revenue Code controlled by one or more trustees of the Foundation, and (viii) the beneficial owner of the
Shares or a party likewise holding the Shares for the account of that beneficial owner. “Ultimate Parent” shall mean the ultimate parent of the relevant entity (corporation, limited liability company, or partnership).
“Principal” means any of the Ultimate Parent of the transferring Shareholder, the trustor in relation to the trust holding the Shares or the Shareholder, the investment adviser (in the case of
sub-clause (iii) of the first sentence above), the fund manager (in the case of sub-clause (iii) of the first sentence above), and the beneficial owner of the
Shares or the Shareholder, in each case if applicable. 

  

	14.3	 Section 9.3 remains unaffected. 

 

	15.	 Liquidation Preference 

 

	15.1	 Upon the occurrence of a Liquidation Event (as defined below), the Liquidation Proceeds (as defined below)
shall be allocated as follows: 

  

	15.1.1	 Firstly, in priority to all other Shareholders, to each Summer 2019 LP Shareholder 

 

	 	a)	 an amount for each of its Summer 2019 LiqPref Share equal to the sum for its Summer 2019 LiqPref Shares of
(A) the Investment per Share and (B) the average arrears or accruals of dividend (if any) on each such Share (as the case may be) due or declared but unpaid down to the date of the return of assets (with the Investment per Share being
subject to adjustment for any sub-division of the Summer 2019 LiqPref Shares, and subject to the issuance of additional Shares pursuant to Section 17), or, if the Liquidation Proceeds are not sufficient
to satisfy the preference pursuant to this letter a), 

  

	 	b)	 the same fraction of the total amount which the relevant Summer 2019 LP Shareholder would receive pursuant to
letter a) if the Liquidation Proceeds were indeed sufficient to satisfy the preference pursuant to such letter a) such that all of the Liquidation Proceeds are allocated pursuant to this letter b) (as a result of which, for the avoidance of doubt,
the other Shareholders will not receive any Liquidation Proceeds) 

 (in the case of each such Summer 2019 LP Shareholder
the “First Preferred Allocation”) 

  
 23/44 

	15.1.2	 secondly, in the event that Liquidation Proceeds remain after the First Preferred Allocations, to each of the
2017/2018 LP Shareholders 

  

	 	a)	 an amount for each of its 2017/2018 LiqPref Share equal to the sum for its 2017/2018 LiqPref Shares of
(A) the Investment per Share and (B) the average arrears or accruals of dividend (if any) on each such Share (as the case may be) due or declared but unpaid down to the date of the return of assets, (with the Investment per Share being
subject to adjustment for any sub-division of the 2017/2018 LiqPref Shares, and subject to the issuance of additional Shares pursuant to Section 17), or, if the Liquidation Proceeds are not sufficient to
satisfy the preference pursuant to this letter a), 

  

	 	b)	 the same fraction of the total amount which the relevant 2017/2018 LP Shareholder would receive pursuant to
letter a) if the Liquidation Proceeds were indeed sufficient to satisfy the preference pursuant to such letter a) such that all of the Liquidation Proceeds remaining after the application of Section 15.1.1 are allocated pursuant to this letter
b) (as a result of which, for the avoidance of doubt, the Shareholders who are not Preferred Shareholders will not receive any Liquidation Proceeds) 

(in the case of each such 2017/2018 LP Shareholder the “Second Preferred Allocation” and any First Preferred Allocation or
Second Preferred Allocation a “Preferred Allocation”), 
  

	15.1.3	 thirdly, in the event that Liquidation Proceeds remain after the Preferred Allocations (i.e. only potentially
in the case of Section 15.1.2 letter a)), to each Shareholder an amount per Share equal to the Liquidation Proceeds divided by the total number of Shares in issue (in each case the “Pro Rata Share”) provided that

  

	 	a)	 for the calculation of the Pro Rata Shares it shall be disregarded that the Preferred Allocations have been
made (i.e. the Pro Rata Shares shall be calculated on the basis of the Liquidation Proceeds before deducting the Preferred Allocations), 

  

	 	b)	 to the extent a Preferred Shareholder has received a Preferred Allocation its entitlement to the Pro Rata Share
shall be deemed satisfied (i.e. it shall only receive any Pro Rata Share to the extent the Pro Rata Share exceeds its Preferred Allocation), 

  

	 	c)	 where in the case of one or more Preferred Shareholders the Pro Rata Share is less than its Preferred
Allocation, those Preferred Allocations shall, for the avoidance of doubt, not be affected and the Pro Rata Share of each other Shareholder shall reduce by the same percentage such that the total amount of such reductions is equal to the aggregate
amount by which the Pro Rata Shares of such Preferred Shareholders are less than their Preferred Allocations provided that to the extent, in the case of any such other Shareholder who is a Preferred Shareholder, such reduction would be to an amount
less than that Preferred Shareholder’s Preferred Allocation the reduction under this letter c) shall not apply and the reduction of the Pro Rata Shares of the remaining other Shareholders shall increase accordingly, and 

 

	 	d)	 if the Shortfall Amount CoC or the Shortfall Amount IPO is to be paid to the Series A Investors as provided for
in Section 5.3 and Section 5.4, the amount that would otherwise be allocated to each of the holders of Common Shares pursuant to this para. 15.1.3 will (in addition to any reduction pursuant to letter c)) be reduced by the same percentage
for each such holder of Common Shares and the amount of such reduction will additionally be allocated to the Series A 

  
 24/44 

	 	
Investors, each such as is required for the Series A Investors to receive the Shortfall Amount CoC or the Shortfall Amount IPO, respectively, it being understood, however, that such reduction
shall not be to less than nil. The aforementioned applies mutatis mutandis if the Shortfall Amount CoC is to be paid to the Series B Investors as stipulated in Section 5.8. 

 

	15.2	 A “Liquidation Event” shall mean 

 

	15.2.1	 the sale and/or transfer in one or more connected transactions of more than 50% of the Shares in Company,
irrespective of the consideration to be received (cash, shares in other companies or other consideration) and irrespective of whether new Shares or existing Shares are being sold and/or transferred, other than in the framework of an IPO; in case not
all Shares in the Company are sold or transferred within the relevant Liquidation Event the provisions under Section 15.1 and 15.2 shall only apply to the Shares sold or transferred in the relevant Liquidation Event; 

 

	15.2.2	 a share exchange, transfer of shares by contribution in kind, merger, or other reorganization within the
meaning of sec. 1 of the German Reorganization Act (Umwandlungsgesetz) if the Company is the transferring entity, provided the Shareholders have, after completion of the merger, 50 % or less of the voting rights in the absorbing entity;
or 

  

	15.2.3	 a direct or indirect (including exclusive licenses) sale of more than 50% of the assets of the Company and
subsequent distribution of the proceeds to the Shareholders (also in the context of a liquidation); or 

  

	15.2.4	 a liquidation, dissolution or winding-up of the Company.

  

	15.3	 “Liquidation Proceeds” shall mean any and all proceeds received by the Shareholders including,
but not limited to purchase prices less applicable Value-Added tax (“VAT”), reduced by all third party costs, including advisor costs of sale after settlement of all liabilities of the Company (if such liabilities are not assumed by
the acquiring party), reduced further by any other costs directly related to the Liquidation Event and incurred by the Shareholders (in particular financial and legal counsel acting for and on behalf of the Company and the Shareholders which the
Shareholders shall mutually agree upon in advising on the Liquidation Event), unless such costs are to be borne by the respective Shareholder (for the avoidance of doubt, costs incurred by the Shareholders such as taxes, financing costs or costs for
own advisors are to be borne by the Shareholders). 

  

	15.4	 In the event that the Liquidation Event consists in a share exchange, transfer of shares by contribution in
kind, merger, or other reorganization within the meaning of sec. 1 of the German Reorganization Act (Umwandlungsgesetz), or any other form of transformation, the rights set forth under this Section 15 shall be serviced by transferring to
the Shareholders shares in Company prior to the implementation of the Liquidation Event on a fair market valuation, i.e. shares transferred to the Shareholders shall be treated as consideration in application of Section 15.1.

  

	15.5	 In the event that Liquidation Proceeds are other than cash, the following shall apply: 

 

	15.5.1	 To the extent that the consideration received upon occurrence of a Liquidation Event is not in cash, for the
purpose of this Section 15 its value shall be amicably determined by the Shareholders. If no amicable determination can be reached, each dissenting Shareholder shall notify the other Shareholders of the value it considers appropriate for the
non–cash consideration. After this notice is received and if required by any of the Shareholders (the “Requesting Shareholder”), the determination shall be pursued by an auditor designated by the chairman of the IDW
(Institut der Wirtschaftsprüfer in Deutschland e.V.). Any related costs and expenses shall be allocated by the auditor in 

  
 25/44 

	 	
accordance with the application mutatis mutandis of sections 91 et seq. of the German Code of Civil Procedure (Zivilprozessordnung) between the Requesting Shareholder and the
other Shareholders in the proportion of the determination made by the auditor to the value notified pursuant to the foregoing sentence. 

  

	15.5.2	 In the event that the assets comprise securities traded on an internationally recognized securities exchange,
then – as an exemption to Section 15.5.1– the value of the securities shall be deemed to be the average of the closing prices of the securities on such exchange over the ten (10) Business Day period ending five (5) Business
Days prior to the distribution of the Liquidation Proceeds. 

  

	15.6	 The provisions of this Section 15 shall apply accordingly to any type of distribution made with respect to
the Shares and shall include in particular payments of profits, dividend claims, claims to settlements pursuant to the German Reorganisation of Companies Act (Umwandlungsgesetz), distributions of free reserves and commercially equivalent
measures. 

  

	15.7	 The Liquidation Preferences shall be deemed to be an agreement between the Shareholders even if the contrary is
agreed in the contract or contracts underlying the Liquidation Event. The Shareholders hereby in advance declare the assignment of such claims. 

  

	16.	 Initial Public Offering (IPO) 

 

	16.1	 It is the common goal of the Shareholders that an initial public offering (an “Initial Public
Offering” or “IPO”) is the preferred option to realize the value of the Company, and subject to prevailing market conditions and after consultation of the Shareholders, and subject to the provisions according to
Section 5.2(ii), the Company will be entitled to initiate an IPO. 

  

	16.2	 Subject to the consent or deemed consent of the Series A Majority required pursuant to Section 5.2(ii),
the Company shall have the sole power to direct any IPO process, to decide about its scope, disclosure of information, timing, advisors, termination and the like, and shall be entitled to negotiate any transaction documents, provided that in each
case the Company shall consult with the other Shareholders on the general strategy of the IPO process. 

  

	16.3	 To the extent applicable, given that the preferences of the Series A Shares are set forth in this Agreement,
each holder of Series A Shares shall be entitled at any time to request to have its Series A Shares converted into Ordinary Shares. In doing so, such holder of Series A Shares may further request that its Series A Shares shall be treated, for all
purposes of this Agreement, as if they were converted into Ordinary Shares with immediate effect, and all Parties shall comply with such request even before the conversion is implemented. In case a conversion of Series A Shares into Ordinary Shares
is implemented in preparation of an IPO, and unless a Series A Majority has requested otherwise, the Parties shall treat each other, during the time period from such conversion until the successful implementation of the IPO, as if the holders of the
so converted Shares would still hold respective Series A Shares and be holders of Series A Shares. Furthermore, the Series A Majority is entitled to demand from the other holders of Series A Shares, in particular, but not limited with the
consummation of an IPO that the Series A Shares held by it be converted, whether individually or in total, into Ordinary Shares at a ratio of 1:1. 

  

	16.4	 Each Shareholder shall exercise its voting rights attached to its respective Shares in the Company (insofar as
it is able to do so, having regard to the voting rights conferred upon the Shares held by the relevant Shareholder, if any) and take any and all other customary and commercially reasonable action solely in its capacity as a Shareholder of

  
 26/44 

	 	
the Company (including, without limitation, waiving any and all legal and/or statutory requirements as to form and notice for the calling and holding of a shareholders’ meeting and the
passing of a shareholders’ resolution) to cooperate and support in its capacity as Shareholder any action or transaction as reasonably proposed to be taken by the Company in connection with such IPO (for clarity, this Section 16.4 shall
not require the Series A Majority to consent to an IPO in which the Company’s Shares are sold at less than the Return Threshold except if the difference is compensated by the Company or the Existing Shareholders as the case may be). In
particular, the Parties shall, to the extent legally possible, use its influence and admit that: 

  

	16.4.1	 the Company prepares a data room and permits a due diligence; 

 

	16.4.2	 the Company sets up a business plan; 

 

	16.4.3	 the management of the Company performs any management presentations as required or feasible; and

  

	16.4.4	 the Company prepares an offering prospectus in line with applicable law. 

 

	16.5	 The Shareholders shall not be obliged to provide any representations, warranties or undertakings in relation to
an IPO, except as to the ownership of their Shares sold in an IPO. 

  

	16.6	 The underwriter may request, and the Shareholders shall then sign and accept, but only if and to the extent
that at least 99% of the other Shareholders sign and accept, agreements or undertakings concerning transfer restrictions relating to the listed shares on customary market terms and subject to the particularities of the IPO, notably transfer
restrictions for a lock-up period which shall be reasonably determined by the underwriter in accordance with the then customary market practice and the particularities of the IPO to ensure a successful IPO
(the “IPO Lock-Up Period”). The Shareholders will use best efforts to minimize any restrictions requested by the underwriter. Notwithstanding anything to the contrary herein, nothing in this
Agreement shall restrict, or require any Shareholder from entering into a lockup agreement that restricts, any Shareholder from transferring any Shares acquired in the IPO or in open market transactions following the IPO. 

 

	16.7	 The Parties shall have pro rata rights, but no obligation, to sell their Shares in the Company to the extent
existing Shares are to be placed in the IPO through a secondary placement (the “Secondary Placement”). Should one Shareholder not (fully) exercise its rights to place its pro rata portion in the secondary placement the other
Shareholders may increase the volume of their sale pro rata. 

  

	16.8	 Subject to the IPO Lock-Up Period and customary co-ordination obligations for block trades, all Shareholders of the Company shall be free to dispose of their Shares in the Company upon completion of the IPO. 

 

	16.9	 After completion of an IPO, each of the Shareholders shall be entitled to sell its Shares, subject to any
applicable lock-up obligations and subject to any rules applying to block trades, via the stock exchange and/or private placements. 

 

	16.10	 The costs of any IPO process (whether successful or not) initiated by the Company shall be borne by the Company
and/or any of its subsidiaries, to the extent legally permitted and, if not so, by the Shareholders in proportion to the Shares sold or to be sold by them (based on sales proceeds) in such IPO. 

  
 27/44 

	17.	 Anti-Dilution Protection 

 

	17.1	 In the event of any additional increases of the Company’s registered share capital prior to (but not
including) the IPO, each Shareholder shall have the statutory subscription rights under existing German Law to subscribe to such number of new Shares resulting from the capital increase as is necessary to preserve the Shareholder’s pre-capital increase shareholding and voting rights, subject to any authorization to exclude pre-emptive rights as is provided in an authorized capital (genehmigtes
Kapital) pursuant to the Articles (i) in the version put into effect by the Shareholders’ Resolution of 29 December 2017 or (ii) in any amended version of the Articles. Parties shall use their best influence that Company does
not undermine the preceding sentence. The subscription rights of holders of Series A Shares may not be cancelled by a resolution of the shareholders’ meeting without the prior written consent of a Series A Majority nor may any amendment to the
Articles expanding the then existing authorizations to exclude pre-emptive rights be resolved without such consent. Notwithstanding anything to the contrary in this first paragraph of this Section 17.1,
the Shareholders shall upon the request of the Company consent to the exclusion of pre-emptive rights, and to establishing and expanding authorizations in an authorized capital to so exclude pre-emptive rights, as to the issuance of Shares for the purpose of compensating subscribers for breaches of guarantees under the relevant investment agreement (“Remedial Issuance”).

 If a Shareholder so subscribes in any additional capital increases and if the Shareholders can sell shares under the IPO
(Secondary Placement), the subscribing Shareholders in such additional capital increases shall each have the pro rata right to sell Shares so additionally subscribed, but not, in any case, exceeding, in the aggregate, 50% of such Secondary
Placement. 
 The Shareholders shall also have the right to subscribe to share issuances of any
Spin-out company as is necessary for the Shareholders to maintain, in such Spin-out company, in aggregate a direct and indirect (as a Shareholder of the Company)
shareholding up to their respective shareholding of the Company immediately prior to such spin-out. A “Spin-out” company is defined as a company founded
by the Company or its affiliates with the expectation that third parties may invest into such company. 
  

	17.2	 Section 17.1 shall not apply to capital increases to perform an IPO. 

 

	17.3	 At each time after the 2017 Capital Increase when (other than in the framework of the IPO and Remedial
Issuances) new Shares are issued by the Company to any person by way of a capital increase against contribution in cash or in kind (each a “Further Financing Round”) and the volume-weighted average price per Share (including any
premiums or similar payments into the capital reserves of the Company) under collectively that Further Financing Round and all previous Further Financing Rounds (if any) (such volume-weighted average Share price the “Further Financings
Price”) is less than the volume-weighted average price per Share paid by the holder of Series A Shares under collectively the 2017 Capital Increase, that Further Financing Round and all previous Further Financing Rounds (if any) (the
“Average Investor Share Price”), the respective holder of Series A Shares shall be entitled to subscribe for such number of new Shares against cash contribution of Euro 1.00 per Share (i.e. without any further premiums or additional
payments in the capital reserves of the Company) as is necessary in order to increase the number of Shares actually issued to the respective holder of Series A Shares to in aggregate such number of Shares in the Company which under collectively the
2017 Capital Increase, that Further Financing Round and all previous Further Financing Rounds (if any) would have been allotted to the respective holder of Series A Shares against its aggregate investment under such occasions if the

  
 28/44 

	 	
issuance price at all of such occasions had been the Further Financings Price (“Compensatory Issuance”), it being understood that for the above computations the Compensatory
Issuances preceding the relevant Further Financing Round (if any) are to be considered previous Further Financing Rounds; the shares issued under a Compensatory Issuance shall be the “Compensatory Shares”. For the calculation of the
Further Financings Price, the Average Investor Share Price and the Compensatory Shares the formulas stipulated in Annex 17.3 apply. Compensatory Shares shall be Series A Shares. For the avoidance of doubt, in the case of a down-round, the
Return Threshold will be adjusted after each issuance of Compensatory Shares by multiplying the Return Threshold by the ratio of the number of Shares to the sum of number of Shares and number of all issued Compensatory Shares. 

 

	17.4	 In the event that Section 17.3 applies, the Compensatory Issuance shall be resolved immediately after each
or together with each subsequent Further Financing Round. The Existing Shareholders shall waive any statutory or contractual subscription rights in connection with the Compensatory Issuance. 

 

	17.5	 Each holder of Series A Shares shall be entitled to the down-round protection set forth in Sections 17.3
through 17.4 only 

  

	 	(i)	 with respect to each and any capital increase prior to the first Qualified Financing (“First Qualified
Financing”) following the 2017 Capital Increase without any qualification or minimum requirement; 

  

	 	(ii)	 with respect to the First Qualified Financing, if such holder of Series A Shares invests at least the lower of
(i) 40% of the Investment of the respective holder of Series A Shares in the course of the Series A Financing, or (ii) USD 10,000,000 (in words: US-Dollar ten million), or (iii) the maximum amount
otherwise permitted for such holder of Series A Shares to invest in the First Qualified Financing (and, provided, in each case, such investment is on the same terms and conditions as each other investor in the First Qualified Financing) (such holder
of Series A Shares so investing, being a “Participating Investor”); and 

  

	 	(iii)	 For each Participating Investor and if anti-dilution rights were granted to any of the investors in the First
Qualified Financing, with respect to each and any capital increase prior to the first Qualified Financing following the First Qualified Financing (the “Second Qualified Financing”) without any qualification or minimum requirement.

  

	 	(iv)	 For each Participating Investor and if anti-dilution rights were granted to any of the investors in the First
Qualified Financing, with respect to the Second Qualified Financing, if (b) such Participating Investor invests also at least the lower of (i) 40% of the Investment of the respective holder of Series A Shares in the course of the Series A
Financing, or (ii) USD 10,000,000 (in words: US-Dollar ten million), or (iii) the maximum amount otherwise permitted for such holder of Series A Shares to invest in the Second Qualified Financing
(and, provided, in each case, such investment is on the same terms and conditions as each other investor in the Second Qualified Financing). 

For the avoidance of doubt, where in case of (ii) or (iv) above a Series A Investor is not admitted to subscribe to any new shares in the
respective Qualified Financing, such Series A Investor shall still be entitled to the down-round protection set forth in Sections 17.3 and 17.4. After the Second Qualified Financing, no holder of Series A Shares and no other Shareholder shall be
entitled to any further down-round protection according to this Section 17 and each holder of Series A Shares not investing in a Qualified Financing, shall lose its entitlement to such down-round protection according to this Section 17.

  
 29/44 

	17.6	 A “Qualified Financing” means a subsequent financing round following the 2017 Capital Increase
pursuant to which the Company issues new shares and which such issuance of new shares results in aggregate gross proceeds to the Company of at least USD 100,000,000 (in words: US-Dollar one hundred million).

  

	17.7	 Clauses 17.3 through 17.6 (the “Down-round Clauses”) shall apply mutatis mutandis for
the benefit of any 2018 Qualifying Investor provided that 

  

	17.7.1	 for the purposes of this Clause 17.7, the terms “Series A Share”, “holder of Series A
Shares” and “2017 Capital Increase” as used in the Down-round Clauses shall mean 2018 Qualifying Share, 2018 Qualifying Investor and the relevant 2018 Qualifying Investor’s 2018 Qualifying Investment, respectively,

  

	17.7.2	 where the actual volume-weighted average price per Share under a Further Financing Round is less than USD 237,
the volume-weighted average price per Share under that Further Financing Round shall for the purposes of this Clause 17.7 be deemed to amount to USD 237 (and the calculations under this Clause 17.7 in conjunction with the Down-round Clauses shall be
made on this basis rather than on the basis of the actual volume-weighted average price per Share under that Further Financing Round), 

  

	17.7.3	 for the purposes of this Clause 17.7, in each of paragraphs (ii) and (iv) of Clause 17.5, the number
“10%” shall be substituted for the number “40%” and the amount of USD 7,500,000 shall be substituted for the amount of USD 10,000,000. 

  

	17.8	 The Down-round Clauses shall apply mutatis mutandis for the benefit of any Series B Investor
provided that for the purposes of this Section 17.8, the terms “Series A Share”, “holder of Series A Shares” and “2017 Capital Increase” as used in the Down-round Clauses shall mean Series B Share, Series B
Investor and the relevant Series B Investor’s Series B Investment, respectively. 

  

	17.9	 The Down-round Clauses shall apply mutatis mutandis for the benefit of the Foundation provided
that 

  

	17.9.1	 for the purposes of this Section 17.9, the terms “Series A Share”, “holder of Series A
Shares” and “2017 Capital Increase” as used in the Down-round Clauses shall mean Foundation Share, Foundation and the relevant Foundation Investment, respectively, 

 

	17.9.2	 where the actual volume-weighted average price per Share under a Further Financing Round is less than USD 237,
the volume-weighted average price per Share under that Further Financing Round shall for the purposes of this Clause 17.9 be deemed to amount to USD 237 (and the calculations under this Clause 17.9 in conjunction with the Down-round
Clauses shall be made on this basis rather than on the basis of the actual volume-weighted average price per Share under that Further Financing Round), and 

  

	17.9.3	 for the purposes of this Clause 17.9, in each of paragraphs 17.5(ii) and 17.5(iv) of Clause 17.5, the
number “10%” shall be substituted for the number “40%” and the investment threshold of USD 10,000,000 shall not apply. 

  

	18.	 Reporting, Information, Inspection Rights and Further Undertakings 

 

	18.1	 Each Shareholder has the relevant statutory information and inspection rights vis-à-vis the Company. 

  

	18.2	 In addition, the Company shall furnish the following information within the relevant prescribed time periods to
all Shareholders: 

  

	18.2.1	 Within four (4) months after the expiration of a financial year: audited annual financial statements of
the Company. 

  
 30/44 

	18.2.2	 Within sixty (60) calendar days after the expiration of a quarter of a financial year: unaudited quarterly
financial information of the Company. 

  

	18.2.3	 Until first of December of each year: annual budget of the Company for the following financial year.

  

	18.2.4	 The provisions of Annex 18.2.4 apply with respect to the Company and in favour of the Redmile Investors
and in favour of Fidelity Management & Research Company. 

  

	19.	 Confidentiality 

 

	19.1	 Each Party shall keep confidential (and shall use reasonable endeavors to ensure that its officers, employees,
agents and professional and other advisers keep confidential) any information relating to the business of the Company or its subsidiaries or any of the customers or suppliers which it may have or acquire before or after the date of this Agreement as
well as any information relating to this Agreement and the Parties hereto (collectively the “Confidential Information”) except for: 

  

	19.1.1	 information which is independently developed by the relevant Party from information provided other than
pursuant to this Agreement or acquired from a third party to the extent that it is acquired with the right to disclose the same; 

  

	19.1.2	 information which is at the date of disclosure within the public domain (other than as a result of a breach of
this Section 19); or 

  

	19.1.3	 information which the Party is obliged to disclose or announce under mandatory law or the rules of any other
official body or regulatory authority or any court of competent jurisdiction. 

  

	19.2	 In performing its obligations under this Section 19, each Party shall apply confidentiality standards and
procedures at least as stringent as those it applies generally in respect of its own business and affairs, however at least standards of a prudent businessman. 

 

	19.3	 No Party shall use any Confidential Information for any purpose other than its shareholding in the Company or
its affairs with the Company and making decisions in relation to that shareholding or affairs. 

  

	19.4	 The obligation of confidentiality under this Section 19 shall not apply to the disclosure of Confidential
Information: 

  

	19.4.1	 to any professional advisers of a Party or its affiliate of information reasonably required to be disclosed for
a purpose reasonably incidental to this Agreement; 

  

	19.4.2	 to an Affiliate of a Party; and 

 

	19.4.3	 to any direct or indirect, actual or potential investor in a Shareholder or the Company, 

provided that in each case that any disclosure shall be made on a confidential basis. 

 

	19.5	 Each Party is responsible for any breach of this Section 19 by any person to whom the Confidential
Information is disclosed by such Party as if such disclosure had been made by the respective Party itself. 

  

	20.	 No Assignment 

No Party may assign any or all of its rights or obligations under this Agreement, without the prior written consent of the other Parties except
as permitted pursuant to 

  
 31/44 

 
Section 14. This Agreement will inure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns. 

 

	21.	 Form of Notices; Written Form; Special Notice 

 

	21.1	 Any notice or other declaration hereunder (a “Notice”) shall be made at least in text form
(Textform) in accordance with Section 126b German Civil Code (Bürgerliches Gesetzbuch) unless any other specific form is required under this Agreement. 

 

	21.2	 Any requirement in this Agreement for an act or agreement to be “in writing” or in “written
form” or similar may in any event be satisfied by way of the relevant party executing the relevant document and transmitting an electronic copy of the document to the recipient, by email or otherwise. 

 

	21.3	 “Special Notice” means a notice in writing by the Company to each of the other Parties
provided that such notice shall be deemed received by each such other Party if any member of the management board of the Company certifies in writing that the Company has in good faith attempted to transmit such notice to each of the other Parties
at the postal or email address last provided by the relevant Party and it does not have any reason to believe that such notice has not reached each of the other Parties. 

 

	22.	 Delivery Addresses and Authorized Recipients 

 

	22.1	 Each Party shall, at any time while a Party to this Agreement, keep the Company informed of such Party’s
current mailing address and contact data. As of the date hereof, the Parties may direct any and all Notices to be issued in connection with this Agreement or otherwise in relation to the Company vis-à -vis another Party, to the persons and addresses set forth in Annex 22.1, and any Notices directed to such persons and addresses shall be deemed received by the respective Party, to which such Notice is addressed,
subject to the provisions set out in Section 21. 

  

	22.2	 If any Party to this Agreement wishes to change its delivery address, such Party shall inform the other Parties
in writing thereof, and such change shall become effective for the purposes of this Agreement and, in particular, this Section 21, upon the lapse of ten (10) days as of receipt of such information, provided that the first sentence of this
Section 22.1 is complied with. 

  

	22.3	 The persons stated in Annex 22.1 shall be authorized recipients (the “Authorized Recipients”)
for the respective Parties, including for the purposes of serving any statements, applications, declarations, correspondence or court orders relating to disputes in respect of this Agreement or otherwise in connection with the Company
(Zustellungsbevollmächtigte), provided that each such Authorized Recipient shall have an adequate post address for delivery in the Federal Republic of Germany. Section 22.1, last sentence, shall apply accordingly.

  

	22.4	 The receipt of copies of Notices by the Parties’ advisors as set out in Annex 22.1 shall not constitute or
substitute the receipt of such Notices by the Parties themselves. Any Notice hereunder shall be deemed received by a Party regardless of whether any copy of such Notice has been sent to or received by an advisor of such Party as set out in Annex
22.1, irrespective of whether the delivery of such copy was mandated by this Agreement. 

  

	22.5	 The Parties agree that Annex 22.1 is not finalized at execution of this Agreement. They are obliged to
deliver the relevant data within 4 weeks after execution of this Agreement and after that such data and the collecting Annex 22.1 will be part of this Agreement. 

  
 32/44 

	23.	 Accession to Shareholders’ Agreement 

In the event that a transfer of Shares in the Company (or an issuance of Shares in the Company in the case of an additional capital increase)
is intended to a person or to the benefit of a person which is not a Party to this Agreement, all Parties shall procure that, prior to or concurrently with, the relevant transfer becoming effective: (i) all obligations of the transferring
Shareholder continue to be fulfilled after such transfer has been effected, and (ii) a person which as a result of the transfer becomes a shareholder of the Company accedes to this Agreement pursuant to Section 24.4 as
‘Shareholder’ and ‘Party’ unconditionally and without any restrictions and assumes any and all rights and obligations of the transferring Shareholder pursuant to this Agreement and consequently accepts as binding all declarations
made by the transferring Shareholder in this Agreement. The foregoing shall not apply in the event that all Shares in the Company are transferred to a third party. 
  

	24.	 Scope and Amendment of this Agreement 

 

	24.1	 The Shareholders hereby accede to this Agreement with all existing Shares. 

 

	24.2	 This Agreement shall apply to any and all Shares of the Company held by any of its Parties and any Shares a
Party may acquire (irrespective of the nature of such share and its acquisition) shall automatically be subject to this Agreement with no further action required. If a new shareholder accedes to this Agreement or if succession (irrespective of the
nature of such succession) occurs with respect to a Shareholder or a Party who is a Party to this Agreement, then this Agreement shall become binding and effective with respect to all Shares in the Company held by the (new) shareholder or the
succeeding shareholder, respectively. 

  

	24.3	 The Parties shall procure that during the term of this Agreement all shareholders of the Company are or become
a party to this Agreement. 

  

	24.4	 The Parties hereby irrevocably make an offer, and in addition each of them grants irrevocable power of attorney
to the Company and to any Shareholder to on behalf of the relevant Party make an offer, to any legal or natural person that is contemplated to acquire or to subscribe to Shares in the Company to enter into an agreement exclusively to the effect that
such person accedes to this Agreement as ‘Shareholder’ and ‘Party’, thereby waiving the receipt of any declaration of acceptance pursuant to Section 151 sentence 1 German Civil Code (Verzicht auf den Zugang der
Annahmeerklärung), provided that (i) upon any amendment to this Agreement such offer and power of attorney shall relate to the accession to this Agreement as so amended and (ii) any such accession shall be
conditional on the relevant person actually becoming a Shareholder. Any acceptance of such offer shall only be valid provided that (i) it is declared without any condition, addition or other modification of this Agreement, and (ii) it
occurs vis-à -vis the Company in writing with binding effect for all Parties to this Agreement. 

 

	24.5	 The Company shall inform the Parties immediately of any accession to this Agreement. In the event that an
acquirer or subscriber of Shares in the Company refuses to accede to this Agreement without any condition, addition or other modification of this Agreement or in writing, all Shareholders of the Company shall refuse to grant their consent to the
relevant transfer, issuance or subscription of shares in the Company pertaining to such acquirer or subscriber. 

  

	24.6	 Any rights and obligations pursuant to this Agreement shall be effective vis-à-vis the Parties as of today. Any rights and obligations pursuant to this Agreement shall cease at the latest upon forfeiture of the status of shareholder in the Company and upon

  
 33/44 

	 	
discharge of all rights and obligations of a former shareholder resulting from the status of shareholder or pursuant to this Agreement. 

 

	25.	 Term and Termination 

 

	25.1	 This Agreement becomes effective at the date hereof. It runs for an indefinite term and can be terminated by
each Party with a notice period of twelve (12) months in each case to the calendar year, however, for the first time with effect as of 31st December 2030 and the Parties hereby agree that this is a reasonable period. 

 

	25.2	 The right to terminate for good cause (aus wichtigem Grund) remains unaffected. 

 

	25.3	 In the event of the full implementation of an IPO of the Company this Agreement shall cease to have effect. The
IPO shall be deemed to be fully implemented in this sense with the start of trading on a stock exchange. For the avoidance of doubt, the provisions as set forth in Section 15 shall not be applicable in case of an IPO. 

 

	25.4	 If a Shareholder disposes of all of its shares in the Company, such Shareholder shall cease to be a Party to
this Agreement with effect as of such disposal; Section 25.5 remains unaffected. 

  

	25.5	 Any expiration of or termination of this Agreement or any Party ceasing to be a Party to this Agreement shall
be without prejudice to the rights, obligations or liabilities of any Party which have accrued or arisen prior to the expiration or termination date. 

  

	26.	 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of the Federal Republic of Germany, excluding the provisions of
private international law thereof. 
  

	27.	 Massachusetts Business Trust 

A copy of the Agreement and Declaration of Trust of Janus Investment Fund (“Trust”) is on file with the Secretary of State of
the Commonwealth of Massachusetts and all Shareholders acknowledge that this Agreement is executed on behalf of the trustees of the Trust or any affiliate thereof as trustees and not individually and that the obligations of this Agreement are not
binding on any of the trustees, officers or stockholders of the Trust or any affiliate thereof individually but are binding only upon such investor or any affiliate thereof and it assets and property. 

 

	28.	 Arbitration 

  

	28.1	 Any dispute, controversy or claim arising from or in connection with this Agreement or its validity shall be
finally settled by three arbitrators in accordance with the Arbitration Rules of the German Institution of Arbitration e.V. (DIS) as applicable at the time of filing the claim, without recourse to the ordinary courts of law. The place of arbitration
shall be Frankfurt am Main, Germany. The number of arbitrators is three. The language of the arbitral proceedings shall be English, provided, however, that written evidence and other supporting documentation may also be submitted in the German
language. The applicable substantive law is the law of the Federal Republic of Germany. 

  

	28.2	 In the event that mandatory applicable law requires any matter arising out of or in connection with this
Agreement and its execution to be decided upon by an ordinary court of law, the competent courts in Frankfurt am Main shall have the exclusive jurisdiction. 

  
 34/44 

	29.	 Amendments 

  

	29.1	 Subject to the succeeding paragraphs of this Section 29, amendments to this Shareholders’ Agreement,
including this written form requirement, must be made by agreement between all Parties in writing in order to become enforceable and effective unless mandatory law requires a stricter form. 

 

	29.2	 Any amendment to this Agreement, other than any of the amendments specified in Section 29.4, may, if the
prerequisites in Section 29.3 are met, also be made by way of 

  

	 	a)	 the Company by Special Notice making a proposal to each of the other Parties specifying in which way this
Agreement is to be amended (the “Proposal for Amendment”), thereby transmitting a comparison between the Agreement in the form in effect at the relevant time and the Agreement as it will read following the amendment and providing a
form to be used by Shareholders for providing their consent to the amendment (the “Consent Form”), 

  

	 	b)	 within two weeks after the Proposal for Amendment has been sent, Shareholders who in the aggregate hold at
least 60% of the Shares consenting to the Proposal for Amendment in writing, thereby using the Consent Form, provided that all of Medine, ATI, at least one Redmile Investor, and at least one Fidelity Investor must be among the Shareholders so
consenting, and 

  

	 	c)	 the Company by Special Notice confirming that the prerequisites in paragraphs a) and b) have been satisfied and
that upon the confirmation pursuant to this paragraph c) the amendment of this Agreement as per the Proposal for Amendment will take effect pursuant to its terms. 

 

	29.3	 The following prerequisites must be met in order for an amendment to this Agreement to be made pursuant to
Section 29.2: 

  

	 	a)	 To the extent the Proposal for Amendment alters the legal position of any of the
Pre-Amendment Shareholders relative to other Shareholders (existing or future) it must so benefit or burden all Pre-Amendment Shareholders equally provided that
establishing rights or preferences for the holders of New Letter Shares (collectively the “New Preferences”) as such shall be deemed not to violate this prerequisite (with “New Letter Shares” being Shares to be
issued after the amendment has taken effect). 

  

	 	b)	 To the extent the Proposal for Amendment establishes New Preferences this Agreement as amended must, as to each
issuance of the relevant New Letter Shares, either prohibit the Company from issuing the New Letter Shares to any of the Pre-Amendment Shareholders and any of their Affiliates altogether or require the Company
to give all Pre-Amendment Shareholders opportunity to subscribe for the New Letter Shares (and where the number of New Letter Shares available for subscription by the
Pre-Amendment Shareholders is less than the number to which such Pre-Amendment Shareholders would wish to subscribe, to do so pro rata to their shareholdings as
of the date of the pertinent resolution to increase the Company’s stated capital). 

  

	29.4	 The following amendments cannot be made pursuant to Section 29.2 (but require the agreement of each of the
Shareholders): 

  

	 	a)	 Reduction of the shareholding threshold of 10% in Section 11.1 (relevant for scope of ongoing restrictions
to be potentially incurred by tag-seller); 

  
 35/44 

	 	b)	 elimination wholly or in part of the restriction to the exercise of the Drag Along Right set out in sub-clause (ii) of Section 12.1 (proceeds per Share to be at least equal to Investment per Share); and 

  

	 	c)	 elimination wholly or in part of the restriction to the exercise of the Drag Along Right set out in the last
sentence of Section 12.2 (full consideration to be in cash or in freely disposable listed securities within the meaning of section 31 para. 2 of the German Takeover Act (WpÜG)). 

 

	30.	 Interpretation 

 

	30.1	 The headings and sub-headings of the Sections contained herein are for
convenience and reference purposes only and shall not affect the meaning or construction of any of the provisions hereof. 

  

	30.2	 Any reference made in this Agreement to any types of companies or participations, proceedings, authorities or
other bodies, rights, institutions, regulations or legal relationships (herein collectively referred to as the “Legal Terms”) under German law shall extend to any corresponding or identical Legal Terms under foreign law to the
extent that relevant facts and circumstances must be assessed under such foreign law. Where no corresponding or identical Legal Terms under foreign law exist, such Legal Terms shall be introduced as – functionally – come closest to the
Legal Terms under German law. Where the English wording of this Agreement is followed by a German Legal Term set in parenthesis and in italics, the German legal term shall prevail. 

 

	30.3	 All annexes attached hereto form an integral part of this Agreement. 

 

	31.	 No side agreements 

 

	31.1	 With the exception of the agreements set forth in Section 31.2, this Agreement constitutes the final,
complete expression of agreement between the Parties with respect to the subject matter covered herein and supersedes any and all previous negotiations, agreements and understandings, whether written or verbal, between all of the Parties, with
respect to the subject matter of this Agreement or parts thereof in particular but not limited to the shareholders’ agreement dated 10 November 2008, as amended through and as of the date hereof including on 10 May 2010 and 7/12
February 2014, and there are no side agreements to this Agreement. 

  

	31.2	 For the avoidance of doubt, those agreements between Shareholders regarding sales of shares and regarding
replacement of liquidation preferences set forth in Annex 31.2 and any rights and obligations still outstanding from time to time under any of the investment agreements entered into between the Company and any investor at any time
after December 28, 2017 shall survive and remain between the respective parties of such agreements in full force and effect. 

  

	32.	 Consent to Sideletter 

All Parties declare their consent (in the sense of Section 5.2) to the Side Letter attached as Annex 32. They
enter into this Annex 32. 
  

	33.	 Costs 

Save as agreed otherwise in the Investment Agreement, each Party will bear their own fees and expenses in connection with this Agreement and in
connection with the Capital Increases; provided, however, that the Company will bear the costs of its legal counsel regarding the drafting of this Agreement. 

  
 36/44 

	34.	 Currency Conversion 

Any amounts set forth herein and designated in US-Dollar but available only in EUR (e.g. in assessing
whether a minimum investment is made in the case of Qualified Financing under Section 17.5), such currencies shall be converted applying the average last 12 month (LTM) conversion rate. 

 

	35.	 Announcements 

No announcements shall be made by any party naming Fidelity or its affiliates without prior written consent of Fidelity or the respective
affiliate. The same applies to the Redmile Investors, Kendal Global and Filet Capital. 
  

	36.	 Independent Nature of Investors’ Obligations and Rights 

The obligations of each Shareholder under this Agreement, or any such related agreement, are several and not joint with the obligations of each
other Shareholder, and no Shareholder shall be responsible in any way for the performance of the obligations of any other Shareholder under this Agreement. Nothing contained herein or in any related agreement, and no action taken by any Shareholder
pursuant thereto, shall be deemed to constitute the Shareholders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Shareholders are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated by this Agreement or any other related agreement. Each Shareholder acknowledges that no other Investor will be acting as agent of such Shareholder in enforcing its rights under this Agreement.
Each Shareholder shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Shareholder to be joined as an additional party in
any proceeding for such purpose. 
 The obligations of each investor under this Agreement are several and not joint with the obligations of
each other investor, and no Shareholder shall be responsible in any way for the performance of the obligations of any other Shareholder under this Agreement. 
  

	37.	 Severability 

Should any provision of this Agreement be or become invalid, ineffective or unenforceable as a whole or in part, the validity, effectiveness
and enforceability of the remaining provisions shall not be affected thereby. Any such invalid, ineffective or unenforceable provision shall have to be replaced by the Shareholders by such valid, effective and enforceable provision as comes closest
to the economic intent and purpose of such invalid, ineffective or unenforceable provision as regards subject-matter, amount, time, place and extent. The aforesaid shall apply mutatis mutandis to any gap in this Agreement. 

  
 37/44 

 SUMMER 2019 PARTIES 

 

	 	1.	 Medine GmbH[***] 

- “Medine” - 
  

	 	2.	 C.Huber2008 GmbH[***] 

- “C.Huber2008” - 
  

	 	3.	 AT Impf GmbH[***] 

- “ATI” - 
  

	 	4.	 MIG GmbH & Co. Fonds 7 KG[***] 

- “MIG 7” - 
  

	 	5.	 MIG GmbH & Co. Fonds 8 KG[***] 

- “MIG 8” - 
  

	 	6.	 MIG GmbH & Co. Fonds 9 KG[***] 

- “MIG 9” - 

- MIG 7, MIG 8 and MIG 9 individually or together also referred to as one or the
“MIG-Fonds” - 
 - Medine, ATI and the
MIG-Fonds together the “Majority Shareholders” and each a “Majority Shareholder” 
  

	 	7.	 Salvia GmbH[***] 

- “Salvia” - 
  

	 	8.	 Mr. Helmut Jeggle[***] 

- “Mr. Jeggle” - 
  

	 	9.	 Mr. [***] Krauth[***] 

 - “Mr. Krauth” - 

 

	 	10.	 Tofino GmbH[***] 

- “Tofino” - 
  

	 	11.	 RLG GmbH[***] 

- “RLG” - 
 - all of
(1) through and including (11) hereinafter the “Existing Shareholders” and each an “Existing Shareholder” - 
  

	 	12.	 [***] 

- “Redmile 1”- 
  

	 	13.	 (Omissis.) 

 

	 	14.	 [***] 

- “Redmile 3”- 
  

	 	15.	 [***] 

- “Redmile 4”- 
  

	 	16.	 [***] 

- “Redmile 5”- 
  

	 	17.	 [***] 

- “Redmile 6” – 
  

	 	18.	 [***] 

- “Redmile 7” – 
  

	 	19.	 [***] 

- Redmile 8- 
 -
Redmile 1, Redmile 3, Redmile 4, Redmile 5, Redmile 6, Redmile 7, and Redmile 8 
 individually or together also referred to as one or the
“Redmile Investors” 
  

	 	20.	 [***] 

- Fynveur - 
  

	 	21.	 [***] 

- Fidelity HEAL - 
  

	 	22.	 [***] 

  
 39/44 

 - Fidelity FAHEAL - 

 

	 	23.	 [***] 

- Fidelity CIPHEAL - 
  

	 	24.	 [***] 

- Fidelity VIPHLT - 
  

	 	25.	 [***] 

- Fidelity FSGRWCO - 
  

	 	26.	 [***] 

- Fidelity GRTHCOCP - 
  

	 	27.	 [***] 

- Fidelity GROWTHCO - 
  

	 	28.	 [***] 

- Fidelity EPG - 
  

	 	29.	 [***] 

- “Fidelity VIPG ” – 
  

	 	30.	 [***] 

- Fidelity FASEGFD - 
  

	 	31.	 [***] 

- Fidelity F/EQG - 
  

	 	32.	 [***] 

- Fidelity CONT2 - 
 - the
parties listed in nos. 21 through 32 collectively referred to as the Fidelity Investors 
 and each of them individually as a
Fidelity Investor - 
  

	 	33.	 [***] 

Janus Fund 
  

	 	34.	 [***] 

- Janus PLC – 
 - the
parties listed in nos. 33 and 34 collectively referred to as the Janus Investors 
 and each of them individually as a Janus
Investor - 
  

	 	35.	 [***] 

- First Capital – 

  
 40/44 

	 	36.	 [***] 

- “Kendal Global” – 
  

	 	37.	 [***] 

- “Filet Capital” – 

- all of (12) through and including (37) hereinafter 

the “New Investors” and each an “New Investor” – 

and the New Investors and ATI collectively referred to as the “Series A Investors” 

and each of them, only with respect to their respective Series A Shares, a “Series A Investor”, 

 

	 	38.	 Mr. Sean de Gruchy Marett[***], acting solely as indirect Shareholder of the Company

 - “Mr. Marett” - 
  

	 	39.	 Dr. Sierk Poetting[***], acting solely as indirect Shareholder of the Company

 - “Dr. Poetting” - 
  

	 	40.	 Prof. Dr. Ugur Sahin[***], acting solely as indirect Shareholder of the Company

 - “Prof. Dr. Sahin” - 
  

	 	41.	 Prof. Dr. Christoph Huber[***] acting solely as indirect Shareholder of the Company

 - “Prof. Dr. Huber” – 

 

	42.	 Pfizer Inc., a corporation organized and existing under the laws of Delaware and having its principal
place of business at 235 East 42nd Street, New York, New York 10017 United States 

- “Pfizer” - 
  

	 	43.	 [***] 

- “Sanofi” - 
  

	 	44.	 [***] 

- “Eli Lilly” – 

  
 41/44 

	 	45.	 [***] 

- Heiligeland - 
  

	 	46.	 [***] 

- Sa Bassa - 
  

	 	47.	 [***] 

- Jebsen & Company ) 

 

	 	48.	 [***] 

- HMJ) 
  

	 	49.	 [***] 

- Klösges – 
  

	 	50.	 [***] 

- PIHF - 
  

	 	51.	 [***] 

- PEF - 
  

	 	52.	 [***] 

- Asia Growth Fund - 
  

	 	53.	 [***] 

- MAGI HK - 

	 	54.	 [***] 

- MAS HK - 
  

	 	55.	 [***] 

- “Boorberg” - 
  

	 	56.	 [***] 

- “Steam Athena“ - 
  

	 	57.	 [***] 

- „BVCF„- 
  

	58.	 Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation organized and existing under the laws of Washington and having its principal place of business at 500 Fifth Avenue North, Seattle, Washington 98109, United States 

- Foundation - 

  
 42/44EX-10.21

 Exhibit 10.21 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
 This
document is an English translation of a document prepared in German. In preparing this document, an attempt has been made to translate as literally as possible without jeopardizing the overall continuity of the text. Inevitably, however, differences
may occur in translation and if they do, the German text will govern by law. 
 In this translation, German legal concepts are expressed in English
terms and not in their original German terms. The concepts concerned may not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 

SUBLEASE AGREEMENT 
 The following
sublease agreement is entered into 
 between: 

University Medical Centre of the Johannes Gutenberg University of Mainz, 

55131 Mainz, Langenbeckstraße 1, 

represented by 
 the chairman of the
executive board and the Medical Director, [***], 
 the Scientific Director, [***], as well as 

the Commercial Director [***] 

(hereafter referred to “Unimedizin”) 

and 
 BioNTech AG 

55131 Mainz, Hölderlinstraße 8 

represented by 
 the director 

[***] (German business degree) 

(hereafter referred to the subtenant). 

Preamble 
 SANIPharma GmbH has acquired
the plot “An der Goldgrube”, 55131 Mainz (GFZ barracks facility; district Mainz, plot 21, no. 450/5) and intends to erect a building with laboratory and office areas on this land by the
4th quarter of 2013. Unimedizin intends to lease the building to ensure future space requirements are met and to transfer the same to third parties, such as Ganymed Pharmaceuticals AG and BioNTech
AG, by way of subletting the use of part areas. 
 The contract partners agree that the subtenant will take over the lease areas described in more detail
below for commercial purposes to carry out research, development and the marketing of products and services within the biotechnological / medical sector in line with this agreement. The contract partners have individually negotiated all regulations
of the sublease agreement in detail. The following regulations summarise the verbal agreements made in writing. 

  
 1 

 In principle, the property shall be managed by SANIPharma for the term of this agreement unless a third
party becomes the subtenant of the building in question in place of Ganymed Pharmaceuticals AG. Details regarding this are regulated in Section 6 no. 4 of the sublease agreement. 

Section 1 
 Leased
object 
 Lease areas: 
 The probable extent of the
leased areas of this agreement and the number of parking spaces for the contractual leased object are: 
 1.     

 

			
	Office areas	  	approx. 1,012 m2
		
	Laboratory areas	  	approx. 2,632 m2
		
	Archive and storage areas	  	approx. 365 m2
		
	Animal accommodation areas	  	approx. 331 m2
		
	Conference rooms	  	approx. 68 m2
		
	Shared rental areas	  	approx. 339 m2
		
	Parking spaces	  	approx. 50 spaces

 The useable area (Appendix 1) has been calculated on the basis of the current plan status in line with
planning approval as well as the guideline for calculating the lease area of commercial facilities (MF-G gif e.V.), status 01.11.2004 (Appendix 2, calculation and guideline). The parties agree that the
object will be measured in a way that is binding for both sides as soon as the building status allows this. Once these measurements are available the final useable areas will be recorded in an addendum and added as a tabular list of the lease areas.
Should the area change from the one listed under Section 1 no. 1 the rent according to Section 6 no. 1 will change accordingly. 
  

	2.	 The leased object is clear from the plans enclosed with this lease agreement as Appendices 3, 5 and 6.

  

	3.	 The fit-out standard is laid down in the building specification
enclosed as Appendix 4. Should special requests by the subtenant necessitate changes to the fixed fit-out standard, the parties will confirm these together with SANIPharma GmbH in an addendum to the
main lease agreement or the sublease agreement by mutual consent. Any additional costs incurred due to this will be borne by the subtenant in the form of a construction cost surcharge. The owner, namely SANIPharma GmbH, assures the future building
status of the rental premises in line with the building specification (Appendix 4) under the conditions of the planned building quality. 

  
 2 

	 	
Changes to this functional building specification (Appendix 4) by the owner, namely SANIPharma GmbH, are admissible as long as material of the same quality and grade is used and the
justified interests of the subtenant are adequately taken into consideration. 

  

	4.	 With regard to the technical laboratory equipment (cost groups 300 and 400) the facilities serve as a reference
object for Ganymed Pharmaceuticals GmbH, Freilingrathstraße 12 in Mainz. Permanently fitted office furniture (cost group 600) will be installed on the basis of the plans (Appendix 3). Moveable laboratory objects and laboratory furniture
will not be part of the lease agreement. The subtenant itself will acquire these objects. Changes with regard to technology and/or laboratory furniture made by SANIPharma GmbH in the building plans will be recorded in the final plans and added to
the property management contract between SANIPharma GmbH and the subtenant as an addendum. 

  

	5.	 With regard to the equipment and building services to be supplied only the building specification enclosed as
Appendix 4 applies. Illustrations that deviate from the same, for example in the planning documentation of the architects or the building contractor, are not binding for Unimedizin. The subtenant will not be able to make claims from this.

 The leased object will be completed and handed over as a turn-key project in
line with accepted technical rules, bearing in mind all currently valid public law provisions and official stipulations. Regulations already agreed and published that will however come into force only within six months from approval application must
also be taken into consideration, as these may lead to subsequent object-related stipulations. If higher requirements are defined in the building specification these are considered to be owed. 

Deviations from the documents enclosed as Appendices 3 and 4 due to building law or technical requirements or official stipulations are
admissible as long as the contractual serviceability of the leased object is not substantially affected and the justified interests of the subtenant are adequately taken into consideration. 

Possible deviations must be notified to the subtenant within at least 28 days from Unimedizin becoming aware of the same. 

Section 2 
 Leasing
purpose 
  

	1.	 The subtenant intends to use the leased areas for operating a laboratory (S1, S2 and animal laboratory) as well
as an office area. 

  
 3 

	2.	 Any change to the type of business operated at the lease facility, the use or the profession carried out there,
requires the prior written approval of Unimedizin. 

  

	3.	 The subtenant is solely responsible for obtaining and maintaining other official
non-object related approvals that may be required for the business operation of the subtenant at its own cost and its risk. If approvals required for the business operation within the meaning of Section 2
no. 1 are granted only under specific stipulations the subtenant is obliged to comply with the same at its own cost. In the case of a final refusal of the initial operating approval the subtenant will have the right to withdraw from this agreement
according to sections 346 et seq. BGB if the refusal is based on a non-compliance with building and/or technical requirements. 

The subtenant will comply with official instructions and stipulations relating to the use of the leased object passed following handover within
the meaning of Section 3 at its own cost. If such instructions or stipulations are object (building) related or will necessitate object related measures the subtenant will implement these in agreement with Unimedizin. Should such object related
stipulations or measures require investments of more than one total annual net rent p.a. the parties will endeavour to agree a regulation concerning the covering of additional costs. 

The issue of official instructions, stipulations or other provisions will not grant the subtenant a withdrawal, termination or performance
refusal right as long as operating approval still exists and the reason for this is not the fault of Unimedizin. The same applies for impairments of the commercial use of the leased object due to external circumstances such as traffic diversions,
excavations, road closures, noise, odour and dust nuisance etc. 
 Section 3 

Handover of the leased object 
  

	1.	 The subtenant will inform Unimedizin in good time prior to handover of the leased object, who will implement
this for the subtenant. 

  

	2.	 A protocol documenting the handover will be generated and signed by both contract partners. Defects found will
be included in the protocol. If the leased object contains defects the obligation of Unimedizin will initially be limited to rectifying the same. Should this fail or is not likely to be successful, a claim to rent reduction and/or compensation or
withdrawal will exist in line with statutory provisions. If the contractual parties cannot agree, any rectifications may have to be implemented following a corresponding expert report. 

  
 4 

	3.	 As construction progresses, SANIPharma GmbH will carry out a so-called
technical inspection - possibly also for spatially or technically separate part areas - prior to handover to the subtenant together with individual companies participating in the construction. SANIPharma GmbH undertakes to inform the subtenant of
the date of the technical inspection three weeks prior to the same. 

  

	4.	 Following timely notification of the date, the subtenant shall attend and cooperate in the technical
inspection. 

  

	5.	 If recognisable defects or the non-contractual condition of the leased
object are not claimed in the handover protocol, defects will be considered not to exist and the leased object as contractually compliant in this regard. Hidden defects are excluded from this. SANIPharma GmbH will send the subtenant protocols of the
building planning meetings. 

 Section 4 

Lease period and termination 
  

	1.	 The lease relationship begins upon handover, provisionally during the 4th quarter of 2013. 

  

	2.	 If the leased object cannot be handed over on the date listed under point 1 - irrespective of the reason - the
handover date and the start of the lease relationship will be postponed accordingly for up to nine months. There will be no possibility for the subtenant to withdraw in this case. Reference is made to the right of termination without notice (Section
5 para. 2). 

  

	3.	 The sublease relationship is limited to a period of ten years. The parties will set a start and end date of the
fixed term in an addendum to the sublease agreement immediately after handover according to Section 3. The subtenant will have the option to extend the lease agreement three times by a further 5 years. Exercise of the option must be declared in
writing at least 18 months prior to expiry of the (possibly extended) lease agreement in writing in each case. The receipt of the declaration by the landlord is crucial for compliance with this deadline. 

If Ganymed Pharmaceuticals AG vacates the leased object in the future, the remaining subtenant will be granted preferential lease rights to
also lease the facilities of Ganymed Pharmaceuticals AG about to become vacant under the conditions of this sublease agreement for a period yet to be agreed by the parties. Exercising the preferential lease right must then be declared by the
subtenant within four weeks from service of the request to Unimedizin in writing. Following expiry of the deadline without a written declaration exercising the preferential lease right, the said preferential lease right will lapse. 

  
 5 

 The subtenant further has no preferential lease right for the period that exceeds the 25-year term of the main lease agreement of Unimedizin or an earlier end of the main lease agreement of Unimedizin. 

Should the tax authorities revise the economic tax allocation of the leased object such that the subtenant is deemed to be the economic owner,
the contractual parties and SANIPharma shall negotiate a regulation that will not lead to disadvantages or advantages for the contractual parties. 
  

	4.	 If the subtenant continues to use the leased object once the lease period has expired the lease relationship
will be considered to have been extended. Section 545 BGB will therefore not apply. 

  

	5.	 Splits, mergers or conversions under company law by the subtenant will not lead to an end of the lease
agreement and will not grant special termination rights. The subtenant will inform Unimedizin of the legal entity who is the successor on the side of the subtenant. The liquidity of the subtenant may not be negatively affected by this.

 Section 5 

Extraordinary termination 
  

	1.	 The right to an extraordinary termination without notice shall be based on the statutory provisions and this
must be declared in writing unless agreed otherwise below. Unimedizin may terminate the sublease relationship with immediate effect and without complying with a notice period, 

 

	 	a)	 if the subtenant is in default with payment of the rent for two consecutive rent payment dates or with payment
of a not insubstantial part of the rent, or has defaulted on payment of the rent for an amount that totals the rent for two months during a period that extends over more than two payment dates; 

 

	 	b)	 if the subtenant continues using the leased object contrary to the agreement irrespective of a written reminder
by Unimedizin, in particular sub-lets the same without approval; 

  

	 	c)	 if the subtenant violates its obligations to such an extent that Unimedizin cannot be expected to continue the
sublease relationship, in particular continues to make late payments (of total or part amounts) despite written reminders by Unimedizin; 

  

	 	d)	 for another important reason. 

  
 6 

	2.	 If the leased object is not ready for occupation, or not on the agreed date, and is not ready for occupation
within the extended completion period listed under Section 4 paragraph 2 above, or if the leased object is found to have defects that will void its suitability for the contractually agreed occupation, the subtenant has the right to set
Unimedizin a suitable deadline that does not need to be longer than three months, and to terminate without notice upon expiry of this deadline. 

Excluded from this are: force majeure, strike, insolvency of the builder(s); in these cases the contractual parties will agree a suitable
further deadline. 
 Compensation claims are excluded unless Unimedizin has acted with intent or gross negligence or if they relate to
injuries to life, body or health. 
 Section 6 

Rent and security deposit 
 The total rent
amount for the building including installations and parking spaces will be set according to Section 1 para. 1 and in line with the respective usage areas at the following prices per m2 and
per month, plus VAT at the respective statutory rate. 
  

	1.	 The monthly rent at the time of completing the agreement is therefore: 

 

													
	 Utilisation units
	  	Price/ m2	 	  	Area in m2	 	  	Price per utilisation area	 
	 Office areas
	  	€	12.50	 	  	 	1,012	 	  	€	 12,650.00	 
	 Laboratory areas
	  	€	24.00	 	  	 	2,632	 	  	€	 63,168.00	 
	 Archive and storage areas
	  	€	12.50	 	  	 	365	 	  	€	 4,562.50	 
	 Animal accommodation areas
	  	€	52.00	 	  	 	331	 	  	€	 17,212.00	 
	 Conference rooms
	  	€	12.50	 	  	 	68	 	  	€	 850.00	 
	 Shared rental areas or traffic areas
	  	€	12.50	 	  	 	339	 	  	€	 4,237.50	 
	 Parking spaces
	  	€	30.00	 	  	 	50 spaces	 	  	€	 1,500.00	 
	 Sub-total
	  				  				  	€	104,180.00	 
	 Surcharge 1%
	  				  				  	€	 1,041.80	 
	 Total
	  				  				  	€	105,221.80	 

  

	2.	 SANIPharma GmbH has claimed input tax deduction for the costs of purchasing and equipping the leased object.
For this reason, the subtenant may use the leased object only for realising income that will not exclude the deduction of input tax by SANIPharma GmbH and Unimedizin. 

  
 7 

	 	
The subtenant is aware that only income liable to VAT allows this VAT option in principle and that the financial authorities and courts will accept other income that rules out an input tax
deduction only within very strict and low limits. The subtenant must provide Unimedizin with all information required by Unimedizin for enforcing and maintaining the VAT option. It undertakes upon request by Unimedizin to provide Unimedizin and
SANIPharma GmbH or the responsible tax office with corresponding documents. This regulation also applies for the case of a possible subletting where this is permitted in this agreement. The subtenant will be required to reimburse any damage incurred
or apparent in cases of violation. 

  

	3.	 The rent according to point 1 is set on the basis of the consumer price index for the cost of living of all
private households in Germany (published by the Federal Office for Statistics in Wiesbaden) at the time of signing the agreement (base year 2005 = 100). If the status of this index changes by more than 7.5 points either up or down 12 months after
the start of the contract or at the time of the last rent adjustment, the rent (excluding auxiliary costs and VAT) will change at a corresponding ratio with effect from the month following the change without requiring a special declaration of either
of the contractual parties or another contractual amendment. The percentage of the rent adjustment will be converted by means of the formula ([index status new x 100]: index status old) - 100 = rent adjustment in percent. If the index should not be
continued in its present form it will be replaced with the statistics recorded by the Federal Office for Statistics that come as close as possible to the same with a new base year. 

 

	4.	 The subtenant undertakes to complete a property management contract with SANIPharma GmbH, the owner of the
plot, for the entire term of the sublease agreement, unless a third party replaces Ganymed as subtenant, in which measures and operating costs invoices according to Sections 7 and 10 are regulated where these are not provided by the subtenant itself
at its own cost or paid directly to the service providers, or where these are not provided by the subtenant at its own cost or paid directly to the service providers. 

The subtenant thus agrees to SANIPharma GmbH commissioning a third party for the fulfilment of the property management contract. 

The subtenant agrees to a future property management by Unimedizin when the property management by SANIPharma GmbH ends. Property management
includes all measures and operating cost statements according to Sections 7 and 10 unless this is not provided by the subtenant itself at its own cost or paid directly to the service providers, details of which with regard to the operating costs to
be invoiced and the distribution principles to be applied are regulated in Section 7a. 

  
 8 

 The subtenant will not be able to enforce claims from the above property management by
SANIPharma GmbH against Unimedizin. 
 Section 7 

Operation and use of the leased object 
  

	1.	 The subtenant shall implement all measures and bear all costs necessary for the use of the leased object. These
include in particular, but not exclusively: 

  

	 	•	 	 all public safety obligations with regard to the leased object; 

 

	 	•	 	 cleaning responsibilities for paths bordering the leased object where this exists on the basis of corresponding
local statutes; 

  

	 	•	 	 completion of supply contracts with the respective suppliers (electricity, gas, water, drainage, heating, chimney
sweeping, road cleaning and waste disposal) and corresponding statements; 

  

	 	•	 	 operation, monitoring and maintenance of the heating system including exhaust gas system and the regular
inspection of operational readiness and safety, including adjustments to be carried out by a professional, cleaning of the system and the equipment room, implementation of necessary measures in line with the Federal Emission Protection Act,
implementation of calibrations; 

  

	 	•	 	 operation of a passenger or freight lift including supervision, operation, monitoring and maintenance of the
system, regular inspection of operational readiness and safety including adjustments to be carried out by a professional and cleaning of the system; 

  

	 	•	 	 cleaning of the building and pest control, including the external cleaning of windows; 

 

	 	•	 	 operation, maintenance and upkeep of all technical and mechanical building components; 

 

	 	•	 	 maintenance of fire extinguishers as well as obtaining official test certificates; 

 

	 	•	 	 testing, maintenance and upkeep of fire and safety-technical equipment. This for example includes fault and fire
alarm systems with auxiliary equipment, sprinkler systems, smoke and heat extraction systems, hydrants; 

  

	 	•	 	 maintenance, upkeep and regular inspection of lighting protection system as well as roof vegetation and roof
drainage; 

  

	 	•	 	 garden maintenance including the replacement of plants and bushes as well as the upkeep of open spaces, access
paths and access roads that do not serve the general public; 

  

	 	•	 	 supply of traffic areas, equipment spaces and facilities with water, electricity, heat etc., including the
acquisition of lighting equipment; 

  

	 	•	 	 operation of an antenna system or a broadband cable network; 

 

	 	•	 	 implementation of cosmetic repairs in public areas; 

  
 9 

 If the (prior) agreement of SANIPharma GmbH is required for implementing these measures such
agreement must be obtained. 
  

	2.	 Costs charged directly to SANIPharma GmbH or Unimedizin, such as for example ongoing public charges, namely
property taxes or other costs, will be borne by the subtenant. These costs will be invoiced annually by the 31.08. at the latest. The same applies for the cost of insurances taken out by SANIPharma GmbH or Unimedizin according to Section 15.
The subtenant must inform Unimedizin of any objections at least 6 weeks after receipt of the invoice. The subtenant will no longer be able to object to an invoice after this deadline has expired. 

Section 7a 

Property management by Unimedizin 
 For the
case of a termination of property management activities by SANIPharma GmbH the parties will agree the following in a supplementary agreement to this sublease agreement: 
  

	1.	 The subtenant will pay the operating costs resulting from Sections 7 and 10 of the sublease agreement, the
respective valid operating cost regulations and from property management activities to Unimedizin where these are not provided by the subtenant himself at its own cost or paid for directly to the service providers. 

A copy of the currently valid operating cost regulations is enclosed as Appendix 7 and form the object of this agreement. 

Monthly advance payments will be paid for the aforementioned costs and auxiliary costs charged according to Section 7 no. 1 as follows:

  

							
	 a)
	  	for heating and hot water supplies	  	€	            	 
	 b)
	  	for all other operating costs	  	€		 
	 c)
	  	for administration costs	  	€		 
		  	Total monthly ancillary cost advance payment	  	€		 
		  		  	  
	  
	 

  

	2.	 Distribution ratios: 

 

	 	a)	 Heating and hot water supply costs will be distributed in line with the allocation principle specified under
no. 5. 

  

	 	b)	 Costs for hot water supplies will be invoiced depending on the consumption for the whole building/ the economic
unit where corresponding measuring equipment is available. Failing this they will be distributed in line with the following allocation principle:  

                       
                                         
                                         
                                         
                                         
                          

  
 10 

	 	c)	 Drainage costs will be distributed proportionate to the water supply. 

 

	 	d)	 Lift costs will be charged in line with the conversion code specified under no. 6. 

 

	 	e)	 All other operating costs and administration costs will be distributed in line with the ratio of usage area to
total area of the building / the economic unit unless the following conversion ratio is agreed:
                                         
                    

  

	 	f)	 If Unimedizin incurs specific costs as a consequence of the usage type of the object (for example surcharge for
fire insurance, additional waste containers), these amounts will be passed on to the subtenant in full. 

  

	 	g)	 Unimedizin may change the conversion ratios at its discretion if reasons for a correct upkeep of the building /
the economic unit demand this. 

  

	3.	 An invoice for the prepayments shall be issued annually by 31 August at the latest. Unimedizin may change
the invoice period for reasons of expedience. The subtenant must inform Unimedizin of any objections at least 6 weeks from receipt of the invoice. The subtenant may no longer submit objections against the invoice following expiry of this deadline.
In the case of an increase or reduction in ancillary costs Unimedizin will have the right to review advance payments with effect from the month following the annual statement. Unimedizin may demand appropriate advance payments from the date of
notification of newly incurred ancillary costs, in particular operating costs. 

  

	4.	 If increases in operating costs occur, Unimedizin will have the right to distribute such increases
proportionally to the subtenant by means of a written declaration; the reason for the conversion must be stated and explained in the declaration. In a case of retrospective increases in operating costs the declaration of Unimedizin will apply from
the date of the increase. This also applies if new operating costs as defined in the operating costs regulations are incurred or arise following completion of the sublease agreement. 

If operating costs fall, they will be reduced accordingly from the date of the fall. 

 

	5.	 Heating and hot water supply 

 

	 	a)	 Unimedizin will maintain the shared hot water system for respective use throughout the year to the usual
extent. The hot water supply system will be operational at all times. 

  

	 	b)	 Heating costs to be paid by means of allocation include: 

the cost of fuels used and their delivery, the cost of operating currents, the cost of operating, monitoring and maintaining the heating system
including the exhaust gas system, the regular inspection of its operational readiness and operational safety including adjustments to be carried out by a professional, the cleaning of the system including the tank and

  
 11 

 
equipment room, the cost of measurements in line with the Federal Emissions Protection Act, the cost of leasing or other types of transfer of use of equipment for consumption recording as well as
the cost of using equipment for consumption recording including calculation and distribution costs. 
 The above regulations apply
correspondingly for the costs of hot water supply systems of the building / the economic unit. 
  

	 	c)	 Heating and hot water costs will be allocated as follows: 

Hot water consumption will be recorded with a heat meter and invoiced in line with actual consumption. Heating costs will be distributed at the
ratio of usage area to total area of the building or the economic unit. 
 Unimedizin will be entitled to change invoicing ratios at its
discretion within the legally admissible scope if justified interests necessitate this for a correct maintenance of the building / the economic unit. 

It is clear from the technical calculations of Appendix 8 that an exception from the application of sections 3 to 7 Heating Costs
Ordinance with regard to the supply of heat and hot water according to section 11 para. 1 no. 1 lit. b and para. 2 Heating Costs Ordinance exists, so that the aforementioned stipulations of the Heating Costs Ordinance do not apply. 

 

	6.	 Lift 

  

	 	a)	 The lift costs to be allocated for the operation of a passenger and/or freight lift include:

 the costs for operating electricity, supervision costs, the cost of operating, monitoring and upkeep of the system, the
regular inspection of its operational readiness and operational safety including adjustments to be carried out by a professional as well as the costs of cleaning the system. 
  

	 	b)	 Lift costs will be allocated according to the ratio of usage area to total area of the building or the economic
unit or according to the following allocation principle:  

                       
                                         
                                         
                                         
                                         
                              

 

	 	c)	 Unimedizin reserves the right to change the allocation principle at its discretion if reasons for the correct
maintenance of the building / the economic unit necessitate this. 

  
 12 

 Section 8 

Payment of rent 
  

	1.	 Rent plus VAT must be paid to Unimedizin monthly in advance, by the fourth of every month at the latest, free
of charge, with a releasing effect only to the following account: 

 Account holder:    [***]
                    Sort code: [***] 

Account number:  [***]
                    Bank: [***] 

Unimedizin will provide the debtor number as a payment reference. 
  

	2.	 The timeliness of the payment will depend not on the transfer, but on the receipt of the money.

  

	3.	 Late payment of rent will entitle Unimedizin to charge interest on appears from their due date until the date
when payment is received according to section 288 BGB. The claiming of higher interest charges is not ruled out by this. Irrespective of this further compensation claims and the statutory or contractually agreed termination rights of Unimedizin
remain unaffected. 

 Section 9 

Reduction, set-off, right of retention, compensation claims 

 

	1.	 A reduction or retention of rent and set-off against claims of
Unimedizin are excluded if circumstances outside of Unimedizin’s control (for example road closures, construction work on neighbouring buildings, changes to or cessation of the delivery of supply media which Unimedizin is unable to influence
etc.) affect the use of the facilities. Unimedizin will assign corresponding claims against third parties to the subtenant in this regard. 

  

	2.	 Apart from this the subtenant may set off counterclaims against rent demand claims or exercise a right of
reduction or retention only if the counterclaim is undisputed or has been legally confirmed. 

 Section 10 

Maintenance and use of the leased object 
  

	1.	 The subtenant undertakes to maintain and repair the leased object including other facilities and equipment also
let at its own cost. Not included in the maintenance obligation of the subtenant are the underlying construction components (work on roof and the building shell), although the moveable parts of doors and windows are. The same applies if a case of
force majeure exists or if maintenance or repair become necessary due to a construction defect. Costs may not exceed a total charge of 10% of the annual rent per year. Any costs exceeding this will be borne

  
 13 

	 	
by SANIPharma GmbH. VAT will not be included, i.e. only net amounts will be included in the calculation of limit values where the parties to the lease agreement are entitled to withhold input
tax. Work on installations and objects, in particular on technical systems that affect the entire building (air-conditioning shafts, water and heating pipes) must be agreed with SANIPharma GmbH in advance.

  

	2.	 The subtenant undertakes to carry out ongoing cosmetic repairs at its own cost as appropriate as soon as the
degree of wear requires this for the type of commercial operation or the contractual use. Cosmetic repairs include all internal painting, wallpapering, whitewashing and the painting of walls and ceilings, the painting or gloss painting of radiators,
heating pipes, internal doors, windows and the insides of external doors. The subtenant undertakes to have existing floor coverings including skirting boards treated by a qualified tradesperson if necessary. 

 

	3.	 The subtenant undertakes to treat the leased object including all components as well as the common facilities
(yard areas, vestibules, stairwells, lifts etc.) with care and consideration. 

  

	4.	 The subtenant must request information about admissible load limits of respective story ceilings from
SANIPharma GmbH prior to erecting machines, heavy apparatus and safes in the lease facility and must obtain the latter’s written approval. The subtenant is liable for damage caused through disregarding this provision. If machines have a
negative effect on the building, for example due to vibration, cracks etc., SANIPharma GmbH may revoke any approvals granted. 

  
 14 

	5.	 Damage caused to and inside the lease as well as to the rental premises must be notified to Unimedizin or
SANIPharma GmbH as soon as the subtenant becomes aware of it and must be rectified by the subtenant in line with the above obligations as well as according to the obligations of Section 7. Should the subtenant not comply with this obligation
within an appropriate period of time even following a written reminder, Unimedizin or SANIPharma GmbH may have necessary work carried out at the cost of the subtenant. If a risk of further damage exists the written reminder and the setting of a
deadline are not required. 

  

	6.	 If the subtenant is not subject to a rectification obligation it will nevertheless be liable towards Unimedizin
for damage culpably caused by itself through violation of its obligatory duty of care. The same applies if corresponding damage is culpably caused by employees, family members, vicarious agents, lodgers, visitors, suppliers, customers and tradesmen
etc. of the subtenant who do not have a rectification obligation. 

 Section 11 

Repairs and construction changes 
  

	1.	 Unimedizin or SANIPharma GmbH may carry out repairs, improvements, modernisations or other construction changes
necessary or expedient for the upkeep, operation or for the development of the building or the rental premises or for preventing anticipated danger or rectifying damage without agreement of the subtenant. Unimedizin undertakes to inform the
subtenant of the measures in good time prior to the start of the same without having to comply to the form, scope and deadline requirements of section 554 para. 3 BGB. If rental premises are affected, access to the same for the subtenant must be
retained wherever possible. The subtenant must not obstruct or delay such work. A right of the subtenant to terminate for a special reason due to work that has to be tolerated is excluded. The possible construction of a further building wing will be
tolerated by the subtenant without compensation. 

  

	2.	 Unimedizin or SANIPharma GmbH may not compromise the operational processes of the subtenant unduly. The
subtenant will have rent reduction claims because of such measures only if the measure lasts longer than two weeks and the subtenant is severely affected. Claims under tort remain unaffected by this. 

 

	3.	 If such measures result in the improved value of the rental premises, Unimedizin will have the right to
increase the rent by an appropriate value improvement surcharge, which will come into effect on the first of the month following the corresponding written declaration by Unimedizin. If the subtenant objects to the increase within a period of one
month from receipt of the increase request, an expert appointed by the responsible Chamber of Commerce will decide as an arbitrator. The costs of the arbitrator will be borne by the unsuccessful contract party. 

  
 15 

 Section 12 

Installations and conversions by the subtenant as well as advertising 

and special operating equipment 
  

	1.	 The subtenant requires the written approval of Unimedizin for installations and conversions in the rental
premises including any changes to technical equipment, for which suitable plans must be submitted upon request. The same applies for the fitting of other special operating equipment (for example automats, awnings, antennae) outside of the rental
premises, Unimedizin may make any approval dependent on proof of safety measures against risks posed by such equipment and demand the removal of such equipment if an important reasons exists for the same (retrospectively ascertained harmful effects
on the building, building components or other object users). A right to the granting of approval does not exist. 

  

	2.	 The obtaining of official approvals that may be required as well as the costs connected with this (also for the
compliance with stipulations) are the responsibility of the subtenant, who must also regularly check the safety of installations. The subtenant is liable for compliance with inspectorate stipulations and all damage caused during installation or
conversion work, irrespective of the type. Costs for the fitting, the operation and the upkeep of the equipment will also be borne by the subtenant. 

  

	3.	 The subtenant is liable for all damage caused in connection with installing and/or operating the equipment
provided by itself or at its request by a third party or by Unimedizin. It will release Unimedizin from third party claims. The subtenant will further notify all intended changes in or to the leased object, and in particular all changes to the risk
assessment in the sense of the fire prevention regulations of Unimedizin. If surcharges are applied to insurance premiums on the basis of such changes the subtenant will reimburse Unimedizin for the corresponding amount upon request.

 Section 13 

Subletting 
 The subtenant is not permitted
to sublet the facilities without the prior written approval of Unimedizin. 

  
 16 

 Section 14 

Destruction of the leased object 
 In a
case of a complete destruction or the destruction of most of the leased object due to an event that is outside of the control of Unimedizin (for example fire etc.), Unimedizin is not liable to reinstate the leased object. It may declare the end of
the lease relationship with effect from the date of the destruction of the leased object irrespective of whether the rental premises are to be reinstated at a later date or not. Upon reinstatement of the rental premises the subtenant will have
priority rights regarding the completion of a new lease agreement over other applicants. 
 Section 15 

Insurance policies 
  

	1.	 SANIPharma GmbH will take out the following insurance policies: 

 

	 	•	 	 fire insurance for the building, 

 

	 	•	 	 insurance against storm and damage to water supply, 

 

	 	•	 	 occupiers and building liability insurance. 

and will invoice the subtenant directly as part of the property management contract, failing which Unimedizin will forward the invoice to the
subtenant, who is then liable for a proportional payment to Unimedizin according to Section 7 no. 2 to the account listed in Section 8 no. 1. 
  

	2.	 The subtenant will take out operational liability insurance to the normal extent of the industry section at its
own cost as well as all normal insurances for its operation including fire, furniture, glass breakage and business disruption insurance with adequate sums insured, maintain the same and pay premiums on time. Claims against Unimedizin are excluded
where the subtenant receives payments from the aforementioned insurances or is no insurance cover exists in a case where he has failed to adequately insure such risks or has not paid insurance premiums or has notified any damage too late. The
liability of Unimedizin for intent and gross negligence or for injuries to life, body and health remain unaffected. 

Section 16 
 End of
the lease relationship 
  

	1.	 The subtenant will return the leased object completely empty and in a clean condition with all keys - also
those obtained by the subtenant - to Unimedizin when the lease relationship ends. The return must be notified with an appropriate notice period and must take place on the last working day prior to the end of the lease period at the latest. Upon
return the subtenant will also return all accessories and equipment components provided by Unimedizin in a clean condition ready for use. The subtenant undertakes to rectify all damage to the leased object caused through use that exceeds the
consequences of normal wear during the lease period prior to its return. 

  
 17 

	2.	 Unless specifically agreed otherwise as part of the landlord’s approval (Section 12) the subtenant
undertakes to remove installations, removals and conversions as well as installations it has carried out in or on the leased object, and to return the condition in which the leased object was upon handover to itself where reinstatement liability
exists and no takeover by Unimedizin will take place. 

 Section 17 

Plurality of persons 
 If several persons
act as a contract partner, they will be liable as joint debtors for all liabilities arising from this agreement. 
 Section 18

 Access to the leased object 
 The
subtenant must guarantee that Unimedizin, an authorised expert or interested parties are able to inspect the leased object during normal business hours for the purpose of ascertaining its state of repair. In cases of risk access must be permitted at
any time of the day or night. 
 Section 19 

House rules 
 Possible house rules yet to
be compiled will become part of this agreement. They will apply in their respective valid version. SANIPharma GmbH will expect all subtenants to comply with the house rules as part of the property management contract and will provide them with a
current copy, Appendix 9. 
 Section 20 

Miscellaneous agreements 
  

	1.	 Unimedizin has the right to transfer the lease agreement with all rights and duties to a group company. The
subtenant agrees to such a transfer. 

  
 18 

	2.	 The subtenant undertakes to provide a rent security deposit for three months, namely a total of
€ [***] (in words: [***]. This amount must be transferred to the account listed in Section 8 para. 1 within 14 days from the start of the sublease agreement at the latest. 

The rent deposit will be held in a savings account for the period of the sublease agreement by Unimedizin. Interest will be paid into this account. 

The subtenant may optionally provide an absolute, irrevocable and unconditional bank guarantee for € [***] from a major bank or public saving bank
based on the above period according to Appendix 10. 
 If the subtenant does not comply with its lease contract obligations during the sublease
period Unimedizin will have the right but is not obliged to satisfy these claims from the bank guarantee. If Unimedizin makes use of the bank guarantee to fulfil lease contractual obligations of the subtenant during the term of the sublease
agreement the subtenant undertakes upon request by Unimedizin to provide the same with further securities up to a height of the security deposit due to a subsequently reduced available security deposit. The same applies for the rent deposit. 

In a case of a valid exercising of an extension option for the sublease agreement the preferential lease right according to Section 4 no. 3 the parties
undertake to adjust the size of the security deposit acc. to Section 20 para. 2 to the current sum of three months’ rent. 

Section 21 
 Closing
provisions 
  

	1.	 Other agreements, in particular additional verbal agreements, do not exist. All contract amendments and
additions require the written form. 

  

	2.	 All appendices listed in this agreement become a major part of this agreement upon inclusion or approval of the
same. 

  

	3.	 Declarations of intent to be issued to the other contract partner require the written form to become effective.

  

	4.	 Should a provision of this agreement be or become invalid or unenforceable this will not affect the validity of
the remaining provisions. The invalid provision will be replaced one that comes closest to the intention of the invalid provision in a legally admissible way. The contractual parties undertake to amend the agreement according to sections 242, 313
BGB in exceptional circumstances, such as for example a currency change or inflation that will endanger the existence of the contract. 

  
 19 

	5.	 This agreement consists of 23 pages and the appendices. 

 

	6.	 Each party will receive one copy of this agreement including the appendices. 

 

	7.	 The place of jurisdiction is Mainz. 

 

	8.	 The law of the Federal Republic of Germany applies. 

Appendices 
  

	 	•	 	 Appendix 1 - Summary of lease areas according to MF-G

  

	 	•	 	 Appendix 2 - Lease area calculation and guideline (MF-G)

  

	 	•	 	 Appendix 3 - Installation status plans 

 

	 	•	 	 Appendix 4 - Building specification 

 

	 	•	 	 Appendix 5 - Open space layout 

 

	 	•	 	 Appendix 6 - Section drawing 

 

	 	•	 	 Appendix 7 - Operating cost     regulations 

 

	 	•	 	 Appendix 8 - Expert report regarding exceptions from the Heating Costs Ordinance (to
be    submitted by SANIPharma GmbH upon 

 handover of the leased object in the autumn of 2013 latest)

  

	 	•	 	 Appendix 9 - House rules 

(to be submitted by SANIPharma GmbH upon handover of the leased object in the autumn of 2013 latest) 

 

	 	•	 	 Appendix 10 - Bank guarantee form 

 

							
	Mainz, on 12.12.12	 		  	Mains, on 14.01.2013	  	
				
		 		  	[stamp - illegible]	  	
				
	Subtenant	 		  	University Medical Centre of the	  	
		 		  	Johannes Gutenberg University of Mainz	  	
				
	
                    
[signature]
	 		  	
                    
[signature]
	  	
	[***]	 		  	[***]	  	
	Chairman	 		  	Chairman of the executive board	  	
				
		 		  	
                    
[signature]
	  	
		 		  	[***]	  	
		 		  	Scientific Director	  	

  
 20 

							
				
	                        	 		  	
                    
[signature]
	  	
	            	 		  	[***]	  	
	        	 		  	Commercial Director	  	

 Approved by the owner of the plot and building, SANIPharma GmbH, Haidgraben 5, 85521 Ottobrun: 

 

							
	
                    
[signature]
	 		  	[stamp - Sanipharma GmbH	  	
	[***]	 		  	Haidgraben 5	  	
	Managing Director	 		  	            85521 Ottobrun]	  	

  
 21 

									
		  		  	App. 1
	Calculation of lease areas according to GIF (status 11/2004)	  		  	Ries + Ries
		  		  		  		  	Architectural
	Project:	  	New construction of administration and laboratory building in Mainz	  	Engineers
		  	Project no. 606 2	  	Key	  		  	
		  		  	Bfl.Gany	  		  	Ganymed office area
		  		  	Bfl.BioN	  		  	BioNTech office area
	Client:	  	SANIPharma GmbH	  	Lfl.Gany	  		  	Ganymed laboratory area
		  	Haidgraben 5	  	Lfl.BioN	  		  	BioNTech laboratory area
		  	85521 Ottobrun	  	Fl.TL	  		  	Animal laboratory area
		  		  	Fl.Konf.	  		  	Conference rooms
	User:	  	Ganymed Pharmaceuticals AG	  	AfluLfl.G	  		  	Ganymed archive & storage area
		  	Freiligrathstraße 12, 55131 Mainz	  	AfluLfl.B	  		  	BioNTech archive & storage area
		  		  	gg Mfl.	  		  	Common use lease area
		  	BioNTech AG	  	gg Mfl.L	  		  	Common use laboratory lease area
		  	Hölderlinstraße 8, 55131 Mainz	  	gg Mfl.AL	  	Common use archive & storage
		  		  		  	lease area	  	
	Areas are CAD calculated	  		  		  	
		  		  		  	MF - G1	  	Ganymed lease area
		  		  		  	MF - G2	  	BioNTech lease area
		  		  		  	MF - G	  	General lease area
		  		  		  	MF - 0	  	No lease area

 Cellar 
  

																									
	 Area
type
	  	Division	 	  	Room
number	  	 Room description
	  	NF
(m2)	 	  	VF
(m2)	 	  	TF
(m2)	 	  	 	 
	MF-G	  	 	ggMfl	 	  	-1-010	  	Stairwell 1	  				  	 	5.01	 	  				  	 	            	 
	MF-0	  				  	-1-004	  	Lift 1	  				  	 	3.33	 	  				  			
	MF-G	  	 	Fl.TL	 	  	-1-003	  	Corridor	  				  	 	27.65	 	  				  			
	MF-G	  	 	Fl.TL	 	  		  	Autoclave	  	 	8.67	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  		  	MAT H202	  	 	4.51	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-114	  	Material entry access	  	 	13.47	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-102	  	Personal entry access “unclean”	  	 	5.95	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-103	  	Shower	  	 	3.64	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-104	  	Personal entry access “clean”	  	 	5.70	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-101	  	Corridor “clean”	  				  	 	56.97	 	  				  			
	MF-G	  	 	Fl.TL	 	  	-1-113	  	Corridor “unclean”	  				  	 	49.89	 	  				  			
	MF-G	  	 	Fl.TL	 	  	-1-112	  	Laboratory 1	  	 	10.60	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-111	  	Laboratory 2	  	 	10.70	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-110	  	Laboratory 3	  	 	10.63	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-105	  	Experiment 1	  	 	21.62	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-106	  	Experiment 2	  	 	21.78	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-107	  	Experiment 3	  	 	21.72	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-108	  	Breeding	  	 	32.52	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-109	  	Ventilation centre animal laboratory	  				  				  	 	100.14	 	  			
	MF-G	  	 	Fl.TL	 	  	-1-001	  	Corridor	  				  	 	30.55	 	  				  			
	MF-G	  	 	Fl.TL	 	  	-1-011	  	Animal keeper changing room, female	  	 	8.69	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-007	  	Animal keeper changing room, male	  	 	8.67	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-012	  	Toilet, female	  	 	3.57	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-008	  	Toilet, male	  	 	3.57	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-009	  	Shower	  	 	2.08	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-014	  	Animal keepers store	  	 	88.06	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-006	  	Transition point IT/animal keeping	  				  				  	 	15.11	 	  			
	MF-G	  	 	Fl.TL	 	  	-1-017	  	Kitchen	  	 	61.57	 	  				  				  			
	MF-G	  	 	Fl.TL	 	  	-1-015	  	Animal laboratory storage room, litter waste disposal	  	 	26.11	 	  				  				  			
	MF-G	  	 	Fl. TL	 	  	-1-016	  	Carcass room	  	 	7.13	 	  				  				  			
	MF-G	  	 	ggMfl	 	  	-1-003	  	Corridor 1	  				  	 	33.81	 	  				  			
	MF-G1	  	 	AfluLfl.G	 	  	-1-018	  	Goods storage	  	 	40.75	 	  				  				  			
	MF-G	  	 	ggMfl.L	 	  	-1-020	  	Lock	  	 	5.37	 	  				  				  			
	MF-G	  	 	ggMfl.L	 	  	-1-021	  	Isotope laboratory	  	 	27.19	 	  				  				  			
	MF-G1	  	 	Lfl.Gany	 	  	-1-022	  	Server room 1	  	 	26.83	 	  				  				  			
	MF-0	  				  	-1-019	  	SiBe	  				  				  	 	8.79	 	  			
	MF-G	  	 	ggMfl.AL	 	  	-1-024	  	Nitrogen store. -80C (celcius) refrigerators	  	 	73.24	 	  				  				  			
	MF-G	  	 	ggMfl	 	  	-1-038	  	Corridor 2	  				  	 	65.87	 	  				  			
	MF-G	  	 	ggMfl	 	  	-1-040	  	Stairwell 2	  				  	 	4.83	 	  				  			
	MF-0	  				  	-1-039	  	Shaft 2    	  				  				  	 	8.28	 	  			

  
 22 

																									
	MF-0	  				  	-1-043	  	Shaft 3	  				  				  	 	8.70	 	  			
	MF-0	  				  	-1-046	  	Shaft 4	  				  				  	 	8.70	 	  			
	MF-0	  				  	-1-042	  	Shaft 5	  				  				  	 	8.28	 	  			
	MF-0	  				  	-1-044	  	List 2	  				  	 	6.98	 	  				  			
	MF-0	  				  	-1-041	  	BMA	  				  				  	 	8.97	 	  			
	MF-0	  				  	-1-051	  	NSHV	  				  				  	 	25.10	 	  			
	MF-G2	  	 	Lfl.BioN	 	  	-1-053	  	Server room 2	  	 	27.71	 	  				  				  			
	MF-G2	  	 	AfluLfl.B	 	  	-1-055	  	Central goods store	  	 	66.29	 	  				  				  			
	MF-0	  				  	-1-058	  	Building technology 1	  				  				  	 	62.97	 	  			
	MF-0	  				  	-1-056	  	Building technology 2	  				  				  	 	51.38	 	  			
	MF-0	  				  	-1-057	  	Waste water neutralization	  				  				  	 	15.79	 	  			
	MF-0	  				  	-1-059	  	Building technology 3	  				  				  	 	146.97	 	  			
	MF-G	  	 	ggMfl	 	  	-1-052	  	Corridor 3	  				  	 	51.58	 	  				  			
	MF-G	  	 	ggMfl	 	  	-1-038	  	Stairwell 3	  				  	 	4.63	 	  				  			
	MF-G	  	 	ggMfl	 	  	-1-083	  	Corridor 4	  				  	 	19.77	 	  				  			
	MF-0	  				  	-1-040	  	Lift 3	  				  	 	3.33	 	  				  			
	MF-G	  	 	ggMfl.AL	 	  	-1-035	  	Disposal room	  	 	120.24	 	  				  				  			
	MF-G	  	 	ggMfl.AL	 	  	-1-036	  	Liquid waste store	  	 	9.18	 	  				  				  			
	MG-0	  				  	-1-034	  	Lift 4	  				  	 	5.53	 	  				  			
	MF-G	  	 	ggMfl	 	  	-1-204	  	Corridor 5	  				  	 	52.52	 	  				  			
	MF-0	  				  	-1-202	  	Building technology 4	  				  				  	 	77.80	 	  			
	MF-G2	  	 	AfluLfl.B	 	  	-1-203	  	Archive QA	  	 	37.27	 	  				  				  			
	MF-G2	  	 	AfluLfl.B	 	  	-1-204	  	Archive IP	  	 	39.16	 	  				  				  			
	MF-G1	  	 	AfluLfl.G	 	  	-1-205	  	Archive 1	  	 	39.16	 	  				  				  			
	MF-G1	  	 	AfluLfl.G	 	  	-1-207	  	Archive 2	  	 	39.44	 	  				  				  			
	MF-G	  	 	ggMfl.AL	 	  	-1-208	  	Archive 3	  	 	39.14	 	  				  				  			
	MF-G2	  	 	AfluLfl.B	 	  	-1-206	  	Archive General	  	 	38.87	 	  				  				  			
	 MF-G1/2 Subtotal Cellar
	  	 	1010.80	 	  	 	403.08	 	  	 	115.25	 	  	 	1529.13	 
	 MF-0 Subtotal Cellar
	  	 	0.00	 	  	 	19.17	 	  	 	431.73	 	  	 	450.90	 

 Ground floor 
  

																			
	 Area

type
	  	 Division
	  	Room
number	  	 Room description
	  	NF
(m2)	 	  	VF
(m2)	 	  	 TF

(m2)
	  	 
	 MF-G
	  	ggMfl	  	0-119	  	Porch	  				  	 	13.40	 	  		  	            
	 MF-G
	  	ggMfl	  	0-118	  	Foyer/reception	  				  	 	42.51	 	  		  	
	 MF-G1
	  	Bfl.Gany	  	0-101	  	Corridor 1	  				  	 	62.96	 	  		  	
	 MF-G1
	  	Bfl.Gany	  	0-102	  	Combination zone	  	 	27.33	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-103	  	Office 01	  	 	29.62	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-104	  	Office 02	  	 	11.53	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-105	  	Office 03	  	 	17.31	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-106	  	Office 04	  	 	17.29	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-107	  	Office 05	  	 	24.91	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-108	  	Office 06	  	 	15.12	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-109	  	Office 07	  	 	29.20	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-110	  	Office 08	  	 	17.29	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-111	  	Office 09	  	 	17.31	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-112	  	Office 10	  	 	11.53	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-113	  	Office 11	  	 	29.62	 	  				  		  	
	 MF-0
	  		  		  	E-UV	  				  				  	0.56	  	
	 MF-G
	  	ggMfl	  	0-001	  	Corridor 2	  				  	 	17.77	 	  		  	
	 MF-G
	  	ggMfl	  	0-010	  	Stairwell 1	  				  	 	18.39	 	  		  	
	 MF-0
	  		  	0-004	  	Lift 1	  				  	 	3.33	 	  		  	
	 MF-0
	  		  	0-006	  	E-/EDV-UV 1	  				  				  	7.24	  	
	 MF-0
	  		  	0-005	  	Shaft 1	  				  				  	5.83	  	
	 MF-G1
	  	Bfl.Gany	  	0-007	  	Vestibule toilet, male	  	 	3.90	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-008	  	Toilet, male	  	 	5.06	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-011	  	Vestibule toilet, female	  	 	3.90	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-012	  	Toilet, female	  	 	5.06	 	  				  		  	
	 MF-G1
	  	Bfl.Gany	  	0-003	  	Disabled toilet	  	 	5.81	 	  				  		  	
	 MF-G
	  	Fl.Konf	  	0-013	  	Meeting room 1	  	 	80.61	 	  				  		  	
	 MF-G
	  	Fl.Konf	  	0-014	  	Meeting room 2	  	 	40.50	 	  				  		  	
	 MF-G
	  	Fl.Konf	  	0-009	  	Chair storage	  	 	14.30	 	  				  		  	
	 MF-G
	  	ggMfl	  		  	Communication zone	  				  	 	43.58	 	  		  	

  
 23 

																			
	 MF-G1
	  	 Bfl.Gany
	  	0-002	  	Corridor 3	  				  	 	33.79	 	  		  	
	 MF-G2
	  	 Bfl.BioN
	  	0-015	  	Office, animal cages 1 (BioNTech)	  	 	21.87	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-016	  	Office, animal cages 2 (Ganymed)	  	 	21.85	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-018	  	Meetings (Ganymed)	  	 	29.13	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-021	  	Typing pool 1	  	 	21.85	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-022	  	Typing pool 2	  	 	21.07	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-017	  	Social area	  	 	43.20	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-019	  	Copy room	  	 	6.26	 	  				  		  	
	 MF-G
	  	 ggMfl.AL
	  	0-020	  	Purchasing office	  	 	31.87	 	  				  		  	
	 MF-G
	  	 ggMfl.AL
	  	0-023	  	Temporary goods storage	  	 	33.72	 	  				  		  	
	 MF-G
	  	 ggMfl
	  	0-038	  	Corridor 4	  				  	 	62.08	 	  		  	
	 MF-G
	  	 ggMfl
	  	0-040	  	Stairwell 2	  				  	 	18.01	 	  		  	
	 MF-0
	  		  	0-044	  	Lift 2	  				  	 	6.98	 	  		  	
	 MF-0
	  		  	0-039	  	Shaft 2	  				  				  	8.28	  	
	 MF-0
	  		  	0-043	  	Shaft 3	  				  				  	8.70	  	
	 MF-0
	  		  	0-046	  	Shaft 4	  				  				  	8.70	  	
	 MF-0
	  		  	0-042	  	Shaft 5	  				  				  	8.28	  	
	 MF-G
	  	 ggMfl
	  	0-035	  	Corridor 5	  				  	 	26.59	 	  		  	
	 MF-G
	  	 ggMfl.AL
	  	0-033	  	Goods-in (liquid nitrogen tank)	  				  				  	43.33	  	
	 MF-G
	  	 ggMfl.AL
	  	0-036	  	Gas bottle store	  				  				  	15.22	  	
	 MF-0
	  		  	0-034	  	Lift 4	  				  	 	5.53	 	  		  	
	 MF-0
	  		  		  	Air supply opening, waste disposal room	  				  				  	1.13	  	
	 MF-G1
	  	 Lfl.Gany
	  	0-051	  	Lock	  				  	 	5.42	 	  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-047	  	Changing room, female	  	 	15.70	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-048	  	Washroom, female	  	 	5.70	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-049	  	Changing room, male	  	 	11.98	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-050	  	Washroom, male	  	 	5.56	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-058	  	Corridor 6	  				  	 	57.89	 	  		  	
	 MG-G1
	  	 Lfl.Gany
	  	0-058	  	Electrophoresis	  	 	21.30	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-056	  	Centrifuge	  	 	9.01	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-053	  	Microscopy	  	 	9.23	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-054	  	Copy room	  	 	6.16	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-055	  	Storage	  	 	8.35	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-061	  	Typing pool	  	 	17.57	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-062	  	Typing pool	  	 	13.45	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-060	  	RNA laboratory	  	 	15.49	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-059	  	pre PCR	  	 	14.82	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-063	  	post PCR	  	 	21.69	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-064	  	Typing pool	  	 	8.94	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-065	  	Plasma preparation	  	 	21.34	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-066	  	Typing pool	  	 	14.35	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-067	  	Kitchen	  	 	9.08	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-081	  	Vestibule toilet, female	  	 	3.90	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-082	  	Toilet, female	  	 	5.06	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-087	  	Vestibule toilet, male	  	 	3.90	 	  				  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-088	  	Toilet, male	  	 	5.06	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-079	  	Corridor 7	  				  	 	30.50	 	  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-068	  	Histology laboratory	  	 	44.40	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-069	  	Histology equipment	  	 	17.28	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-070	  	Typing pool histology	  	 	21.27	 	  				  		  	
	 MF-G1
	  	 Lfl.Gany
	  	0-071	  	Histology documents	  	 	12.69	 	  				  		  	
	 MF-0
	  		  	0-085	  	Shaft 6	  				  				  	5.83	  	
	 MF-0
	  		  	0-086	  	E-EDV-UV 2	  				  				  	7.24	  	
	 MF-0
	  		  	0-084	  	Lift 3	  				  	 	3.33	 	  		  	
	 MF-G
	  	 ggMfl
	  	0-080	  	Stairwell 3	  				  	 	18.39	 	  		  	
	 MF-G1
	  	 Bfl.Gany
	  	0-083	  	Corridor 8	  				  	 	18.23	 	  		  	
	 MF-G1/2 Subtotal Ground Floor
	  	 	981.30	 	  	 	469.51	 	  	58.55	  	1509.36
	 MF-0 Subtotal Ground Floor
	  		  	 	0.00	 	  	 	19.17	 	  	61.79	  	80.96

  
 24 

 1st Floor 

 

																							
	 Area

type
	  	 Division
	  	Room
number	  	 Room description
	  	NF
(m2)	 	  	VF
(m2)	 	  	TF
(m2)	 	  	 	 
	 MF-G1
	  	Bfl.Gany	  	1-101	  	Corridor 1	  				  	 	59.48	 	  				  	 	            	 
	 MF-G1
	  	Bfl.Gany	  	1-102	  	Combination zone	  	 	35.89	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-103	  	Storage	  	 	7.93	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-104	  	Office 01	  	 	23.02	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-105	  	Office 02	  	 	17.29	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-106	  	Office 03	  	 	17.32	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-107	  	Office 04	  	 	17.29	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-108	  	Office 05	  	 	24.00	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-109	  	Office 06	  	 	14.54	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-110	  	Office 07	  	 	24.91	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-111	  	Office 08	  	 	11.52	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-112	  	Office 09	  	 	11.55	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-113	  	Office 10	  	 	11.53	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-114	  	Office 11	  	 	11.53	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-115	  	Office 12	  	 	23.02	 	  				  				  			
	 MF-0
	  		  		  	E-UV	  				  				  	 	0.56	 	  			
	 MF-G1
	  	Bfl.Gany	  	1-119	  	Meeting room	  	 	22.32	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-120	  	Social area	  	 	22.37	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-118	  	Corridor 2	  				  	 	15.98	 	  				  			
	 MF-G1
	  	Bfl.Gany	  	1-001	  	Corridor 3	  				  	 	18.26	 	  				  			
	 MF-G
	  	ggMfl	  	1-010	  	Stairwell 1	  				  	 	4.98	 	  				  			
	 MF-0
	  		  	1-004	  	Lift 1	  				  	 	3.33	 	  				  			
	 MF-0
	  		  	1-006	  	E-/EDV-UV 1	  				  				  	 	7.24	 	  			
	 MF-0
	  		  	1-005	  	Shaft 1	  				  				  	 	5.83	 	  			
	 MF-G1
	  	Lfl.Gany	  		  	Communication zone	  				  	 	9.49	 	  				  			
	 MF-G1
	  	Lfl.Gany	  	1-002	  	Corridor 4	  				  	 	53.84	 	  				  			
	 MF-G1
	  	Lfl.Gany	  		  	Communication zone	  				  	 	7.07	 	  				  			
	 MF-G1
	  	Lfl.Gany	  	1-003	  	Darkroom	  	 	13.35	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-009	  	Lock	  	 	8.66	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-013	  	Cell development	  	 	60.84	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-014	  	Typing pool	  	 	8.17	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-015	  	Typing pool	  	 	8.34	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-016	  	Cell development process	  	 	59.76	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	0-007	  	Vestibule toilet, male	  	 	3.90	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	0-008	  	Toilet, male	  	 	5.06	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	0-011	  	Vestibule toilet, female	  	 	3.90	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	0-012	  	Toilet, female	  	 	5.06	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-017	  	Cell culture 4	  	 	30.30	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-019	  	Cell culture 3	  	 	30.39	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-021	  	Cell culture 2	  	 	30.39	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-024	  	Cell culture 1	  	 	59.85	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-018	  	Typing pool	  	 	19.32	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-020	  	Typing pool	  	 	17.57	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-023	  	Typing pool	  	 	17.52	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-022	  	Copy room	  	 	4.72	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-025	  	Storage	  	 	8.81	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-026	  	Refrigerator room	  	 	8.14	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-038	  	Corridor 5	  				  	 	44.27	 	  				  			
	 MF-0
	  		  	1-036	  	Electro UV3	  				  				  	 	7.02	 	  			
	 MF-G
	  	ggMfl.	  	1-040	  	Stairwell 2	  				  	 	5.18	 	  				  			
	 MF-G1
	  	Lfl.Gany	  	1-037	  	Washroom	  	 	4.68	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-041	  	PuMi	  	 	4.65	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-045	  	Freezer room	  	 	15.32	 	  				  				  			
	 MF-0
	  		  	1-044	  	Lift 2	  				  	 	6.98	 	  				  			
	 MF-0
	  		  	1-039	  	Shaft 2	  				  				  	 	8.28	 	  			
	 MF-0
	  		  	1-043	  	Shaft 3	  				  				  	 	8.70	 	  			
	 MF-0
	  		  	1-046	  	Shaft 4	  				  				  	 	8.70	 	  			
	 MF-0
	  		  	1-042	  	Shaft 5	  				  				  	 	8.28	 	  			
	 MF-G1
	  	Lfl.Gany	  	1-052	  	Corridor 6	  				  	 	18.42	 	  				  			
	 MF-G1
	  	Lfl.Gany	  		  	Communication zone	  	 	6.10	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-047	  	Changing room, female	  	 	15.70	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-048	  	Washroom, female	  	 	5.70	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-049	  	Changing room, male	  	 	11.98	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-050	  	Washroom, male	  	 	5.56	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-051	  	Copy room	  	 	6.16	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-055	  	Typing pool    	  	 	29.29	 	  				  				  			

  
 25 

																							
	 MF-G1
	  	Lfl.Gany	  	1-058	  	Storage	  	 	10.13	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-059	  	Freezer room	  	 	9.18	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-060	  	Refrigerator room	  	 	8.91	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-053	  	Chemical storage/scales	  	 	21.97	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-054	  	Kitchen/autoclave	  	 	38.72	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-056	  	Biochemical laboratory function room	  	 	44.25	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-057	  	Typing pool	  	 	16.82	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-064	  	Protein biochemical analysis	  	 	35.76	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-065	  	Typing pool	  	 	13.78	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-062	  	Protein biochemical cleaning	  	 	36.37	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-063	  	Typing pool	  	 	14.04	 	  				  				  			
	 MF-G1
	  	Lfl.Gany	  	1-061	  	FACS	  	 	27.61	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-081	  	Vestibule toilet, female	  	 	3.90	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-082	  	Toilet, female	  	 	5.06	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-087	  	Vestibule toilet, male	  	 	3.90	 	  				  				  			
	 MF-G1
	  	Bfl.Gany	  	1-088	  	Toilet, male	  	 	5.06	 	  				  				  			
	 MF-0
	  		  	1-085	  	Shaft 6	  				  				  	 	5.83	 	  			
	 MF-0
	  		  	1-086	  	E-EDV UV 2	  				  				  	 	7.24	 	  			
	 MF-G1
	  	Lfl.Gany	  	1-079	  	Corridor 7	  				  	 	56.24	 	  				  			
	 MF-G1
	  	Bfl.Gany	  	1-083	  	Corridor 8	  				  	 	18.26	 	  				  			
	 MF-G
	  	ggMfl	  	1-080	  	Stairwell 3	  				  	 	4.98	 	  				  			
	 MF-0
	  		  	1-084	  	Lift 3	  				  	 	3.33	 	  				  			
	 MF-G1/2 Subtotal First Floor
	  	 	1100.68	 	  	 	316.45	 	  	 	0.00	 	  	 	1417.13	 
	 MF-0 Subtotal First Floor
	  	 	0.00	 	  	 	13.64	 	  	 	67.68	 	  	 	81.32	 

 2nd Floor 

 

																			
	 Area

type
	  	 Division
	  	Room
number	  	 Room description
	  	NF
(m2)	 	  	VF
(m2)	 	  	 TF

(m2)
	  	 
	 MF-G2
	  	Bfl.BioN	  	2-101	  	Corridor 1	  				  	 	59.28	 	  		  	            
	 MF-G2
	  	Bfl.BioN	  	2-102	  	Combination zone	  	 	16.33	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-103	  	Storage	  	 	7.72	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-104	  	Copy room	  	 	6.99	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-105	  	Office 01	  	 	29.62	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-106	  	Office 02	  	 	11.53	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-107	  	Office 03	  	 	11.53	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-108	  	Office 04	  	 	11.55	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-109	  	Office 05	  	 	11.51	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-110	  	Office 06	  	 	24.91	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-111	  	Archive	  	 	19.40	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-112	  	Office 07	  	 	24.91	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-113	  	Office 08	  	 	17.29	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-114	  	Office 09	  	 	11.55	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-115	  	Office 10	  	 	17.29	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-116	  	Office 11	  	 	29.62	 	  				  		  	
	 MF-0
	  		  		  	E-UV	  				  				  	0.39	  	
	 MF-G2
	  	Bfl.BioN	  	2-119	  	Meeting room	  	 	22.32	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-120	  	Social area	  	 	22.37	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-118	  	Corridor 2	  				  	 	15.98	 	  		  	
	 MF-G2
	  	Bfl.BioN	  	2-001	  	Corridor 3	  				  	 	18.26	 	  		  	
	 MF-G
	  	ggMfl	  	2-010	  	Stairwell 1	  				  	 	4.98	 	  		  	
	 MF-0
	  		  	2-004	  	Lift 1	  				  	 	3.33	 	  		  	
	 MF-0
	  		  	2-006	  	E-/EDV-UV 1	  				  				  	7.24	  	
	 MF-0
	  		  	2-005	  	Shaft 1	  				  				  	5.83	  	
	 MF-G2
	  	Lfl.BioN	  	2-002	  	Corridor 4	  				  	 	60.97	 	  		  	
	 MF-G2
	  	Lfl.BioN	  	2-009	  	Communication zone	  	 	22.30	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-016	  	Pre-clinical	  	 	32.82	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-003	  	Typing pool	  	 	20.33	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-014	  	Typing pool	  	 	14.56	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-015	  	Typing pool	  	 	21.83	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-017	  	Typing pool	  	 	21.30	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-007	  	Vestibule toilet, male	  	 	3.90	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-008	  	Toilet, male    	  	 	5.06	 	  				  		  	

  
 26 

																			
	 MF-G2
	  	Bfl.BioN	  	2-011	  	Vestibule toilet, female	  	 	3.90	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-012	  	Toilet, female	  	 	5.06	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-013	  	Corridor 5	  				  	 	28.32	 	  		  	
	 MF-G2
	  	Lfl.BioN	  	2-019	  	Tea kitchen	  	 	19.32	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-021	  	Typing pool	  	 	17.57	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-022	  	Typing pool	  	 	17.57	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-024	  	Storage	  	 	17.85	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-018	  	Analytics	  	 	40.50	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-020	  	Laboratory DSP	  	 	50.62	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-026	  	Microscopy room	  	 	10.84	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-023	  	Laboratory USP	  	 	40.46	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-025	  	Kitchen/autoclave	  	 	29.46	 	  				  		  	
	 MF-G2
	  	ggMfl	  	2-038	  	Corridor 6	  				  	 	44.27	 	  		  	
	 MF-G2
	  	ggMfl	  	2-040	  	Stairwell 2	  				  	 	5.18	 	  		  	
	 MF-0
	  		  	2-036	  	Electro UV3	  				  				  	7.02	  	
	 MF-G2
	  	Lfl.BioN	  	2-037	  	Washroom	  	 	4.68	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-041	  	PuMi	  	 	4.65	 	  				  		  	
	 MF-G
	  	ggMfl.L	  	2-045	  	Pipette calibration	  	 	15.32	 	  				  		  	
	 MF-0
	  		  	2-044	  	Lift 2	  				  	 	6.98	 	  		  	
	 MF-0
	  		  	2-039	  	Shaft 2	  				  				  	8.28	  	
	 MF-0
	  		  	2-043	  	Shaft 3	  				  				  	8.70	  	
	 MF-0
	  		  	2-046	  	Shaft 4	  				  				  	8.70	  	
	 MF-0
	  		  	2-042	  	Shaft 5	  				  				  	8.28	  	
	 MF-G2
	  	Lfl.BioN	  	2-052	  	Corridor 7	  				  	 	18.42	 	  		  	
	 MF-G2
	  	Lfl.BioN	  	2-047	  	Changing room, female	  	 	15.70	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-048	  	Washroom, female	  	 	5.70	 	  				  		  	
	 MF-G
	  	Lfl.BioN	  	2-049	  	Changing room, male	  	 	11.98	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-050	  	Washroom, male	  	 	5.56	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-051	  	Copy room	  	 	6.16	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-054	  	Typing pool	  	 	17.59	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-056	  	Typing pool	  	 	17.57	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-058	  	Refrigerator room	  	 	13.45	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-053	  	Testing laboratory	  	 	30.30	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-055	  	Kitchen/autoclave	  	 	30.39	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-057	  	Laboratory ELISA	  	 	30.39	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-059	  	Laboratory Luminex	  	 	30.68	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-060	  	Laboratory Pre-PCR	  	 	29.73	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-061	  	Laboratory Post-PCR	  	 	20.14	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-065	  	Typing pool	  	 	14.67	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-064	  	Typing pool	  	 	14.04	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-063	  	IHC	  	 	51.35	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-062	  	Chemical storage	  	 	12.64	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	2-079	  	Corridor 8	  				  	 	56.24	 	  		  	
	 MF-G2
	  	Bfl.BioN	  	2-081	  	Vestibule toilet, female	  	 	3.90	 	  				  		  	
	 MF-G
	  	Bfl.BioN	  	2-082	  	Toilet, female	  	 	5.06	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	2-087	  	Vestibule toilet, male	  	 	3.90	 	  				  		  	
	 MF-G
	  	Bfl.BioN	  	2-088	  	Toilet, male	  	 	5.06	 	  				  		  	
	 MF-0
	  		  	2-085	  	Shaft 6	  				  				  	5.83	  	
	 MF-0
	  		  	2-086	  	E-EDV UV 2	  				  				  	7.24	  	
	 MF-G2
	  	Bfl.BioN	  	2-083	  	Corridor 9	  				  	 	18.26	 	  		  	
	 MF-G
	  	ggMfl	  	2-080	  	Stairwell 3	  				  	 	4.98	 	  		  	
	 MF-0
	  		  	2-084	  	Lift 3	  				  	 	3.33	 	  		  	
	 MF-G1/2 Subtotal Second Floor
	  	 	1092.30	 	  	 	335.14	 	  	0.00	  	1427.44
	 MF-0 Subtotal Second Floor
	  	 	0.00	 	  	 	13.64	 	  	67.51	  	81.15

  
 27 

 3rd Floor 

 

																			
	 Area

type
	  	 Division
	  	Room
number	  	 Room description
	  	NF
(m2)	 	  	VF
(m2)	 	  	 TF

(m2)
	  	 
	 MF-G2
	  	Bfl.BioN	  	3-101	  	Corridor 1	  				  	 	59.488	 	  		  	            
	 MF-G2
	  	Bfl.BioN	  	3-102	  	Combination zone	  	 	29.34	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-103	  	Storage	  	 	7.22	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-104	  	Copy room	  	 	6.99	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-105	  	Office 01	  	 	17.24	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-106	  	Office 02	  	 	17.31	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-107	  	Office 03	  	 	11.53	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-108	  	Office 04	  	 	11.55	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-109	  	Office 05	  	 	11.52	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-110	  	Office 06	  	 	24.91	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-111	  	Office 07	  	 	9.72	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-112	  	Office 08	  	 	9.68	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-113	  	Office 09	  	 	24.91	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-114	  	Office 10	  	 	17.29	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-115	  	Office 11	  	 	17.31	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-116	  	Office 12	  	 	17.31	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-117	  	Office 13	  	 	17.24	 	  				  		  	
	 MF-0
	  		  		  	E-UV	  				  				  	0.39	  	
	 MF-G2
	  	Bfl.BioN	  	3-119	  	CliFo function room/meetings	  	 	22.32	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-120	  	Social area	  	 	22.37	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-118	  	Corridor 2	  				  	 	15.98	 	  		  	
	 MF-G2
	  	Bfl.BioN	  	3-001	  	Corridor 3	  				  	 	18.26	 	  		  	
	 MF-G
	  	ggMfl	  	3-010	  	Stairwell 1	  				  	 	4.98	 	  		  	
	 MF-0
	  		  	3-004	  	Lift 1	  				  	 	3.33	 	  		  	
	 MF-0
	  		  	3-006	  	E-/EDV-UV 1	  				  				  	7.24	  	
	 MF-0
	  		  	3-005	  	Shaft 1	  				  				  	5.83	  	
	 MF-G2
	  	Lfl.BioN	  	3-002	  	Corridor 4	  				  	 	51.22	 	  		  	
	 MF-G2
	  	Bfl.BioN	  	3-007	  	Vestibule toilet, male	  	 	3.90	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-008	  	Toilet, male	  	 	5.06	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-011	  	Vestibule toilet, female	  	 	3.90	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-012	  	Toilet, female	  	 	5.06	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-015	  	FACS	  	 	21.46	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-009	  	FACS	  	 	22.15	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-017	  	MolBio 2	  	 	20.93	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-003	  	MolBio 1	  	 	27.61	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-014	  	Functional laboratory 1	  	 	29.11	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-016	  	Functional laboratory 2	  	 	21.30	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-018	  	Lock	  	 	5.65	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-019	  	Cell culture 1	  	 	35.18	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-021	  	Cell culture 2	  	 	40.46	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-024	  	Cell culture 3	  	 	29.10	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-025	  	Typing pool	  	 	11.37	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-028	  	Cell culture 4	  	 	39.62	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-013	  	Corridor 5	  				  	 	28.32	 	  		  	
	 MF-G2
	  	Lfl.BioN	  	3-027	  	Kitchen/autoclave	  	 	22.82	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-026	  	Cool room	  	 	11.72	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-023	  	Storage	  	 	17.59	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-022	  	Typing pool	  	 	17.57	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-020	  	Typing pool	  	 	13.45	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-038	  	Corridor 6	  				  	 	44.27	 	  		  	
	 MF-G
	  	ggMfl	  	3-040	  	Stairwell 2	  				  	 	5.18	 	  		  	
	 MF-0
	  		  	3-036	  	Electro UV 3	  				  				  	7.02	  	
	 MF-G2
	  	Lfl.BioN	  	3-037	  	Washroom	  	 	4.65	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-041	  	PuMi	  	 	4.68	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-045	  	Nitrogen store	  	 	15.32	 	  				  		  	
	 MF-0
	  		  	3-044	  	Lift 2	  				  	 	6.98	 	  		  	
	 MF-0
	  		  	3-039	  	Shaft 2	  				  				  	8.28	  	
	 MF-0
	  		  	3-043	  	Shaft 3	  				  				  	8.70	  	
	 MF-0
	  		  	3-046	  	Shaft 4	  				  				  	8.70	  	
	 MF-0
	  		  	3-042	  	Shaft 5	  				  				  	8.28	  	
	 MF-G2
	  	Lfl.BioN	  	3-052	  	Corridor 7	  				  	 	18.42	 	  		  	
	 MF-G2
	  	Lfl.BioN	  	3-047	  	Changing room female	  	 	15.70	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-048	  	Washroom, female	  	 	5.70	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-049	  	Changing room, male	  	 	11.98	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-050	  	Washroom, male	  	 	5.56	 	  				  		  	
	 MF-G2
	  	Lfl.BioN	  	3-051	  	Copy room	  	 	6.16	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-056	  	Secretarial	  	 	11.72	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-053	  	Office managing director	  	 	36.88	 	  				  		  	
	 MF-G
	  	ggMfl	  	3-079	  	Corridor 8	  				  	 	56.24	 	  		  	
	 MF-G2
	  	Lfl.BioN	  	3-054	  	Staff stay	  	 	91.08	 	  				  		  	
	 MF-G
	  	ggMfl.L	  	3-057	  	Chemical laboratory	  	 	30.68	 	  				  		  	

  
 28 

																			
	 MF-G1
	  	Lfl.Gany	  	3-059	  	Storage	  	 	12.61	 	  				  		  	
	 MF-G1
	  	Lfl.Gany	  	3-060	  	Storage GxP analytics	  	 	44.11	 	  				  		  	
	 MF-G1
	  	Lfl.Gany	  	3-061	  	Typing pool	  	 	21.30	 	  				  		  	
	 MF-G1
	  	Lfl.Gany	  	3-058	  	Standard laboratory	  	 	43.61	 	  				  		  	
	 MF-G1
	  	Lfl.Gany	  	3-062	  	Meeting room	  	 	20.93	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-081	  	Vestibule toilet, female	  	 	3.90	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-081	  	Toilet, female	  	 	5.06	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-087	  	Vestibule toilet, male	  	 	3.90	 	  				  		  	
	 MF-G2
	  	Bfl.BioN	  	3-088	  	Toilet, male	  	 	5.06	 	  				  		  	
	 MF-0
	  		  	3-085	  	Shaft 6	  				  				  	5.83	  	
	 MF-0
	  		  	3-086	  	E-EDV UV 2	  				  				  	7.24	  	
	 MF-G
	  	ggMfl	  	3-083	  	Corridor 9	  				  	 	18.26	 	  		  	
	 MF-G
	  	ggMfl	  	3-080	  	Stairwell 3	  				  	 	4.98	 	  		  	
	 MF-0
	  		  	3-084	  	Lift 3	  				  	 	3.33	 	  		  	
	 MF-G1/2 Subtotal Third Floor
	  	 	1101.36	 	  	 	325.59	 	  	0.00	  	1426.95
	 MF-0 Subtotal Third Floor
	  	 	0.00	 	  	 	13.64	 	  	67.51	  	81.15

 Attic floor / penthouse 
  

																							
	 Area

type
	  	 Division
	  	Room
number	  	 Room description
	  	NF
(m2)	 	  	VF
(m2)	 	  	TF
(m2)	 	  	 	 
	 MF-G2
	  	 Bfl.BioN
	  	4-001	  	Corridor 1	  				  	 	18.26	 	  				  	 	            	 
	 MF-G
	  	 ggMfl
	  	4-010	  	Stairwell 1	  				  	 	4.65	 	  				  			
	 MF-0
	  		  	4-004	  	Lift 1	  				  	 	3.33	 	  				  			
	 MF-0
	  		  	4-006	  	E-/EDV-UV 1	  				  				  	 	7.24	 	  			
	 MF-0
	  		  	4-005	  	Shaft 1	  				  				  	 	5.83	 	  			
	 MF-G2
	  	 Lfl.BioN
	  	4-002	  	Corridor 2	  				  	 	65.38	 	  				  			
	 MF-G2
	  	 Bfl.BioN
	  	4-007	  	Vestibule toilet, male	  	 	3.90	 	  				  				  			
	 MF-G2
	  	 Bfl.BioN
	  	4-008	  	Toilet, male	  	 	5.06	 	  				  				  			
	 MF-G2
	  	 Bfl.BioN
	  	4-011	  	Vestibule toilet, female	  	 	3.90	 	  				  				  			
	 MF-G2
	  	 Bfl.BioN
	  	4-012	  	Toilet, female	  	 	5.06	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-003	  	Storage	  	 	12.64	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-014	  	Typing pool	  	 	15.24	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-015	  	Typing pool	  	 	14.29	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-016	  	Typing pool	  	 	12.38	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-017	  	Typing pool	  	 	12.65	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-018	  	Typing pool	  	 	12.69	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-019	  	Typing pool	  	 	12.49	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-009	  	Meeting room	  	 	20.96	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-020	  	Quiet room	  	 	12.75	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-013	  	Corridor 3	  				  	 	39.28	 	  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-021	  	Pre PCR	  	 	30.47	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-023	  	Post PCR	  	 	30.39	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-029	  	Molbio	  	 	43.03	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-027	  	Cycler	  	 	8.89	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-025	  	Chemical storage	  	 	8.90	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-030	  	Plasmide	  	 	31.05	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-022	  	Typing pool	  	 	13.45	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-024	  	Typing pool	  	 	17.57	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-026	  	Typing pool	  	 	17.59	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-028	  	Typing pool	  	 	17.59	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-031	  	Tea kitchen	  	 	16.95	 	  				  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-038	  	Corridor 4	  				  	 	44.27	 	  				  			
	 MF-G
	  	 ggMfl
	  	4-040	  	Stairwell 2	  				  	 	5.18	 	  				  			
	 MF-G2
	  	 Lfl.BioN
	  	4-037	  	Washroom	  	 	7.02	 	  				  				  			
	 MF-G2
	  		  	4-041	  	MSR-technical	  				  				  	 	9.33	 	  			
	 MF-G2
	  	 Lfl.BioN
	  	4-045	  	Nitrogen store	  	 	15.32	 	  				  				  			
	 MF-0
	  		  	4-044	  	Lift 2	  				  	 	6.98	 	  				  			
	 MF-0
	  		  	4-039	  	Shaft 2	  				  				  	 	8.28	 	  			
	 MF-0
	  		  	4-043	  	Shaft 3	  				  				  	 	8.70	 	  			
	 MF-0
	  		  	4-046	  	Shaft 4	  				  				  	 	8.70	 	  			
	 MF-0
	  		  	4-042	  	Shaft 5	  				  				  	 	8.28	 	  			

  
 29 

																							
	 MF-G2
	  	Lfl.BioN	  	4-052	  	Corridor 5	  				  	 	18.42	 	  				  			
	 MF-G2
	  	Lfl.BioN	  	4-047	  	Changing room, female	  	 	15.70	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-048	  	Washroom female	  	 	5.70	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-049	  	Changing room, male	  	 	11.98	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-050	  	Washroom male	  	 	5.56	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-051	  	Copy room	  	 	6.16	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-053	  	Kitchen/autoclave	  	 	30.30	 	  				  				  			
	 MF-0
	  	Lfl.BioN	  	4-055	  	HPLC laboratory	  	 	30.39	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-079	  	Corridor 6	  				  	 	56.28	 	  				  			
	 MF-G
	  	Lfl.BioN	  	4-059	  	Spectroscopy	  	 	17.18	 	  				  				  			
	 MF-0
	  	Lfl.BioN	  	4-058	  	Laboratory formulation	  	 	43.89	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-054	  	Storage	  	 	11.72	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-056	  	Typing pool	  	 	23.44	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-057	  	Refrigerators	  	 	13.45	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-061	  	Laboratory RNA cleaning analysis	  	 	20.33	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-062	  	Laboratory RNA cleaning analysis	  	 	21.83	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-060	  	Laboratory RNA synthesis	  	 	43.91	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-064	  	Typing pool	  	 	20.63	 	  				  				  			
	 MF-G2
	  	Lfl.BioN	  	4-063	  	Process development	  	 	35.89	 	  				  				  			
	 MF-G2
	  	Bfl.BioN	  	4-081	  	Vestibule toilet, female	  	 	3.90	 	  				  				  			
	 MF-G2
	  	Bfl.BioN	  	4-082	  	Toilet, female	  	 	5.06	 	  				  				  			
	 MF-G2
	  	Bfl.BioN	  	4-087	  	Vestibule toilet, male	  	 	3.90	 	  				  				  			
	 MF-G2
	  	Bfl.BioN	  	4-088	  	Toilet, male	  	 	5.06	 	  				  				  			
	 MF-0
	  		  	4-085	  	Shaft 6	  				  				  	 	5.83	 	  			
	 MF-0
	  		  	4-086	  	E-/EDV-UV 2	  				  				  	 	7.24	 	  			
	 MF-G2
	  	Bfl.BioN	  	4-083	  	Corridor 7	  				  	 	18.26	 	  				  			
	 MF-G
	  	ggMfl	  	4-080	  	Stairwell 3	  				  	 	4.66	 	  				  			
	 MF-G
	  		  	4-084	  	Lift 3	  				  	 	3.33	 	  				  			
	 MF-G1/2 Subtotal Attic Floor
	  	 	778.21	 	  	 	274.64	 	  	 	0.00	 	  	 	1052.85	 
	 MF-0 Subtotal Attic Floor
	  	 	0.00	 	  	 	13.64	 	  	 	69.43	 	  	 	83.07	 

  
 30 

 [Floor plans attached to original lease follow] 

  
 31 

 App. 2 

GESELLSCHAFT FÜR 
 IMMOBILIEN-

 WIRTSCHAFTLICHE 
 FORSCHUNG E.V.

  
  

Society of Property 
 Researchers,
Germany 
 Wilhelmstraße 12 

D-65185 Wiesbaden 

Telephone (0611) 3 34 49 70 
 Fax
(0611) 3 34 49 75 

E-mail    info@gif-ev.de 

Internet http://ww.gif-ev.de 

Guideline 
 for the calculation 

of 
 lease areas for commercial properties 

(MF-G) 
 1 November
2004 
  

			
		 	© gif Gesellschaft für
		 	Immobilienwirtschaftliche
		 	Forschung e.V.
		 	Working group
		 	Area Definition
		
		 	in agreement with
		
		 	DIN
		 	Construction Standards Committee
		 	DIN 277

 Supported by 
 RICS Germany,
[illegible] Germany and GFFMA Germany 

  
 32 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	                                gif

 Members of the gif working group Area Definition, guideline MF-G 

[***] 
 This guideline was generated by the gif working group
Area Definition and approved by gif e.V. It represents an approach that is considered correct by the members of gif e.V. This guideline is a source of knowledge for the correct conduct under normal conditions. Individuals must decide at their own
responsibility whether application of the guideline is correct in a specific case and whether it will lead to a correct result. 
 All rights reserved.
Reprinting, also of excerpts, is permitted for internal purposes only whilst citing the source “Guideline for calculating lease areas for commercial property (MF-G)© gif Gesellschaft für Immobilienwirtschaftliche Forschung e.V., 1 November 2004”. 

  
 33 

					
	1 November 2004	  		  	Page 2 / 15
		
	 Guideline for the calculation of lease areas for commercial properties (MF-G) ©
  
	  	gif

 Table of contents 
  

							
	 PREAMBLE
	  	 	4	 
		
	 APPLICATION AND LIMITATIONS
	  	 	5	 
			
	 1
	 	GIF AREA TYPES	  	 	6	 
	 1.1
	 	MF-O no lease area	  	 	7	 
	 1.1.1
	 	Technical function areas (TF)	  	 	7	 
	 1.1.2
	 	Public areas (VF)	  	 	7	 
	 1.1.3
	 	Basic construction areas (KGF)	  	 	7	 
	 1.2
	 	MF-G lease area according to gif	  	 	8	 
	 1.2.1
	 	MF-G	  	 	8	 
	 1.2.2
	 	MF-G and MF-G 2	  	 	8	 
	 2
	 	LEASE AREA LAYOUT	  	 	9	 
	 3
	 	RULES FOR CALCULATION AND ILLUSTRATION	  	 	10	 
	 3.1
	 	Measuring points for area calculation	  	 	10	 
	 3.2
	 	Allocation of jointly used lease area	  	 	10	 
	 3.2.1
	 	Division into sections	  	 	10	 
	 3.2.2
	 	Calculation within a section	  	 	10	 
	 3.3
	 	Illustration and proof	  	 	11	 
	 3.3.1
	 	Table	  	 	11	 
	 3.3.2
	 	Layouts	  	 	11	 
	 4
	 	OTHER LEASED OBJECTS	  	 	12	 
	 4.1
	 	Vehicle parking areas	  	 	12	 
	 4.2
	 	Display windows	  	 	12	 
	 4.3
	 	Customer service zones	  	 	12	 
	 4.4
	 	Ceiling apertures	  	 	12	 
	 4.5
	 	Gastronomy zones	  	 	12	 
	 4.6
	 	Event zones, market stalls	  	 	12	 
	 4.7
	 	Stacked staircases	  	 	12	 
	 4.8
	 	Covered building areas	  	 	12	 
	 5
	 	GRAPHIC EXPLANATIONS	  	 	13	 
	 5.1
	 	MF-G in context MF-0, MF-G 1 and MF-G 2	  	 	13	 
	 5.2
	 	Lease area limits near fascias	  	 	14	 

  
 34 

							
	 5.3
	 	Allocation of partition walls	  	 	15	 

  

			
	1 November 2004	  	Page 3 / 15

  
 35 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

 PREAMBLE 
 When a lease
relationship is created in connection with a property, the lease area plays a crucial role. This is the case in particular because a legally binding definition of the lease area does not currently exist for commercially used objects. It has
therefore always been of particular interest to deal not only with the rent aspect, but also with the definition of what constitutes the lease area. 

Depending on the market and interest position, the area set constituting the lease area was extended more or less on each occasion. This lease area did not
reflect the actual serviceability of the area of the object in question very reliably. 
 The guideline for calculating the rental area of commercial
facilities (MF-G) formulates a set of rules that sees the lease area as a single entity to be deduced directly from the object characteristics. It is therefore no longer subject to regional customs or to
building typology. In the same way it no longer knows variation tolerances for one and the same object. 
 Gif is providing market participants with a set
of rules designed to achieve the following aims as defined in the sense of its working hypothesis Definition and improvement of professional standards in the property industry with the Guideline
MF-G: 
  

	 	•	 	 Increased planning security during the development, realisation and utilisation phases 

 

	 	•	 	 Increased significance and comparability of lease area information 

 

	 	•	 	 Reduction of cases in which a re-calculation of the lease area becomes
necessary 

 Guideline MF-G defines the lease area of commercially leased or used buildings. It
complies with the terminology and features of DIN 277 Floor space and volume capacities of structural engineering buildings. The guideline is market-related but independent, and ensures that calculations can be completed consistently clearly
and reproducibly. 
 This guideline serves for area calculations only and is not suitable for a monetary value assessment of areas. 

  
 36 

			
	1 November 2004	  	Page 4 / 15

  
 37 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

 APPLICATION AND LIMITATIONS 

Guideline MF-G is a summary, harmonisation and further development of the guidelines introduced sine 1996 (MF-B) and 1997 (MF-H) for lease area calculations for office and commercial properties. Upon publication of the guideline MF-G the
same replaces its two predecessors. It means that this guideline applies to all leased or utilised buildings. 
 Guideline
MF-G builds on the definition resources of DIN 277. For this reason, knowledge of DIN 277 is essential for the user of the guideline. DIN 277 is not a lease area definition. It deals with statements regarding
the systemisation of floor space and volumes of building construction. Guideline MF-G exceeds this in that it determines which of these areas are part of the lease area and which are not. The proportional
allocation of common use areas is also regulated. For this reason, we differentiate between exclusively and jointly used areas. 
 Guideline MF-G refers to DIN 277 in the version valid from 2005. The main usage area (HNF) and the additional usage area (NNF) are summarised into one usage area (NF) there. Functional areas (FF) are described as technical
functional areas (TF). DIN 277, 1987, continues to apply for the transition period until DIN 277, 2005 is published. 
 According to guideline MF-G the lease area is normally smaller than the gross floor space (BGF) of DIN 277, as certain areas that form part of BGF are not part of the lease area. 

In an individual case it may transpire that an area forms part of the lease area even though it makes sense not to include it from a monetary point of view.

 Areas not delimited to the required extent in DIN 277 or not forming part of BGF, which can however be rented out as leased objects, are listed in
chapter Other Leased objects. Such leased objects must be specifically listed and calculated separately from the MF-G. 

Guideline MF-G specifies that a change in the sizing of lease units within a building has no effect on the total lease
area of the object. Measure requiring planning approval will however mostly result in changes to the total lease area. 
 Part areas leading to the lease
area should be systematically and clearly recorded in a lease area log, which must be detailed to such a degree that all major qualitative differentiation criteria are recognisable from the same. The lease area calculation should be part of the
lease agreement or a supplementary agreement. 
 The guideline should only be used in its entirety. If use of the same deviates in individual points this
must be stated in summary with direct reference to guideline MF-G. In all other cases a reference to guideline MF-G must be omitted. 

  
 38 

			
	1 November 2004	  	Page 5 / 15

  
 39 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	1	 GIF AREA TYPES 

The area types of this guideline are divided into NF-D (no lease area) and MF-G
(lease area according to gif) based on the gross floor space according to the following structure model. 
  
 

 
  

			
	Brutto-Grundfläche (BGF)	  	= gross floor space (BGF)
	MF-O (Keine Mietfläche)	  	= MF-D (no lease area)
	MF-G (Mietfläche nach gif)	  	= MF-G (lease area according to gif)
	Die MF-G ist ggf. zu unterscheiden nach:	  	= the MF-G may have to be differentiated according to:
	MF-G 1 (Exklusive Nutzung)	  	= MF-G 1 (exclusive use)
	MF-G 2 (Gemeinschaftliche Nutzung)	  	= MF-G 2 (common use)

 The allocation of building floor space to MF-O and
MF-G is obvious and simply object-dependent. It can normally change only following a measure requiring planning approval. 

The factitive case of several tenants occupying the building is assumed for calculating MF-O for just one tenant or
user. 
 Differentiation between the lease areas according to exclusive usage right (MF-G 1) and common usage right (MF-G 2) is realised according to an assumed lease situation during the planning and construction phase. The actual situation must be illustrated during the usage phase. 

Classification as an area with exclusive usage right (MF-G 1) is typically characterised by: 

 

	 	•	 	 the right to exclude other users 

 

	 	•	 	 the right to occupy the area with personnel and/or objects 

The ratio of MF-G 1 to MF-G 2 may change for a new lease situation within
a building. 

  
 40 

			
	1 November 2004	  	Page 6 / 15

  
 41 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	1.1	 MF-O, no lease area 

Areas that are not lease areas are called MF-O. 

None of the following floor space types of DIN 277 are lease areas: 
  

	1.1.1	 Technical function areas (TF) 

 

	a	 All technical function areas 

 

	1.1.2	 Public areas (VF) 

  

	b	 fixed and moveable staircases and ramps and their interim plinths (exception landing plinths), list shaft floor
space per stopping point 

  

	c	 vehicle traffic areas 

 

	d	 paths, stairs and balconies, the main purpose of which serves for escape and rescue 

 

	e	 in shopping centres: entry halls, shopping malls and atriums 

 

	1.1.3	 Basic construction areas (KGF) 

 

	f	 external walls 

  

	g	 floor space of upright construction components such as walls and supports, necessary for the structural, i.e.
supporting and/or reinforcing room construction of a building 

  

	h	 floor space of enclosing walls, technical function and traffic areas forming part of MF-O 

  

	I	 floor space of installation channels and shafts, chimneys as well as crawl spaces representing construction
floor space according to DIN 277 

 All three of the floor space types listed here are lease areas if they are the consequence of an
individual lease requirement. This will be the case where they are specifically agreed between landlord and tenant. 
  

			
	1 November 2004	  	Page 7 / 15

  
 42 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	1.2	 MF-G lease area according to gif 

 

	1.2.1	 MF-G 

A floor space forming part of the gross floor space and not classified as MF-O is a lease area and is called MF-G. 
 The floor space of a lease area separation wall that is not classified as
MF-O is allocated to neighbouring tenants at half each. 
 Vehicle parking areas are not classified as MF-G, but can be leased objects (see chapter 4). 
 All areas of MF-G with a clear
room height of 1.50 m and less must be identified as such. 
  

	1.2.2	 MF-G and MF-G 2

 Depending on the lease situation the lease area MF-G can be divided into lease areas with an
exclusive usage right and those with common usage rights: 
  

	MF-G 1	 Lease area with exclusive usage right 

MF-G areas found inside buildings are classified as exclusive lease areas when they can normally be
allocated to one tenant. 
 They are called exclusive lease areas (MF-G 1). 

 

	MF-G 1	 Lease area with common usage right 

MF-G areas found inside buildings are classified as a common usage area when it is typically allocated
to several or all tenants. 
 These should be allocated to all tenants proportionally (see chapter 3.2). 

They are called common usage areas (MF-G 2). 

  
 43 

			
	1 November 2004	  	Page 8 / 15

  
 44 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	2	 LEASE AREA LAYOUT 

 

					
	 DIN 277
	 	 gif area types *

	 SGF
	 	 MF-O
	  	 MF-G

		 	Vehicle parking areas (parking spaces)	  	 Common rooms, rest rooms, social areas, waiting rooms, dining rooms, detention areas, office facilities, open-plan offices, meeting rooms,
construction rooms, ticket offices,
 operating rooms

monitoring rooms, office technology rooms
 works halls, workshops,
laboratories, rooms for
 keeping animals and plant propagation

kitchens, special work rooms
 storage rooms, archives, collection
rooms, cool rooms
 goods-in and goods despatch rooms

sales and exhibition rooms
 differential steps (max. 3 steps)

teaching and training rooms, library rooms,
 sports room, meeting
rooms
 stages, studio rooms, display rooms, religious rooms

rooms with medical equipment for
 operations, diagnostics and
therapy, bedrooms
 sanitary rooms, wardrobes, storage closets

rooms for central supply technology
 (for example power stations,
radio centres)
 protective spaces
 loggias, balconies, covered
building floor space
 useable roof areas

			
	TF	 	 Wastewater treatment and disposal
 water
supply
 heating and grey water heating
 fuel storage

gases and fluids
 electricity supply

telecommunications technology
 ventilation technical systems

lift and transport system machine rooms
 switching areas

house connection and installation, waste incineration
	  	Technical systems with individual tenant requirement
			
	VF	 	 Paths, stairs and balconies serving mainly escape and rescue purposes

 
 Areas without individual tenant requirement:

fixed and moveable stairs and ramps and their interim plinths

lift shafts, disposal shafts (each per floor)
 vehicle traffic
areas
	  	 Corridors, entry halls, foyers (except in shopping centres)

Storey plinths of stairwells
 areas with individual tenant
requirement:
 fixed and moveable stairs and ramps and their interim plinths

lift shafts, disposal shafts (each per floor)
  

Loading ramps, platforms

			
	KGF	 	 External walls and supports
 internal walls and
supports necessary for construction (supporting or reinforcing) purposes
 enclosure walls

MF-Os surrounding TFs, VFs
	  	 Light separation walls or other moveable or changeable constructions

lease area separation walls between MF-G areas

KGFs necessary on the basis of tenant requirements

  
 45 

	*	 The examples show some typical usage scenarios without claim to completeness. The regulations of the
guideline text precede this lease area plan in cases of doubt. 

  

			
	1 November 2004	  	Page 9 / 15

  
 46 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	3	 RULES FOR CALCULATION AND ILLUSTRATION 

 

	3.1	 Measuring points for area calculation 

In principle floor space is recorded directly above the floor inside the completed surfaces. Skirting boards, guard rails and facing formwork that is not of
ceiling height as well as installations will not be included. 
 In principle, measurements should extend right up to all room-delimiting components
including formwork of ceiling height. 
 Curtain walls with floor-level horizontal support profiles should be measured up to the inside of any glazing.
Vertical fascia profiles are disregarded in the floor plan. 
  

	3.2	 Allocation of jointly used lease area 

MF-G 2 should be allocated to participating parties. The type of allocation must be stated. The calculation must be
comprehensible. 
  

	3.2.1	 Division into sections 

Depending on the lease situation of a property a sectional division must be defined. Sections can include entire properties, individual buildings, storeys,
construction sections or components. 
  

	3.2.2	 Calculation within a section 

Commonly used areas within such sections are added up and allocated to the parties proportionally at the ratio of MF-G
1. 
  

			
	1 November 2004	  	Page 10 / 15

  
 47 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	3.3	 Illustration and proof 

The calculation of MF-G and the listing of other leased objects (chapter 4) will be according to plans, CAD data or to
local measurements. The calculation basis must be stated. 
 The above areas will be confirmed by means of tables and plans. 

 

	3.3.1	 Table 

The lease area calculation must be compiled in table form. The following areas should be identified separately: 

 

	 	•	 	 Division into sections according to chapter 3.2.1; by storey, construction section etc. 

 

	 	•	 	 Lease areas; 

  

	 	•	 	 gif area types (MF-O, MF-G and
possibly MF-G 1, MF-G 2); 

  

	 	•	 	 Area types according to DIN 277, part 1, point 3, separated into different usage and area types recorded as areas
b or c in line with DIN 277, part 1, point 4; 

  

	 	•	 	 Areas with a clear room height of 1.50m and less 

 

	3.3.2	 Layouts 

The various gif area types (MF-O, MF-G and possibly MF-G 1, MF-G 2) must be illustrated on lease area layouts to be graphically distinguishable. 

Each continuous lease area must be equipped with a lease area stamp that will allow the same to be identified in the table. 

The dimensional specifications of DIN 1356 apply; a minimum scale of 1:100 shall be used as a basis unless specified otherwise. 

  
 48 

			
	1 November 2004	  	Page 11 / 15

  
 49 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	4	 OTHER LEASED OBJECTS 

Areas which can be leased objects are listed below, whilst the underlying areas of the same cannot be classified as a
MF-G lease area. These leased objects are subject to individual tenant requirements and must then be agreed separately. 
  

	4.1	 Vehicle parking areas 

Vehicle parking areas (parking spaces) within parking areas. They will be identified by numbers. 

 

	4.2	 Display windows 

The area difference between the inner edge of the fascia alignment and the MF-G area of the sales room at the width of
the fascia opening, measured at floor height. The floor space of all display window components are included. Green areas near upright components of the fascia are not part of the leased object. 

 

	4.3	 Customer service zones 

Customer service zones up to a depth of 1.00 m and a width of the clear sales opening, where these are located outside of a
MF-G area and on the land of the landlord. 
  

	4.4	 Ceiling apertures 

Large-format opening in storey ceilings are not floor space according to DIN 277 unless they lie inside an exclusive lease area. 

 

	4.5	 Gastronomy zones 

Gastronomy or bar areas (outside or inside of general areas) in their actual expansion, where they lie on the land of the landlord. 

 

	4.6	 Event zones, market stalls 

Zones in malls or shopping arcades of shopping centres for temporary campaigns, events or other use. 

 

	4.7	 Stacked staircases 

The additional floor space of staircases inside of exclusive lease areas in a case where these are larger than the simple projection onto the storey above.

  

	4.8	 Covered building areas 

Covered building areas, where these are envisaged for the exclusive or common use by tenants (for example external sales areas of garden centres, shopping
trolley parking areas etc.) 

  
 50 

			
	1 November 2004	  	Page 12 / 15

  
 51 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	5	 GRAPHIC EXPLANATIONS 

 

	5.1	 MF-G in context MF-0, MF-G 1 and MF-G 2 

 Floor plan A shows a storey with two lease
areas, reached via a common stairwell and a common lift vestibule. 
 [***] 

Mieter = tenant 
 The external wall is firstly designed as a
punctuated fascias (top) and secondly as a strip-structured fascia (bottom). The strip-structured fascia consists of a glazed area arranged above a parapet. The lease area separation results from a fixed wall and a light separation wall, which is to
simplify the variation of the lease area layout. 
 [***] 

Mieter = tenant 
 MF-O:
The lift shaft area, the stairs with interim plinth, the shafts required for operating the building reinforcing construction components and the wall that enclose the MF-O areas. 

[***] 
 Mieter = tenant 

MF-G 1: The exclusive lease areas of tenants 1 and 2 

MF-G 2: The common lease area (lift vestibule/ storey plinth) 

 

			
	1 November 2004	  	Page 13 / 15

  
 52 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

	5.2	 Lease area limits near fascias 

The drawings show sections of a punctuated (B) and a strip-structured fascia (C). 

Floor plan B
                                        Floor
plan C 
 [***] 
 Section B
                                         
       Section C 
 [***] 

The floor space is measured at the height of the completed floor up to the room delimiting component, i.e. 

up to the inner edge of the external wall    up to the inner edge of the glazing 

 

			
	1 November 2004	  	Page 14 / 15

  
 53 

			
	Guideline for the calculation of lease areas for commercial properties (MF-G) ©	  	gif

  

					
	5.3	 	Allocation of partition walls	  	15

 The drawings show sanitary areas in which light separation walls are used as room dividers. 

Floor plan D
                                        Floor
plan E 
 [***] 
 Section D
                                         
    Section E 
 [***] 
  

					
	 The area of the installation shaft and
 the
floor space of the light separation walls
 surrounding the same are no lease areas.
	  	The floor space of the light separation wall and the primary walling that is not of room height are lease areas.	  	

  
 54 

			
	1 November 2004	  	Page 15 / 15

  
 55

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]